,Article,Date,Symbol,Time,Title,Url
0,"  Jan 14 (The following statement was released by the rating agency)Fitch Ratings has affirmed and withdrawn the  following ratings for CVS Caremark Corp. (NYSE: CVS):--Long-term Issuer Default Rating (IDR) at 'BBB+';--Senior unsecured bank facilities at 'BBB+';--Senior unsecured notes at 'BBB+';--Short-term IDR at 'F2'; --Commercial paper at 'F2'.The Rating Outlook is Stable.Fitch is discontinuing the ratings, which are uncompensated. KEY RATING DRIVERS The affirmations reflect the company's relatively steady credit metrics and  strong liquidity position. Fitch expects CVS to manage its credit profile and  capital allocation within the context of maintaining its publicly stated  adjusted debt/EBITDA (including NPV of lease obligations) ratio of 2.7 times  (x). The ratings also consider CVS's strong positioning in all prescription  distribution channels, with a #2 market position in the retail segment and  pharmacy benefit management (PBM) and a #1 position in the fast-growing  specialty pharmacy business, making it the largest provider of prescriptions in  the U.S. with a 21% share of 2012 prescription volume.The company is well positioned to drive continued market share gains and  capitalize on favorable industry trends for prescription growth such as the  aging population and expansion of coverage to the uninsured, the continued  growth in higher-margin generics and mid-teens growth in specialty pharmacy over  the next five years. Of concern are the ongoing cyclical pressures on the  industry resulting in soft front end sales, the industry-wide pressure on  pharmacy pricing and reimbursement rates in both the retail and PBM businesses,  and any potential hit to profitability from regulatory issues. Ongoing  healthcare reform initiatives could pressure reimbursement rates but be positive  for prescription volume over the intermediate term as the Affordable Care Act is  implemented.CVS and Cardinal Health recently announced an agreement to jointly source their  generics and also announced a three-year extension through June 2019 of Cardinal  Health's existing pharmaceutical distribution agreements with CVS Caremark. The  U.S.-based joint venture is expected to be operational as soon as July 1, 2014,  and will have an initial term of 10 years. In order to reflect an equitable  50/50 joint venture, the agreement includes a quarterly payment of $25 million  over the life of the agreement from Cardinal Health to CVS Caremark. The  payments have an estimated after-tax present value of $435 million. Fitch  expects large pharmacy chain, distributors and service providers to continue to  find ways to partner together to leverage their buying scale and distribution  networks. This was also evidenced by the announcement of a strategic  relationship in March 2013 between Walgreens and Alliance Boots with  AmeriSourceBergen to collaborate on global supply chain opportunities. Retail EBIT Margins Expected to be up Modestly in 2014-2015  The retail segment which accounts for approximately 70% of operating profit  continues to perform well in spite of near-term cyclical pressures and the  company continues to lead the drug retail sector in sales productivity and other  operating metrics. It has had a successful track record in integrating  large-scale retail acquisitions over the past 10 years, while maintaining a  healthy level of growth and improving profitability on an organic basis.  As large-scale retail acquisition opportunities are limited going forward, share  gains will depend on: generating above-average organic growth; store closings or  share losses by weaker independents and regional chains; and small market  fill-in acquisitions and prescription file buys. Fitch expects retail top-line  growth to be in the 3% - 4% range going forward with comparable store sales  growth in the 2% - 2.5% range and square footage contribution in the 1% - 1.25%  range. Operating profit growth is expected to be 9% in 2013 and in the  mid-single digits in 2014 - 2015, which assumes flat to a modest increase in  gross margin, due to the ongoing benefit of branded to generic conversions  offset by reimbursement pressure on the prescription side. As a result, retail  EBIT margins are expected to increase modestly over the next 2 - 3 years on an  expected base of 9.4% to 9.5% in 2013.PBM EBIT Margin Expand In 2013; Expected to be Flat in 2014/2015 CVS has seen positive momentum in its PBM segment since 2011 from a top line  perspective with strong business wins that were accretive in 2012, including the  ramp up of Aetna and the UAM acquisition which contributed $5.5 billion in  incremental revenue in 2012. The company has won approximately $25 billion in  net new business over the past three years. Revenues have grown in the mid-20%  range in 2011 - 2012 and are expected to grow in the 4% to 6% in 2013 to 2015.  CVS recently announced the acquisition of Coram LLC (Coram), the specialty  infusion services and enteral nutrition business unit of Apria Healthcare Group  Inc. for approximately $2.1 billion. Coram is expected to generate approximately  $1.4 billion in revenues during the first 12 months following the close of the  deal (expected end of 1Q'14) and will further strengthen CVS's leadership  position in the specialty pharmacy market where it controls about 20% of the  market with 2013 estimated revenue of $20 billion.Pharmacy services EBIT margin are expected to expand to 4% from 3.6% in 2013  after four years of decline, as the company integrates large scale contracts  such as Aetna Inc. and is realizing benefits from the streamlining initiatives  that it put in place in late 2009 to deliver over $1 billion in cost savings  from 2011 - 2015.Overall EBIT Growth of Mid-Single Digits; Strong FCFFitch expects total EBIT growth including retail to be in the mid-single digit  over the next 24 months, after growing 11%-12% in 2013. CVS continues to  generate strong free cash flow (FCF) providing the company with significant  financial flexibility. Fitch expects $3.3 billion to $3.5 billion in annual FCF  (after dividends which are expected to grow in the 20% to 25% range annually, as  the company targets a payout ratio of 25% to 30% by 2015, and before any sales  leaseback transactions) over the next few years. Fitch expects FCF will  primarily be used toward share buybacks ($4 billion to $5 billion annually), and  any bolt-on acquisitions within the context of maintaining adjusted debt/EBITDAR  at 2.7x. The company's liquidity is also supported by various credit facilities  that support its $3.5 billion commercial paper program.CVS had $10 billion in debt outstanding at Sept. 30, 2013. CVS recently issued  $4 billion of debt (staggered maturities of 3, 5, 10, and 30 years) to fund the  $2.1 billion acquisition of Coram and to pay down commercial paper borrowings  (which stood at $814 million on Sept. 30, 2013). The company has debt maturities  of $550 million each in 2014 and 2015 and $1.2 billion in 2016, which Fitch  expects will be refinanced.",2014-01-14,CVS,"Tue Jan 14, 2014 | 9:30am EST",RPT-Fitch affirms CVS Caremark at 'BBB+'; withdraws ratings,http://www.reuters.com//article/fitch-affirms-cvs-caremark-at-bbb-withdr-idUSFit68359520140114?type=companyNews
1,"   By Phil Wahba and Julie Steenhuysen  CVS Caremark Corp will stop selling tobacco products at its 7,600 stores by October 1, the company said on Wednesday, making it the first national drugstore chain in the United States to take cigarettes off the shelves.Public health experts hailed the precedent-setting decision by the No. 2 U.S. drugstore as a step that could pressure other retailers to follow suit. With pharmacies taking on a larger role in the U.S. healthcare system with walk-in clinics and services such as managing health plans, many experts say they should no longer offer unhealthy products like tobacco.President Barack Obama, a former smoker, praised CVS, saying in a statement the move will help wider efforts to ""reduce tobacco-related deaths, cancer, and heart disease, as well as bring down healthcare costs.""CVS expects the decision to hurt profits initially, along with a $2 billion hit to annual sales. But the company, whose Caremark unit is a pharmacy benefits manager for corporations and the U.S. government's Medicare program, believes the move will boost its appeal as a healthcare provider.CVS hopes to replace some sales through signing up customers to smoking cessation programs, which will be a selling point with potential corporate contracts.Analysts said CVS could eventually recoup lost sales through increased use of its healthcare services. But investors focused on the short-term pain. CVS shares fell 1 percent. Larger rival Walgreen Co, which will keep selling cigarettes, rose 3.9 percent, while No. 3 Rite Aid Corp which also will still offer cigarettes rose 2 percent.Shares of cigarette makers Lorillard Inc, Altria Group and Reynolds American all slipped.Pharmacists have long been a source of community health information, and drugstore chains have embraced that tradition by adding walk-in clinics. CVS is the largest U.S. pharmacy healthcare provider, with more than 800 MinuteClinic locations.""I think CVS recognized that it was just paradoxical to be both a seller of deadly products and a healthcare provider,"" U.S. Centers for Disease Control and Prevention Director Thomas Frieden told Reuters. CVS Caremark Chief Medical Officer Dr. Troyen Brennan said in a piece in the Journal of the American Medical Association that increased health coverage under the U.S. Affordable Care Act ""comes with a price"" of promoting public health.Experts noted that healthcare organizations and advocacy groups such as Americans for Nonsmokers' Rights have been urging pharmacies for years to get out of the tobacco business.Cornell University communication professor Jeff Niederdeppe cited ""an evolving social climate that has become less and less supportive of the marketing, sale, and use of tobacco products in the U.S.""Some U.S. cities, including Boston and San Francisco, already ban the sale of tobacco products in pharmacies, and nonsmoking advocates hope other chains will follow CVS. ""This is a trend we're going to see many, many retailers and food companies jump on,"" said Alexandra von Plato, president and global chief creative officer of Publicis Healthcare Communications Group.Only 18 percent of U.S. adults smoke, down sharply from 43 percent in 1965. But the habit still kills 480,000 Americans each year, remaining the leading cause of preventable death in the United States.SHORT-TERM HIT CVS said the decision to drop tobacco sales will cost the company 6 cents to 9 cents in profit per share this year. Analysts expect 2014 revenue of $132.9 billion and earnings of $4.47 per share, according to Thomson Reuters I/B/E/S.Overall U.S. cigarette sales fell 31.3 percent from 2003 to 2013, according to Euromonitor International. And CVS faced more competition in selling to that shrinking market, as discount retailers Family Dollar Stores Inc and Dollar General Corp chains charge much less and have far more locations. ""We believe the move will be viewed as a positive long-term decision by CVS, despite the near-term profit drag, as it paves the way for increased credibility with both healthcare consumers and payers,"" ISI Group analyst Ross Muken wrote in a note to investors.CVS has been bolstering its position in the healthcare market in recent months and in December, it said it expected pharmacy benefit manager revenue to rise between 7.25 percent and 8.5 percent in 2014, more than double the rate of retail business growth.Tobacco companies shrugged off the announcement even as shares dipped on concerns about potential disruption to sales.""It's up to retailers to decide if they're going to sell tobacco products,"" said Brian May, spokesman for Altria Group, maker of Marlboro and other popular brands.RBC Capital Markets analyst Nik Modi said he expected little impact on tobacco companies. He noted that they rely on convenience stores for more than 75 percent of sales.But Dr. Richard Wender of the American Cancer Society said CVS's move would have an effect.""Every time we make it more difficult to purchase a pack of cigarettes, someone quits.""(Reporting by Phil Wahba in New York and Julie Steenhuysen in Chicago; Editing by Jilian Mincer, Lisa Shumaker and David Gregorio)",2014-02-05,CVS,"Wed Feb 5, 2014 | 4:49pm EST",CVS becomes first big U.S. drugstore chain to drop tobacco,http://www.reuters.com//article/us-cvscaremark-cigarettes-idUSBREA140RP20140205?type=companyNews
2,"  By Phil Wahba and Julie SteenhuysenFeb 5 CVS Caremark Corp will stop selling tobacco products at its 7,600 stores by Oct. 1, the company said on Wednesday, making it the first national drugstore chain in the United States to take cigarettes off the shelves.Public health experts hailed the precedent-setting decision by the No. 2 U.S. drugstore as a step that could pressure other retailers to follow suit. With pharmacies taking on a larger role in the U.S. healthcare system with walk-in clinics and services such as managing health plans, many experts say they should no longer offer unhealthy products like tobacco.President Barack Obama, a former smoker, praised CVS, saying in a statement the move will help wider efforts to ""reduce tobacco-related deaths, cancer, and heart disease, as well as bring down healthcare costs.""CVS expects the decision to hurt profits initially, along with a $2 billion hit to annual sales. But the company, whose Caremark unit is a pharmacy benefits manager for corporations and the U.S. government's Medicare program, believes the move will boost its appeal as a healthcare provider.CVS hopes to replace some sales through signing up customers to smoking cessation programs, which will be a selling point with potential corporate contracts.Analysts said CVS could eventually recoup lost sales through increased use of its healthcare services. But investors focused on the short-term pain. CVS shares fell 1 percent. Larger rival Walgreen Co, which will keep selling cigarettes, rose 3.9 percent, while No. 3 Rite Aid Corp which also will still offer cigarettes rose 2 percent.Shares of cigarette makers Lorillard Inc, Altria Group and Reynolds American all slipped.Pharmacists have long been a source of community health information, and drugstore chains have embraced that tradition by adding walk-in clinics. CVS is the largest U.S. pharmacy healthcare provider, with more than 800 MinuteClinic locations.""I think CVS recognized that it was just paradoxical to be both a seller of deadly products and a healthcare provider,"" U.S. Centers for Disease Control and Prevention Director Thomas Frieden told Reuters. CVS Caremark Chief Medical Officer Dr. Troyen Brennan said in a piece in the Journal of the American Medical Association that increased health coverage under the U.S. Affordable Care Act ""comes with a price"" of promoting public health.Experts noted that healthcare organizations and advocacy groups such as Americans for Nonsmokers' Rights have been urging pharmacies for years to get out of the tobacco business.Cornell University communication professor Jeff Niederdeppe cited ""an evolving social climate that has become less and less supportive of the marketing, sale, and use of tobacco products in the U.S.""Some U.S. cities, including Boston and San Francisco, already ban the sale of tobacco products in pharmacies, and nonsmoking advocates hope other chains will follow CVS.""This is a trend we're going to see many, many retailers and food companies jump on,"" said Alexandra von Plato, president and global chief creative officer of Publicis Healthcare Communications Group. Only 18 percent of U.S. adults smoke, down sharply from 43 percent in 1965. But the habit still kills 480,000 Americans each year, remaining the leading cause of preventable death in the United States. SHORT-TERM HIT CVS said the decision to drop tobacco sales will cost the company 6 cents to 9 cents in profit per share this year. Analysts expect 2014 revenue of $132.9 billion and earnings of $4.47 per share, according to Thomson Reuters I/B/E/S.Overall U.S. cigarette sales fell 31.3 percent from 2003 to 2013, according to Euromonitor International. And CVS faced more competition in selling to that shrinking market, as discount retailers Family Dollar Stores Inc and Dollar General Corp chains charge much less and have far more locations.""We believe the move will be viewed as a positive long-term decision by CVS, despite the near-term profit drag, as it paves the way for increased credibility with both healthcare consumers and payers,"" ISI Group analyst Ross Muken wrote in a note to investors.CVS has been bolstering its position in the healthcare market in recent months and in December, it said it expected pharmacy benefit manager revenue to rise between 7.25 percent and 8.5 percent in 2014, more than double the rate of retail business growth.Tobacco companies shrugged off the announcement even as shares dipped on concerns about potential disruption to sales.""It's up to retailers to decide if they're going to sell tobacco products,"" said Brian May, spokesman for Altria Group , maker of Marlboro and other popular brands.RBC Capital Markets analyst Nik Modi said he expected little impact on tobacco companies. He noted that they rely on convenience stores for more than 75 percent of sales.But Dr. Richard Wender of the American Cancer Society said CVS's move would have an effect.""Every time we make it more difficult to purchase a pack of cigarettes, someone quits.""",2014-02-05,CVS,"Wed Feb 5, 2014 | 4:45pm EST",UPDATE 3-CVS becomes first big U.S. drugstore chain to drop tobacco,http://www.reuters.com//article/cvscaremark-cigarettes-idUSL2N0LA11S20140205?type=companyNews
3,"  By Phil Wahba and Julie SteenhuysenFeb 5 CVS Caremark Corp said on Wednesday that it would stop selling tobacco products at its 7,600 stores by October, becoming the first national drugstore chain in the United States to take cigarettes off the shelf.Public health experts called the decision by the No. 2 U.S. drugstore chain a precedent-setting step that could pressure other retailers to follow suit.President Barack Obama, a former smoker, praised the move, saying CVS had set a powerful example.""Today's decision will help advance my Administration's efforts to reduce tobacco-related deaths, cancer, and heart disease, as well as bring down healthcare costs,"" Obama said in a statement.CVS, whose Caremark unit is a major pharmacy benefits manager for corporations and the U.S. government's Medicare program, said the decision would strengthen its position as a healthcare provider.""I think it will put pressure on other retailers who want to be in healthcare,"" said CVS Caremark Chief Medical Officer Dr. Troyen Brennan.Although some U.S. cities, including Boston and San Francisco, already ban the sale of tobacco products in pharmacies, advocates hope the voluntary move by CVS will have a ripple effect across other drugstore chains.Walgreen Co, the largest pharmacy chain, said it would still sell cigarettes for now but will continue to evaluate the product category. Third-ranked Rite Aid Corp  did not immediately respond to a request for comment. Some retailers stopped selling cigarettes years ago:  Target Corp decided to drop them in 1996, while East Coast supermarket chain Wegmans Food Markets did so in 2008.Dr. Risa Lavizzo-Mourey, chief executive officer of the Robert Wood Johnson Foundation, which focuses on public health, said CVS had made ""a bold, precedent-setting move because it acknowledges that pharmacies have become healthcare settings.""SMALL FINANCIAL IMPACT However, CVS said the decision would not make a big dent in its financial results. The company said the cost would be about $2 billion in annual sales and 6 cents to 9 cents in profit per share this year. Analysts expect CVS to report 2014 revenue of $132.9 billion and earnings of $4.47 per share, according to Thomson Reuters.Declining smoking rates, along with new competition in the last two years from the low-cost Family Dollar Stores Inc  and Dollar General Corp chains, suggest prospects for tobacco product sales were shrinking at CVS. Dollar stores have far more locations and offer goods at lower prices.""We believe the move will be viewed as a positive long-term decision by CVS, despite the near-term profit drag, as it paves the way for increased credibility with both healthcare consumers and payors,"" ISI Group analyst Ross Muken wrote in a note.Matthew Myers, president of the Campaign for Tobacco-Free Kids, said CVS's announcement could help lead more people to quit smoking.U.S. cigarette sales fell 31.3 percent between 2003 and 2013, according to Euromonitor International. Although adult smoking rates have fallen from 43 percent of Americans in 1965 to 18 percent currently, the habit remains the leading cause of preventable death in the United States, killing more than 480,000 people each year.Last month, the American Lung Association and other advocacy organizations called on political leaders to commit to cutting smoking rates to less than 10 percent of the population in a decade and to protect all Americans from secondhand smoke within five years.FOCUS ON HEALTHCARE The decision by CVS comes on the heels of several recent deals bolstering the company's position in the healthcare market.CVS in December said it expected its pharmacy benefit manager revenue to rise between 7.25 percent and 8.5 percent in 2014, easily outpacing growth of 2 percent to 3.25 percent in its retail business.In December, CVS and pharmaceutical distributor Cardinal Health Inc announced a 10-year agreement to form the largest generic drug sourcing operation in the United States. A month earlier, CVS said it was buying Coram LLC, Apria Healthcare Group Inc's specialty infusion services business.CVS executives said the company would replace some of lost cigarette sales through smoking cessation programs at its pharmacies and through Caremark.The company said the programs would be also be a key selling point as it tries to land more corporate contracts this year.",2014-02-05,CVS,"Wed Feb 5, 2014 | 9:05am EST",RPT-UPDATE 1-CVS to become first major U.S. drugstore chain to drop cigarettes,http://www.reuters.com//article/cvscaremark-cigarettes-idUSL2N0LA0QB20140205?type=companyNews
4,"  By Phil Wahba and Julie SteenhuysenFeb 5 CVS Caremark Corp said on Wednesday that it would stop selling tobacco products at its 7,600 stores by October, becoming the first national drugstore chain in the United States to take cigarettes off the shelf.Public health experts called the decision by the No. 2 U.S. drugstore chain a precedent-setting step that could pressure other retailers to follow suit.President Barack Obama, a former smoker, praised the move, saying CVS had set a powerful example.""Today's decision will help advance my Administration's efforts to reduce tobacco-related deaths, cancer, and heart disease, as well as bring down healthcare costs,"" Obama said in a statement.CVS, whose Caremark unit is a major pharmacy benefits manager for corporations and the U.S. government's Medicare program, said the decision would strengthen its position as a healthcare provider.""I think it will put pressure on other retailers who want to be in healthcare,"" said CVS Caremark Chief Medical Officer Dr. Troyen Brennan.Although some U.S. cities, including Boston and San Francisco, already ban the sale of tobacco products in pharmacies, advocates hope the voluntary move by CVS will have a ripple effect across other drugstore chains.Walgreen Co, the largest pharmacy chain, said it would still sell cigarettes for now but will continue to evaluate the product category. Third-ranked Rite Aid Corp  did not immediately respond to a request for comment. Some retailers stopped selling cigarettes years ago:  Target Corp decided to drop them in 1996, while East Coast supermarket chain Wegmans Food Markets did so in 2008.Dr. Risa Lavizzo-Mourey, chief executive officer of the Robert Wood Johnson Foundation, which focuses on public health, said CVS had made ""a bold, precedent-setting move because it acknowledges that pharmacies have become healthcare settings.""SMALL FINANCIAL IMPACT However, CVS said the decision would not make a big dent in its financial results. The company said the cost would be about $2 billion in annual sales and 6 cents to 9 cents in profit per share this year. Analysts expect CVS to report 2014 revenue of $132.9 billion and earnings of $4.47 per share, according to Thomson Reuters.Declining smoking rates, along with new competition in the last two years from the low-cost Family Dollar Stores Inc  and Dollar General Corp chains, suggest prospects for tobacco product sales were shrinking at CVS. Dollar stores have far more locations and offer goods at lower prices.""We believe the move will be viewed as a positive long-term decision by CVS, despite the near-term profit drag, as it paves the way for increased credibility with both healthcare consumers and payors,"" ISI Group analyst Ross Muken wrote in a note.Matthew Myers, president of the Campaign for Tobacco-Free Kids, said CVS's announcement could help lead more people to quit smoking.U.S. cigarette sales fell 31.3 percent between 2003 and 2013, according to Euromonitor International. Although adult smoking rates have fallen from 43 percent of Americans in 1965 to 18 percent currently, the habit remains the leading cause of preventable death in the United States, killing more than 480,000 people each year.Last month, the American Lung Association and other advocacy organizations called on political leaders to commit to cutting smoking rates to less than 10 percent of the population in a decade and to protect all Americans from secondhand smoke within five years.FOCUS ON HEALTHCARE The decision by CVS comes on the heels of several recent deals bolstering the company's position in the healthcare market.CVS in December said it expected its pharmacy benefit manager revenue to rise between 7.25 percent and 8.5 percent in 2014, easily outpacing growth of 2 percent to 3.25 percent in its retail business.In December, CVS and pharmaceutical distributor Cardinal Health Inc announced a 10-year agreement to form the largest generic drug sourcing operation in the United States. A month earlier, CVS said it was buying Coram LLC, Apria Healthcare Group Inc's specialty infusion services business.CVS executives said the company would replace some of lost cigarette sales through smoking cessation programs at its pharmacies and through Caremark.The company said the programs would be also be a key selling point as it tries to land more corporate contracts this year.",2014-02-05,CVS,"Wed Feb 5, 2014 | 8:59am EST",UPDATE 1-CVS to become first major U.S. drugstore chain to drop cigarettes,http://www.reuters.com//article/cvscaremark-cigarettes-idUSL2N0LA0I720140205?type=companyNews
5,"   By Phil Wahba and Julie Steenhuysen  Feb 5 CVS Caremark Corp said on Wednesday that it would stop selling tobacco products at its 7,600 stores by October, becoming the first U.S. drugstore chain to take cigarettes off the shelf.Public health experts called the decision by the No. 2 U.S. drugstore chain a precedent-setting step that could pressure other stores to follow suit.CVS, whose Caremark unit is a major pharmacy benefits manager for corporations and the government Medicare program, believes the decision will strengthen its position as a healthcare provider.""I think it will put pressure on other retailers who want to be in healthcare,"" said CVS Caremark Chief Medical Officer Dr. Troyen Brennan.Although some U.S. cities, including Boston and San Francisco, already ban the sale of tobacco products in pharmacies, advocates hope CVS' voluntary decision will have a ripple effect among other pharmacy chains.Some retailers stopped selling cigarettes years ago:  Target Corp decided to drop them in 1996, while East Coast supermarket chain Wegmans Food Markets did so in 2008.Matthew Myers, president of the Campaign for Tobacco-Free Kids, which advocates for tobacco control, said that CVS's announcement could drive momentum for declining tobacco use. Dr. Risa Lavizzo-Mourey, chief executive officer of the Robert Wood Johnson Foundation, which focuses on public health, called CVS' decision ""a bold, precedent-setting move because it acknowledges that pharmacies have become healthcare settings.""While headline grabbing, CVS said the move will not make a big dent in its profits.CVS said it will lose about $2 billion in annual sales and between 6 and 9 cents of profit per share this year. Analysts expect the company to report 2014 revenue of $132.9 billion and a profit of $4.47 per share, according to Thomson Reuters. U.S. cigarette sales have fallen 31.3 percent between 2003 and 2013, according to Euromonitor International.The falling smoking rates, along with new competition in the last two years from the low-cost Family Dollar Stores Inc  and Dollar General Corp chains, suggest shrinking prospects for tobacco product sales at CVS. Dollar stores have far more locations and offer goods at lower prices.Although adult smoking rates have fallen from 43 percent of Americans in 1965 to the current 18 percent, smoking remains the leading cause of preventable death in the United States, killing more than 480,000 people each year.Last month, the American Lung Association and other advocacy organizations called on political leaders to commit to cutting smoking rates to less than 10 percent of the population in a decade and to protect all Americans from secondhand smoke within five years. FOCUS ON HEALTHCARE The CVS decision comes on the heels of several recent deals bolstering CVS Caremark's position in the healthcare market.CVS in December said it expected its pharmacy benefit manager revenues to rise between 7.25 percent and 8.5 percent in 2014, easily outpacing growth of 2 percent to 3.25 percent in its retail business.In December, CVS and pharmaceutical distributor Cardinal Health Inc announced a 10-year agreement to form the largest generic drug sourcing operation in the United States. A month earlier it said it was buying Coram LLC, Apria Healthcare Group Inc's specialty infusion services business unit.CVS executives said the company will replace some of lost cigarette sales through smoking cessation programs at its pharmacies and will offer more programs to Caremark members. CVS said the programs will be also be a key selling point as it tries to land more corporate contracts this year.",2014-02-05,CVS,"Wed Feb 5, 2014 | 7:00am EST",CVS to become first major U.S. drugstore to drop cigarettes,http://www.reuters.com//article/cvscaremark-cigarettes-idUSL2N0L91KI20140205?type=companyNews
6,"  * All 10 S&P sectors rally after Yellen's statement* House Republicans aim to pass debt-limit bill* Sprint and CVS climb after results, Dean Foods down* Dow up 1.2 pct, S&P 500 up 1.1 pct, Nasdaq up 1 pctBy Ryan VlastelicaNEW YORK, Feb 11 Wall Street rose for a fourth straight session on Tuesday as Congress agreed to advance legislation extending U.S. borrowing authority and the Federal Reserve's new chief held off from making any changes to its schedule for trimming stimulus.The gains were broad, with all 10 S&P 500 sectors up for the day and about 75 percent of New York Stock Exchange-traded stocks ending higher. About 67 percent of Nasdaq-listed shares closed in positive territory, while the S&P 500 ended just 1.6 percent away from its record closing high.Republican leaders in the U.S. House of Representatives caved in to demands by President Barack Obama and agreed to advance legislation increasing Washington's borrowing authority, removing a potential market headwind. Fed Chair Janet Yellen emphasized continuity in the U.S. central bank's policy strategy of cutting asset purchases by $10 billion a month, saying she strongly supports the approach of her predecessor, Ben Bernanke. In her first public comments as Fed chief, Yellen also said that while the U.S. unemployment rate has fallen recently, labor market conditions needed to improve further.""No one was really expecting a major debt ceiling showdown or changes in tapering, but anticipation is one thing, and the experience is another,"" said John Carey, portfolio manager at Pioneer Investment Management in Boston. ""Everyone is more relaxed now that those issues are officially off the table.""The Fed's policies have been credited with driving the market's steep gains in 2013, and those accommodative measures are expected to keep a floor under stock prices for as long as they continue. However, had the pace of ending the program been slowed, it may have raised concerns that the economy was still not strong enough to grow on its own. The Dow Jones industrial average jumped 192.98 points, or 1.22 percent, to end at 15,994.77. The Standard & Poor's 500 Index rose 19.91 points, or 1.11 percent, to finish at 1,819.75. The Nasdaq Composite Index climbed 42.87 points, or 1.03 percent, to close at 4,191.05.All three indexes scored a fourth straight gain, with the S&P 500 jumping about 4 percent over that period. The index also moved above its 50-day moving average for the first time since Jan. 24, a positive sign of near-term momentum. The index has recovered much of its recent weakness, which took the index down as much as 6 percent from its record close on Jan. 15.Sprint Corp rose 2.7 percent to end at $7.90 after the company reported quarterly revenue ahead of analysts' expectations and said it added wireless subscribers in the fourth quarter.CVS Caremark Corp shares climbed 2.7 percent to finish at $68.77 after the company posted higher quarterly profit as it processed more prescriptions. Of the 357 companies in the S&P 500 that have reported earnings through Tuesday morning, 67.8 percent have beaten profit expectations, above the long-term average of 63 percent, according to Thomson Reuters data. Almost 66 percent have topped revenue forecasts, above the historical average of 61 percent.On the downside, the shares of both Dean Foods Co and ConAgra Foods fell after the companies gave weak outlooks. Dean Foods warned of a first-quarter loss while ConAgra cut its full-year outlook. Dean's stock slid 7.4 percent to $14.08 while ConAgra's stock lost 6.3 percent to $29.08.After the market closed, shares of Fossil Group Inc  rose 5 percent to $122.80 after the watch and accessories company reported fourth-quarter results, while TripAdvisor Inc  shares rose 1 percent to $85 after the travel website company's results.Infloblox Inc shares plunged 48.1 percent to $17.19 after the network equipment maker estimated second-quarter revenue below analysts' average forecast.Cadence Pharmaceuticals Inc surged 26.5 percent to $14 after the company agreed to be acquired by specialty pharmaceuticals company Mallinckrodt Plc for about $1.3 billion. Mallinckrodt's stock climbed 11.6 percent to $66.19.About 5.94 billion shares traded on all U.S. platforms, according to BATS exchange data.",2014-02-11,CVS,"Tue Feb 11, 2014 | 4:28pm EST","US STOCKS-Relief over debt ceiling, Fed lift Wall St for 4th day",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LG21Y20140211?type=companyNews
7,"  * Dow industrials pop back above 16,000* All 10 S&P sectors rally after Yellen's statement* House Republicans aim to pass debt-limit bill* Sprint and CVS climb after results, Dean Foods down* Dow up 1.4 pct, S&P 500 up 1.3 pct, Nasdaq up 1.2 pctBy Ryan VlastelicaNEW YORK, Feb 11 U.S. stocks rallied on Tuesday as Congress agreed to advance legislation that extends borrowing authority and Federal Reserve Chair Janet Yellen said she wouldn't make any changes to the central bank's schedule for trimming its market-friendly stimulus. All 10 S&P 500 sectors rose on the day, with most climbing more than 1 percent. The benchmark index is now 1.4 percent away from its record closing high, recovering much of its recent weakness, which took the index down as much as 6 percent.Republican leaders in the U.S. House of Representatives caved in to demands by President Barack Obama and agreed to advance legislation increasing Washington's borrowing authority, removing a potential market headwind.Yellen, who has just stepped into the Fed's top job, emphasized continuity in the central bank's policy strategy of cutting asset purchases by $10 billion a month, saying she strongly supports the approach of her predecessor, Ben Bernanke. In her first public comments as Fed chief, Yellen also said that while the U.S. unemployment rate has fallen recently, labor market conditions needed to improve further.""No one was really expecting a major debt ceiling showdown or changes in tapering, but anticipation is one thing, and the experience is another,"" said John Carey, portfolio manager at Pioneer Investment Management in Boston. ""Everyone is more relaxed now that those issues are officially off the table."" The Fed's policies have been credited with driving the market's steep gains in 2013, and those accommodative measures are expected to keep a floor under stock prices for as long as they continue. However, had the pace of ending the program been slowed, it may have raised concerns that the economy was still not strong enough to grow on its own.The Dow Jones industrial average was up 219.12 points, or 1.39 percent, at 16,020.91. The Standard & Poor's 500 Index was up 22.70 points, or 1.26 percent, at 1,822.54. The Nasdaq Composite Index was up 48.55 points, or 1.17 percent, at 4,196.72.The S&P 500 rose above its 50-day moving average for the first time since Jan. 24, a technical resistance level that could fuel further gains if convincingly held. Sprint Corp, the No. 3 U.S. mobile provider, reported quarterly revenue ahead of analysts' expectations and said it added wireless subscribers in the fourth quarter. The stock shot up 2.6 percent to $7.89.CVS Caremark Corp shares climbed 2.7 percent to $68.74 after the company posted higher quarterly profit as it processed more prescriptions.Of the 357 companies in the S&P 500 that have reported earnings through Tuesday morning, 67.8 percent have beaten profit expectations, above the long-term average of 63 percent, according to Thomson Reuters data. Almost 66 percent have topped revenue forecasts, above the historical average of 61 percent.On the downside, the shares of both Dean Foods Co and ConAgra Foods slumped after the companies gave weak outlooks. Dean Foods warned of a first-quarter loss while ConAgra cut its full-year outlook. Dean's stock slid 7.9 percent to $14 while ConAgra's stock lost 6.5 percent to $29.04.Infloblox Inc shares plunged 47 percent to $17.58 after the network equipment maker estimated second-quarter revenue below analysts' average forecast.Cadence Pharmaceuticals Inc surged 26.6 percent to $14.01 after the company agreed to be acquired by specialty pharmaceuticals company Mallinckrodt Plc for about $1.3 billion. Mallinckrodt climbed 12.1 percent to $66.46.",2014-02-11,CVS,"Tue Feb 11, 2014 | 3:22pm EST","US STOCKS-Wall St jumps 1 pct on relief over debt ceiling, Fed",http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LG1UH20140211?type=companyNews
8,"  * All 10 S&P sectors rally after Yellen statement* House Republicans aim to pass debt limit bill* Sprint and CVS climb after results, Dean Foods down* Indexes up: Dow 1.2 pct, S&P 1 pct, Nasdaq 1 pctBy Ryan VlastelicaNEW YORK, Feb 11 U.S. stocks rose 1 percent in a broad rally on Tuesday, with investors relieved the Federal Reserve wouldn't make any changes to its schedule for trimming its market-friendly stimulus.All 10 S&P sectors rose on the day, with most climbing more than 1 percent. The benchmark index is now 1.6 percent away from its record closing high, recovering much of its recent weakness, which took the index down as much as 6 percent.In her first public comments as Fed chief, Chair Janet Yellen emphasized continuity in the central bank's policy strategy of cutting asset purchases by $10 billion a month, saying she strongly supports the approach of her predecessor, Ben Bernanke. Yellen also said that while the unemployment rate has fallen recently, labor market conditions needed to improve further.""Nothing unexpected was said, but the market is very encouraged to hear it confirmed that the policy of being accommodative will continue,"" said Weyman Gong, chief investment strategist at Signature in Norfolk, Virginia.The policies have been credited with fueling the market's steep gains in 2013, and they are expected to keep a floor under equity prices for as long as they continue.The Fed first announced a slowing in the bond-buying program in December, followed by another one in January. Had that pace been slowed, it may have raised concerns that the economy was still not strong enough to grow on its own. In other positive news, Republican leaders in the U.S. House of Representatives caved in to demands by President Barack Obama and agreed to advance legislation raising Washington's borrowing authority, removing a potential market headwind.The Dow Jones industrial average was up 192.24 points, or 1.22 percent, at 15,994.03. The Standard & Poor's 500 Index was up 18.58 points, or 1.03 percent, at 1,818.42. The Nasdaq Composite Index was up 40.85 points, or 0.98 percent, at 4,189.03.The S&P 500 rose above its 50-day moving average for the first time since January 24, a technical resistance level that could fuel further gains if convincingly held. ""The market's valuation is at a high level, probably a little too high,"" said Gong, who helps oversee $3 billion in assets. ""Our economy is growing modestly, but we don't expect earnings will continue to expand at their current pace.""Sprint Corp, the No. 3 U.S. mobile provider, reported quarterly revenue ahead of analysts' expectations and said it added wireless subscribers in the fourth quarter. The stock was up 2.5 percent to $7.88.CVS Caremark Corp rose 2.6 percent to $68.66 after the company posted higher quarterly profit as it processed more prescriptions.Of the 357 companies in the S&P 500 that have reported earnings through Tuesday morning, 67.8 percent have beaten profit expectations, above the long-term average of 63 percent, according to Thomson Reuters data. Almost 66 percent have topped revenue forecasts, above the historical average of 61 percent.On the downside, both Dean Foods Co and ConAgra Foods  slumped after giving weak outlooks. Dean warned of a first-quarter loss while ConAgra cut its full-year outlook. Shares of Dean slumped 8.2 percent to $13.96 while ConAgra lost 6.5 percent to $29.02.Infloblox Inc plunged 48 percent to $17.28 after the network equipment maker estimated second-quarter revenue below analysts' average forecast.Cadence Pharmaceuticals Inc surged 26.4 percent to $13.99 after the company agreed to be acquired by specialty pharmaceuticals company Mallinckrodt Plc said for about $1.3 billion. Mallinckrodt climbed 10.2 percent to $65.35.",2014-02-11,CVS,"Tue Feb 11, 2014 | 1:40pm EST",US STOCKS-Wall St up 1 pct as Yellen keeps Fed policy intact,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LG1KM20140211?type=companyNews
9,"  * Yellen statement yields no surprises* House Republicans aim to pass debt limit bill* Sprint, CVS climb after results* Indexes up: Dow 0.85 pct, S&P 0.75 pct, Nasdaq 0.62 pctBy Chuck MikolajczakNEW YORK, Feb 11 U.S. stocks rose on Tuesday after new Federal Reserve Chair Janet Yellen reinforced the central bank's plan to trim its market-friendly stimulus, while also noting labor market conditions needed to improve. In her first public comments as Fed chief, Yellen emphasized continuity in the Fed's policy strategy, saying she strongly supports the approach of her predecessor, Ben Bernanke.""They are apparently loving what Janet Yellen has to say which is really, 'hold the course steady, here is what I am.'  She is not any different than what they expected her to be,"" said Ken Polcari, Director of the NYSE floor division at O'Neil Securities in New York.The gains helped push the S&P 500 through its 50-day moving average for the first time since January 24, a technical resistance level which could fuel further gains if it's is convincingly held.""They challenged the 50-day moving average, now it depends if we hold up through there today, it will give them every opportunity to try to challenge the (record) high - which isn't necessarily coming in a day or two - but if we hold up through the 50-day there is a real possibility that it goes there."" The Dow Jones industrial average rose 133.67 points or 0.85 percent, to 15,935.46, the S&P 500 gained 13.44 points or 0.75 percent, to 1,813.28 and the Nasdaq Composite  added 25.71 points or 0.62 percent, to 4,173.884.The central bank has cut its bond-buying program by $10 billion at each of its last two meetings, reducing the monthly purchases to $65 billion.Stocks also saw a potential headwind removed when Republican leaders in the U.S. House of Representatives caved in to demands by President Barack Obama and agreed to advance legislation raising Washington's borrowing authority. Sprint Corp, the No. 3 U.S. mobile provider, reported quarterly revenue ahead of analysts' expectations and said it added wireless subscribers in the fourth quarter. The stock was up 2.5 percent to $7.88.CVS Caremark Corp posted higher quarterly profit as it processed more prescriptions and benefited from the introduction of new generic drugs. The stock rose 2.6 percent to $68.66.Of the 357 companies in the S&P 500 that have reported earnings through Tuesday morning, 67.8 percent have beaten profit expectations, above the long-term average of 63 percent, according to Thomson Reuters data. Almost 66 percent have topped revenue forecasts, above the historical average of 61 percent.ConAgra Foods lost 6.5 percent to $29.02 as one of the worst performers on the S&P 500. The maker of Chef Boyardee pastas and Slim Jim beef jerky cut its full-year profit outlook, citing weaker profits in its private label business and lower sales of certain consumer foods brands.Infloblox Inc plunged 46.7 percent to $17.67 after the network equipment maker estimated second-quarter revenue below analysts' average forecast.Cadence Pharmaceuticals Inc surged 26.4 percent to $13.99 after the company agreed to be acquired by specialty pharmaceuticals company Mallinckrodt Plc said for about $1.3 billion. Mallinckrodt climbed 10.2 percent to $65.35.",2014-02-11,CVS,"Tue Feb 11, 2014 | 1:19pm EST",REFILE-US STOCKS-Wall St advances as Yellen keeps Fed policy intact,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LG1AL20140211?type=companyNews
10,"   By Phil Wahba  CVS Caremark Corp (CVS.N) stuck to its 2014 sales forecast on Tuesday, a week after announcing it was giving up its $2 billion a year tobacco business, and said sales at its drugstores are off to a good start this year.Shares in CVS, which reported a better than expected quarterly profit, rose 2.5 percent to $68.79.""The ongoing strength in our core retail pharmacy business will help offset the loss from our decision to exit the tobacco category,"" Chief Financial Officer Dave Denton told Wall Street analysts on a call.CVS, which operates the No. 2 U.S. drugstore chain with 7,600 stores, and a major pharmacy benefits management business, reported a higher profit for the quarter ended December 31, as it processed more prescriptions and benefited from the introduction of new generic drugs, helping it offset a drop in store visits by customers.The company raised its first-quarter profit forecast by 7 cents per share to a range of $1.03 to $1.06, saying sales have been strong this quarter so far. Revenue in the quarter ended December 31 rose 4.6 percent to $32.83 billion, beating analyst forecasts of $32.67 billion, according to Thomson Reuters I/B/E/S, despite two impediments.CVS's pharmacy services unit processed 0.3 percent fewer network claims because of lower membership in a Medicare plan aimed at seniors. The company was hit by sanctions placed on CVS last year by the Centers for Medicare and Medicaid Services over its marketing of the plan.The government lifted its sanctions in December, allowing CVS to resume enrolling members last month. Another challenge was a drop in the number of visits to stores, a problem that has also hit rivals Walgreen Co WAG.N and Rite Aid Corp. (RAD.N) That contributed to a 1.9 percent decline in sales of general merchandise at stores open at least a year last quarter.Still, the company filled 3.8 percent more prescriptions and sold more generic drugs which cost less but have larger profit margins, lifting overall same-store sales well above Wall Street expectations. CVS earned $1.27 billion from continuing operations, or $1.05 per share, in the fourth quarter, up from $1.13 billion, or 90 cents per share, a year earlier. On an adjusted basis, it reported a profit of $1.12 per share, a penny better than expected.CVS announced last week it would stop selling all tobacco products at its drugstores by October, making it the first national drugstore chain in the United States to take cigarettes off the shelves.The decision was aimed at bolstering CVS' position in the healthcare market in recent months. At its analyst day in December, the company said it expected pharmacy benefit manager revenue to rise between 7.25 percent and 8.5 percent in 2014, more than double the rate of retail business growth.It stuck to the 2014 forecast from December and still expects adjusted profit of $4.36 to $4.50 per share this year.(Reporting by Phil Wahba in New York; Editing by Jeffrey Benkoe and Sofina Mirza-Reid)",2014-02-11,CVS,"Tue Feb 11, 2014 | 12:28pm EST",CVS sticks to 2014 sales forecast despite tobacco exit,http://www.reuters.com//article/us-cvscaremark-results-idUSBREA1A0VC20140211?type=companyNews
11,"  By Phil Wahba     Feb 11 CVS Caremark Corp stuck to its 2014 sales forecast on Tuesday, a week after announcing it was giving up its $2 billion a year tobacco business, and said sales at its drugstores are off to a good start this year.     Shares in CVS, which reported a better than expected quarterly profit, rose 2.5 percent to $68.79.     ""The ongoing strength in our core retail pharmacy business will help offset the loss from our decision to exit the tobacco category,"" Chief Financial Officer Dave Denton told Wall Street analysts on a call.     CVS, which operates the No. 2 U.S. drugstore chain with 7,600 stores, and a major pharmacy benefits management business, reported a higher profit for the quarter ended Dec. 31, as it processed more prescriptions and benefited from the introduction of new generic drugs, helping it offset a drop in store visits by customers.     The company raised its first-quarter profit forecast by 7 cents per share to a range of $1.03 to $1.06, saying sales have been strong this quarter so far.     Revenue in the quarter ended Dec. 31 rose 4.6 percent to $32.83 billion, beating analyst forecasts of $32.67 billion, according to Thomson Reuters I/B/E/S, despite two impediments.     CVS's pharmacy services unit processed 0.3 percent fewer network claims because of lower membership in a Medicare plan aimed at seniors. The company was hit by sanctions placed on CVS last year by the Centers for Medicare and Medicaid Services over its marketing of the plan.       The government lifted its sanctions in December, allowing CVS to resume enrolling members last month.     Another challenge was a drop in the number of visits to stores, a problem that has also hit rivals Walgreen Co  and Rite Aid Corp. That contributed to a 1.9 percent decline in sales of general merchandise at stores open at least a year last quarter.     Still, the company filled 3.8 percent more prescriptions and sold more generic drugs which cost less but have larger profit margins, lifting overall same-store sales well above Wall Street expectations.     CVS earned $1.27 billion from continuing operations, or $1.05 per share, in the fourth quarter, up from $1.13 billion, or 90 cents per share, a year earlier. On an adjusted basis, it reported a profit of $1.12 per share, a penny better than expected.     CVS announced last week it would stop selling all tobacco products at its drugstores by October, making it the first national drugstore chain in the United States to take cigarettes off the shelves.       The decision was aimed at bolstering CVS' position in the healthcare market in recent months. At its analyst day in December, the company said it expected pharmacy benefit manager revenue to rise between 7.25 percent and 8.5 percent in 2014, more than double the rate of retail business growth.     It stuck to the 2014 forecast from December and still expects adjusted profit of $4.36 to $4.50 per share this year.   ",2014-02-11,CVS,"Tue Feb 11, 2014 | 12:27pm EST",UPDATE 2-CVS sticks to 2014 sales forecast despite tobacco exit,http://www.reuters.com//article/cvscaremark-results-idUSL2N0LG0IP20140211?type=companyNews
12,"  * Yellen, new Fed chair, takes hot seat at Capitol* Yellen says labor market recovery far from complete* Sprint, CVS climb after results* Indexes up: Dow 0.53 pct, S&P 0.43 pct, Nasdaq 0.45 pctBy Chuck MikolajczakNEW YORK, Feb 11 U.S. stocks rose on Tuesday after new Federal Reserve Chair Janet Yellen reinforced the central bank's plan to trim its market-friendly stimulus while noting the health of the labor market needed to improve.In her first public comments as Fed chief, Yellen, giving a balanced testimony to a House committee, acknowledged recent volatility in global financial markets but said it did ""not pose a substantial risk to the U.S. economic outlook,"" and that she strongly supported the policy approach of her predecessor, Ben Bernanke. Yellen's appearance before the House Financial Services Committee began at 10 a.m. (1500 GMT).""We didn't see anything, at least in the written release that would cause us any concerns,"" said Paul Mangus, head of equity research and strategy at Wells Fargo Private Bank in Charlotte, North Carolina.""Naturally the testimony is just beginning so that will be very interesting to watch, the written testimony was in many ways a continuation of what the Bernanke policies had been."" The Dow Jones industrial average rose 83.69 points or 0.53 percent, to 15,885.48, the S&P 500 gained 7.74 points or 0.43 percent, to 1,807.58 and the Nasdaq Composite  added 18.85 points or 0.45 percent, to 4,167.023.The central bank has cut its bond-buying program by $10 billion at each of its last two meetings, reducing the monthly purchases to $65 billion.Stocks also saw a potential headwind removed when Republican leaders in the U.S. House of Representatives caved in to demands by President Barack Obama and agreed to advance legislation raising Washington's borrowing authority. Sprint Corp, the No. 3 U.S. mobile provider, reported quarterly revenue ahead of analysts' expectations and said it added wireless subscribers in the fourth quarter. The stock was up 5.3 percent to $8.10.CVS Caremark Corp posted higher quarterly profit as it processed more prescriptions and benefited from the introduction of new generic drugs. The stock rose 2.2 percent to $68.40.Of 345 companies in the S&P 500 that have reported earnings through Monday morning, 67.8 percent have beaten profit expectations, above the long-term average of 63 percent, according to Thomson Reuters data. Almost 66 percent have topped revenue forecasts, above the historical average of 61 percent.Conagra Foods lost 7.6 percent to $28.68 as one of the worst performers on the S&P 500. The maker of Chef Boyardee pastas and Slim Jim beef jerky cut its full-year profit outlook, citing weaker profits in its private label business and lower sales of certain consumer foods brands.Infloblox Inc plunged 48 percent to $17.22 after the network equipment maker estimated second-quarter revenue below analysts' average forecast.Cadence Pharmaceuticals Inc surged 26.2 percent to $13.97 after the company agreed to be acquired by specialty pharmaceuticals company Mallinckrodt Plc said for about $1.3 billion. Mallinckrodt climbed 11.3 percent to $66.01.",2014-02-11,CVS,"Tue Feb 11, 2014 | 10:37am EST",US STOCKS-Wall St advances as Yellen keeps Fed policy intact,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LG10B20140211?type=companyNews
13,"  * Yellen, new Fed chair, takes hot seat at Capitol* Yellen says labor market recovery far from complete* CVS climbs after results* Futures up: S&P 1.75 pts; Dow 26 pts; Nasdaq 8.5 ptsBy Chuck MikolajczakNEW YORK, Feb 11 U.S. stocks were set for a slightly higher open on Tuesday after Federal Reserve Chair Janet Yellen reinforced the Fed's plan to scale back its market-friendly stimulus while noting the health of the labor market needed to improve. In her first public comments as Fed chief, Yellen, giving a balanced testimony to a House committee, acknowledged recent volatility in global financial markets but said it did ""not pose a substantial risk to the U.S. economic outlook,"" and that she strongly supported the policy approach of her predecessor, Ben Bernanke.""Obviously it's all about Yellen today,"" said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.""We are setting ourselves up for what could be a volatile session if there are any negative surprises, by that I mean if she is not as dovish as the market may be expecting."" S&P 500 e-mini futures rose 1.75 points and were slightly above fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures  rose 26 points and Nasdaq 100 futures added 8.5 points.The central bank has cut its monthly bond-buying program by $10 billion at each of its last two meetings, reducing the total amount of purchases to $65 billion.Sprint Corp, the No. 3 U.S. mobile provider, reported an increase in quarterly revenue that was ahead of analysts' expectations and said it added wireless subscribers in the fourth quarter. The stock was up 7.2 percent to $8.24 in premarket trading. CVS Caremark Corp posted higher quarterly profit as it processed more prescriptions and benefited from the introduction of new generic drugs. The stock rose 1.9 percent to $68.24 in premarket trading.Of 345 companies in the S&P 500 that have reported earnings through Monday morning, 67.8 percent have beaten profit expectations, above the long-term average of 63 percent, according to Thomson Reuters data. Almost 66 percent have topped revenue forecasts, above the historical average of 61 percent.Conagra Foods lost 5.8 percent to $29.25 before the opening bell after the maker of Chef Boyardee pastas and Slim Jim beef jerky cut its full-year profit outlook, citing weaker profits in its private label business and lower sales of certain key brands in its consumer foods division.Infloblox Inc plunged 42.8 percent to $18.97 in premarket trading after the network equipment maker estimated second-quarter revenue below analysts' average forecast.Cadence Pharmaceuticals Inc surged 26.4 percent to $13.99 in premarket trading after the company agreed to be acquired by specialty pharmaceuticals company Mallinckrodt Plc  said for about $1.3 billion.",2014-02-11,CVS,"Tue Feb 11, 2014 | 9:15am EST",US STOCKS-Wall St to open slightly higher; Yellen testimony due,http://www.reuters.com//article/markets-usa-stocks-idUSL2N0LG0M320140211?type=companyNews
14,"  Feb 11 CVS Caremark Corp :  * Continues to expect a modest net positive benefit from health reform thisyear- presentation slides  * Says 96 percent retention rate in 2014 for pbm business - presentation slides  * Says specialty pharmacy revenue rose 22 percent in Q4- presentation slides  * Expects ""no further loss"" of business back to Walgreen Co  after resolution of Walgreen-Express Scripts Holding Co  fight -  presentation slides",2014-02-11,CVS,"Tue Feb 11, 2014 | 8:41am EST","BRIEF-CVS still expects  ""modest"" benefit from health reform in 2014",http://www.reuters.com//article/cvscaremark-results-idUSWEN00CIQ20140211?type=companyNews
15,"  Feb 11 CVS Caremark Corp on Tuesday posted higher quarterly profit as it processed more prescriptions and benefited from the introduction of new generic drugs.CVS, which operates the No. 2 U.S. drugstore chain and a major pharmacy benefits management business, earned $1.27 billion from continuing operations, or $1.05 per share, in the fourth quarter, up from $1.13 billion, or 90 cents per share, a year earlier.  Revenue rose 4.6 percent to $32.83 billion. Sales of general merchandise at stores open at least a year fell 1.9 percent as fewer shoppers came in to CVS' drugstores. ",2014-02-11,CVS,"Tue Feb 11, 2014 | 7:25am EST",CVS 4th-quarter profit rises on higher prescription volume,http://www.reuters.com//article/cvscaremark-results-idUSL2N0LF14C20140211?type=companyNews
16,"  By Jonathan StempelNEW YORK Feb 18 A divided federal appeals court on Tuesday strengthened the U.S. Securities and Exchange Commission's ability to recover insider trading profit from people who do not personally benefit directly from their alleged illegal trades.By a 2-1 vote, the 2nd U.S. Circuit Court of Appeals in New York said former Jefferies Group Inc portfolio manager Joseph Contorinis, convicted in 2010 of insider trading, must give up $7.26 million of alleged illegal profit that he made for the firm's Paragon Fund, plus $2.42 million in interest.""Whether the defendant's motive is direct economic profit, selfaggrandizement, psychic satisfaction from benefiting a loved one, or future profits by enhancing one's reputation as a successful fund manager, the insider trader who trades for another's account has engaged in a fraud, secured a benefit thereby, and directed the profits of the fraud where he has chosen them to go,"" Circuit Judge Gerard Lynch wrote for the majority.The decision could affect how much people convicted of insider trading on behalf of hedge funds may have to pay in related SEC civil cases. Many of these cases are in New York, which is part of the 2nd Circuit.""This is a huge decision, and ratchets up substantially the deterrent effect of prosecutions,"" James Cox, a law professor at Duke University, said in a phone interview.Contorinis, 49, is serving a six-year prison term following his October 2010 conviction for securities fraud and conspiracy over trades in supermarket chain Albertsons Inc ahead of its 2006 buyout by Supervalu Inc, CVS Corp and investors led by Cerberus Capital Management LP. Prosecutors said Contorinis' trades were based on tips from Nicos Stephanou, a friend and former banker at UBS AG, which was advising the Cerberus group on the buyout.U.S. District Judge Richard Sullivan in Manhattan, who oversaw the criminal and civil cases, previously ordered Contorinis to forfeit $427,875 in the criminal case. Tuesday's decision upheld the penalty in the SEC civil case.Roberto Finzi, a partner at Paul, Weiss, Rifkind, Wharton & Garrison who represents Contorinis, did not immediately respond to requests for comment. SEC spokesman John Nester said the regulator is pleased with the decision. 'NO INJUSTICE' In his appeal of the civil penalty, Contorinis said he should not have to give up, or disgorge, profit he made for Paragon because he did not personally control that profit.Writing for the 2nd Circuit majority, however, Lynch said there was ""no injustice"" in holding Contorinis liable, given that successful trading could boost his reputation and pay. Circuit Judge Denny Chin dissented. He said disgorgement is supposed to be remedial rather than punitive, and that ""while Contorinis undeniably deserved to be punished, disgorgement was not the proper mechanism.""Cox, the Duke professor, said ""the level of profits that could be subject to disgorgement by employees could be so huge that it would be seen as a punishment.""Stephanou pleaded guilty to securities fraud and conspiracy and testified against Contorinis. After spending 19 months in jail, Stephanou was sentenced by Sullivan to time served.According to the Federal Bureau of Prisons, Contorinis is housed at the Beckley prison complex in Beaver, West Virginia, and not eligible for release until December 2015.Jefferies is now part of Leucadia National Corp, and CVS is now known as CVS Caremark Corp.The case is SEC v. Contorinis, 2nd U.S. Circuit Court of Appeals, No. 12-1723.",2014-02-18,CVS,"Tue Feb 18, 2014 | 2:23pm EST",UPDATE 1-U.S. court boosts SEC's power to recoup insider trading profits,http://www.reuters.com//article/sec-insidertrading-contorinis-idUSL2N0LN1BH20140218?type=companyNews
17,"   By Jonathan Stempel | NEW YORK  NEW YORK Feb 18 A divided federal appeals court on Tuesday strengthened the U.S. Securities and Exchange Commission's ability to recover insider trading profit from people who do not personally benefit directly from their alleged illegal trades.By a 2-1 vote, a panel of the 2nd U.S. Circuit Court of Appeals in New York said former Jefferies Group Inc portfolio manager Joseph Contorinis must give up $7.26 million of alleged illegal profit that he made for the firm's Paragon Fund, plus $2.42 million in interest, in an SEC civil forfeiture case.""Whether the defendant's motive is direct economic profit, selfaggrandizement, psychic satisfaction from benefiting a loved one, or future profits by enhancing one's reputation as a successful fund manager, the insider trader who trades for another's account has engaged in a fraud, secured a benefit thereby, and directed the profits of the fraud where he has chosen them to go,"" Circuit Judge Gerard Lynch wrote.The decision could have an impact on how much people convicted of insider trading on behalf of hedge funds may have to pay in related SEC civil cases. Many of these cases are in New York, which is part of the 2nd Circuit.Contorinis, 49, is serving a six-year prison term following his October 2010 conviction for securities fraud and conspiracy over trades in supermarket chain Albertsons Inc ahead of its 2006 buyout by Supervalu Inc, CVS Corp and investors led by Cerberus Capital Management LP. U.S. District Judge Richard Sullivan in Manhattan, who oversaw the criminal and civil cases, previously ordered Contorinis to forfeit $427,875 in the criminal case. Tuesday's decision upheld the penalty in the SEC case.Roberto Finzi, a partner at Paul, Weiss, Rifkind, Wharton & Garrison who represents Contorinis, did not immediately respond to a request for comment. SEC spokesman John Nester said the regulator is pleased with the decision.Prosecutors said Contorinis' trades were based on tips from Nicos Stephanou, a friend and former banker at UBS AG, which was advising the Cerberus group on the buyout. In his appeal of the civil penalty, Contorinis said he should not have to give up, or ""disgorge,"" profit he made for Paragon because he did not personally control that profit.Writing for the 2nd Circuit, however, Lynch said there was ""no injustice"" in holding Contorinis civilly liable, given how successful trading could boost his reputation and pay. Circuit Judge Denny Chin dissented. He said disgorgement is supposed to be remedial rather than punitive, and that ""while Contorinis undeniably deserved to be punished, disgorgement was not the proper mechanism.""Stephanou pleaded guilty to securities fraud and conspiracy charges and testified against Contorinis. After spending 19 months in jail, Stephanou was sentenced by Sullivan to time served.According to the Federal Bureau of Prisons, Contorinis is housed at the Beckley prison complex in Beaver, West Virginia, and not eligible for release until December 2015.Jefferies is now part of Leucadia National Corp, and CVS is now known as CVS Caremark Corp.The case is SEC v. Contorinis, 2nd U.S. Circuit Court of Appeals, No. 12-1723.",2014-02-18,CVS,"Tue Feb 18, 2014 | 12:52pm EST",Ex-Jefferies manager loses appeal in SEC insider trading case,http://www.reuters.com//article/sec-insidertrading-contorinis-idUSL2N0LN0VC20140218?type=companyNews
18,"  March 6 Safeway Inc, the second-largest U.S. mainstream grocery store operator, said private equity firm Cerberus Capital Management would acquire the company in a deal valued at about $9.4 billion.The offer price of $40 per share represents a premium of 1.3 percent to Safeway's Thursday closing stock price of $39.47 on the New York Stock Exchange.The deal combines Safeway with Cerberus' Albertsons chain, creating a dominant grocery franchise on the West Coast. It also creates a grocery network of more than 2,400 stores and 250,000 employees.No store closures are expected, according to the company.Safeway shareholders will receive $32.50 per share in cash plus other distributions with a value of $3.65 per share. Cerberus is a seasoned investor in the supermarket sector. Last March, a Cerberus-led investor group acquired a group of grocery chains from Supervalu Inc, including Albertsons and Jewel-Osco, for $3.3 billion.Cerberus previously owned 650 Albertsons locations as a result of a 2006 deal under which the chain was acquired and its stores broken up between the private equity investor, Supervalu and CVS Caremark Corp. Safeway has been in the hands of private equity before. KKR & Co LP took Safeway private in 1986, and then sold its stake in 1999.Safeway has been trying to streamline its business by selling off non-core units. Last year, it spun off its gift card provider, Blackhawk Network Holdings Inc, into a separate publicly traded company.It also sold off its Canadian business to the operator of Canadian retailer Sobeys for $5.8 billion in cash. More recently, Safeway has revealed plans to leave the Chicago market by early this year. That announcement came after activist investor Jana Partners pressured the company to review strategic alternatives, including exiting weak markets.Reuters first reported that Cerberus was exploring a buyout of Safeway last October.Goldman Sachs Group Inc and Greenhill & Co Inc  advised Safeway on the transaction. Latham & Watkins LLP served as outside counsel.Citigroup Inc, Bank of America Corp and Credit Suisse AG advised Albertsons, Cerberus and its investor group.",2014-03-06,CVS,"Thu Mar 6, 2014 | 5:50pm EST",UPDATE 1-Cerberus Capital to buy Safeway for about $9.4 bln,http://www.reuters.com//article/safeway-inc-mergers-idUSL3N0M356520140306?type=companyNews
19,"   By Victoria Cavaliere  Residents of southern California were rattled by a 4.1 magnitude earthquake Saturday afternoon, the largest of more than 100 aftershocks following Friday's 5.1 rumbler that caused light scattered damage around the Los Angeles area.Saturday's quake rippled through an area near Rowland Heights, California, about 2:32 p.m., according to the U.S. Geological Survey. The temblor was considered relatively shallow with a depth of 5.6 miles, the USGS said.Aftershocks are expected following earthquakes, according to the USGS. Seismologists said there was about a 5 percent chance that Friday's quake, which struck at 9:09 p.m., was a foreshock to a bigger temblor.No injuries were immediately reported from either Saturday's quake or the more significant earthquake that struck Friday evening outside La Habra, California, which is about 20 miles east of downtown Los Angeles. Friday's temblor displaced at least 50 people in Fullerton, about 5 miles from the epicenter, because of minor damage to homes and apartment dwellings, Fullerton Police Lieutenant Mike Chlebowski said.As well, a water main break in the city forced the closure of some streets due to flooding, he said.The quake also shook items off tables, rattled chandeliers and resulted in scattered damage to cars and property, including setting off a rockslide in the Orange County city of Brea that flipped a car on its roof. Friday's quake was felt as far away as Palm Springs in the east, San Diego in the south and Ventura County to the north. While not large, the event ""seems unusual, of course, because a lot of people felt it,"" said Doug Given, a USGS geophysicist.""These quakes occur in populated areas and people try to put two and two together and predict that something more is coming, but that's simply not the case,"" he said. The quake shut down Metrolink trains to allow for inspection of tracks and cars. In Anaheim, Disneyland briefly turned off park rides as a precaution and asked guests to remain seated.But the Los Angeles Philharmonic didn't miss a note even as the quake rattled downtown Los Angeles's Walt Disney Concert Hall, The Los Angeles Times reported.""The L.A. Philharmonic should get combat pay,"" audience member Michael Healy told the newspaper.(Reporting by Victoria Cavaliere and Carey Gillam; Editing by Cynthia Johnston, James Dalgleish and Cynthia Osterman)",2014-03-29,CVS,"Sat Mar 29, 2014 | 6:46pm EDT",Another earthquake rattles southern California following 5.1 quake,http://www.reuters.com//article/us-earthquake-california-idUSBREA2S03H20140329?type=companyNews
20,"   By Jonathan Stempel  CVS Caremark Corp, the second largest U.S. drugstore chain, will pay $20 million to settle U.S. Securities and Exchange Commission charges that it defrauded investors in 2009 during a debt offering and by accounting improperly for an acquisition.The SEC, which announced the settlement on Tuesday, said CVS failed to disclose while marketing $1.5 billion of bonds in September 2009 having recently lost significant Medicare and contract revenue streams in its pharmacy benefits manager (PBM) business, including from the former Caremark Rx Inc that it bought in March 2007.After CVS disclosed the problems on November 5, 2009, which resulted in a 20-percent plunge in its share price, the company further misled investors by manipulating its ""retention rate,"" thereby inflating its ability to retain business, the SEC said.CVS was also accused of having in November 2009 manipulated accounting for its October 2008 purchase of Longs Drug Stores Corp. The SEC said the changes improperly boosted profit by as much as 11.7 cents per share for the third quarter of 2009, enabling CVS to exceed rather than miss analyst forecasts. ""CVS broke faith with investors,"" Andrew Ceresney, director of the SEC enforcement division, said in a statement. ""The intentional misconduct by CVS breached the core principle of fair and accurate reporting of financial performance.""The Woonsocket, Rhode Island-based company did not admit or deny wrongdoing in agreeing to settle, and on Tuesday said it is not restating any financial results.Separately, the SEC said Laird Daniels, CVS' senior vice president for international operations and business development, agreed to pay $75,000 and accept a one-year accounting ban to settle related charges over the Longs accounting. He also did not admit or deny wrongdoing. In court papers, the SEC said Daniels, who in 2009 was a CVS retail controller, characterized the accounting changes as turning the Longs purchase into a ""good guy"" rather than a ""bad guy"" for CVS, referring to its impact on profitability.Daniels, 44, lives in North Attleboro, Massachusetts, the SEC said. His lawyer Robert Cleary, a partner at Proskauer Rose specializing in white collar defense, declined to comment. A shareholder lawsuit against CVS over the PBM disclosures remains pending in a federal court in Providence, Rhode Island.The SEC's evidence ""confirms our allegations about the PBM business and that the wrongful conduct was occurring at least since year-end 2008,"" Joseph Fonti, a partner at Labaton Sucharow representing the shareholders, said in an interview.The cases are SEC v CVS Caremark Corp, U.S. District Court, District of Rhode Island, No. 14-00177; and In re: Daniels, SEC Administrative Proceeding No. 3-15825.(Reporting by Jonathan Stempel in New York; Additional reporting by Alison Frankel; Editing by Alden Bentley)",2014-04-08,CVS,"Tue Apr 8, 2014 | 3:54pm EDT",CVS to pay $20 million to settle SEC fraud charges,http://www.reuters.com//article/us-cvscaremark-sec-settlement-idUSBREA371L020140408?type=companyNews
21,"  (Adds lawyer comment)By Jonathan StempelApril 8 CVS Caremark Corp, the second largest U.S. drugstore chain, will pay $20 million to settle U.S. Securities and Exchange Commission charges that it defrauded investors in 2009 during a debt offering and by accounting improperly for an acquisition.The SEC, which announced the settlement on Tuesday, said CVS failed to disclose while marketing $1.5 billion of bonds in September 2009 having recently lost significant Medicare and contract revenue streams in its pharmacy benefits manager (PBM) business, including from the former Caremark Rx Inc that it bought in March 2007.After CVS disclosed the problems on Nov. 5, 2009, which resulted in a 20-percent plunge in its share price, the company further misled investors by manipulating its ""retention rate,"" thereby inflating its ability to retain business, the SEC said. CVS was also accused of having in November 2009 manipulated  accounting for its October 2008 purchase of Longs Drug Stores Corp. The SEC said the changes improperly boosted profit by as much as 11.7 cents per share for the third quarter of 2009, enabling CVS to exceed rather than miss analyst forecasts.""CVS broke faith with investors,"" Andrew Ceresney, director of the SEC enforcement division, said in a statement. ""The intentional misconduct by CVS breached the core principle of fair and accurate reporting of financial performance.""The Woonsocket, Rhode Island-based company did not admit or deny wrongdoing in agreeing to settle, and on Tuesday said it is not restating any financial results. Separately, the SEC said Laird Daniels, CVS' senior vice president for international operations and business development, agreed to pay $75,000 and accept a one-year accounting ban to settle related charges over the Longs accounting. He also did not admit or deny wrongdoing.In court papers, the SEC said Daniels, who in 2009 was a CVS retail controller, characterized the accounting changes as turning the Longs purchase into a ""good guy"" rather than a ""bad guy"" for CVS, referring to its impact on profitability. Daniels, 44, lives in North Attleboro, Massachusetts, the SEC said. His lawyer Robert Cleary, a partner at Proskauer Rose specializing in white collar defense, declined to comment.A shareholder lawsuit against CVS over the PBM disclosures remains pending in a federal court in Providence, Rhode Island.The SEC's evidence ""confirms our allegations about the PBM business and that the wrongful conduct was occurring at least since year-end 2008,"" Joseph Fonti, a partner at Labaton Sucharow representing the shareholders, said in an interview.The cases are SEC v CVS Caremark Corp, U.S. District Court, District of Rhode Island, No. 14-00177; and In re: Daniels, SEC Administrative Proceeding No. 3-15825.   (Reporting by Jonathan Stempel in New York; Additional reporting by Alison Frankel; Editing by Alden Bentley)",2014-04-08,CVS,"Tue Apr 8, 2014 | 3:53pm EDT",UPDATE 2-CVS to pay $20 mln to settle SEC fraud charges,http://www.reuters.com//article/cvscaremark-sec-settlement-idUSL2N0N019620140408?type=companyNews
22,"  April 8 CVS Caremark Corp agreed to pay $20 million to settle U.S. Securities and Exchange Commission charges that it misled investors about significant financial setbacks and used improper accounting to artificially boost its results.The Woonsocket, Rhode Island-based company did not admit or deny wrongdoing in agreeing to settle.  CVS operates the second-largest U.S. drugstore chain.   (Reporting by Jonathan Stempel in New York) ",2014-04-08,CVS,"Tue Apr 8, 2014 | 1:22pm EDT",CVS to pay $20 mln to settle SEC charges,http://www.reuters.com//article/cvscaremark-sec-settlement-idUSL2N0N018220140408?type=companyNews
23,"  April 8 CVS Caremark Corp :  * SEC files civil lawsuit against CVS Caremark Corp  over allegedmisleading disclosures in 2009-2010, inappropriate accounting in 2009 --court filing  * SEC says accuses CVS of materially incompete and misleading disclosures regarding expected results in its pharmacy benefits manager business for 2010  * SEC says accuses CVS of inappropriate accounting treatment for acquisition ofchain of drugstores, causing retail operating results to be materially overstated in Q3 2009  * SEC says CVS agrees to pay $20 million to settle charges  * SEC says CVS neither admitted nor denied the allegations  * SEC says former CVS retail controller laird daniels, who it accused of improper accounting adjustments, to pay $75,000 penalty in relatedsettlement, also without admitting wrongdoing",2014-04-08,CVS,"Tue Apr 8, 2014 | 1:12pm EDT","BRIEF-CVS to pay $20 mln to settle SEC case over disclosures, accounting",http://www.reuters.com//article/cvscaremark-brief-idUSWEN00CUN20140408?type=companyNews
24,"   By Phil Wahba  CVS Caremark Corp (CVS.N) reported a weaker-than-expected quarterly profit on Friday on a sharp drop in sales of general merchandise, which the drugstore chain blamed on a harsh winter, milder flu season and aggressive competition.Sales of merchandise sold at the front of its stores open at least a year, such as toothpaste and snacks, fell 3.8 percent in the first quarter, a sharper drop than those at rivals Walgreen Co WAG.N and Rite Aid Corp (RAD.N).""We continued to see an increase in both the breadth and depth of promotional activity out in the marketplace,"" CVS Chief Executive Officer Larry Merlo told analysts on a conference call. CVS shares were down 1.4 percent to $72.05 in premarket trading as the company reported what analysts at Guggenheim Partners said was its first earnings miss in ""at least three years.""CVS, which operates the No. 2 U.S. drugstore chain and a major pharmacy benefits management business, earned $1.13 billion, or 95 cents per share, in the quarter, up from $954 million, or 77 cents per share, a year earlier. Adjusted profit, which factors in acquisitions and other times, was $1.02 per share, 2 cents below analysts' estimates, according to Thomson Reuters I/B/E/S.Total revenue rose 6.3 percent to $32.69 billion. CVS Caremark stuck to its 2014 profit forecast, still expecting an adjusted profit of $4.36 to $4.50 per share.Revenue in its pharmacy services segment rose 10.3 percent to $20.2 billion. The company noted in slides posted on its website that more potential customers are seeking requests for proposals, suggesting the business was getting more competitive.(Reporting by Phil Wahba in New York; Editing by Lisa Von Ahn and Jeffrey Benkoe)",2014-05-02,CVS,"Fri May 2, 2014 | 9:21am EDT",CVS profit misses as general merchandise sales fall,http://www.reuters.com//article/us-cvscaremark-results-idUSBREA410BC20140502?type=companyNews
25,"  (Adds details on PBM contracts, analyst, CEO comments, stock price)By Phil WahbaMay 2 CVS Caremark Corp reported a weaker-than-expected quarterly profit on Friday on a sharp drop in sales of general merchandise, which the drugstore chain blamed on a harsh winter, milder flu season and aggressive competition.Sales of merchandise sold at the front of its stores open at least a year, such as toothpaste and snacks, fell 3.8 percent in the first quarter, a sharper drop than those at rivals Walgreen Co and Rite Aid Corp. ""We continued to see an increase in both the breadth and depth of promotional activity out in the marketplace,"" CVS Chief Executive Officer Larry Merlo told analysts on a conference call.CVS shares were down 1.4 percent to $72.05 in premarket trading as the company reported what analysts at Guggenheim Partners said was its first earnings miss in ""at least three years."" CVS, which operates the No. 2 U.S. drugstore chain and a major pharmacy benefits management business, earned $1.13 billion, or 95 cents per share, in the quarter, up from $954 million, or 77 cents per share, a year earlier.Adjusted profit, which factors in acquisitions and other times, was $1.02 per share, 2 cents below analysts' estimates, according to Thomson Reuters I/B/E/S. Total revenue rose 6.3 percent to $32.69 billion.CVS Caremark stuck to its 2014 profit forecast, still expecting an adjusted profit of $4.36 to $4.50 per share.Revenue in its pharmacy services segment rose 10.3 percent to $20.2 billion. The company noted in slides posted on its website that more potential customers are seeking requests for proposals, suggesting the business was getting more competitive.   (Reporting by Phil Wahba in New York; Editing by Lisa Von Ahn and Jeffrey Benkoe)",2014-05-02,CVS,"Fri May 2, 2014 | 9:20am EDT",UPDATE 1-CVS profit misses as general merchandise sales fall,http://www.reuters.com//article/cvscaremark-results-idUSL2N0NO0IT20140502?type=companyNews
26,"  NEW YORK CVS Caremark Corp (CVS.N) said on Friday it expects revenue in its Caremark pharmacy benefits management (PBM) unit to rise between 8.75 percent and 10 percent this year.In presentation slides released ahead of a conference call, the company said its new PBM contracts secured this year have risen to $3 billion.  (Reporting by Phil Wahba in New York, Editing by Franklin Paul) ",2014-05-02,CVS,"Fri May 2, 2014 | 8:52am EDT",CVS Caremark sees PBM revenue growth of 8.75-10 percent,http://www.reuters.com//article/us-cvscarmark-results-idUSBREA410ET20140502?type=companyNews
27,"  NEW YORK May 2 CVS Caremark Corp said on Friday it expects revenue in its Caremark pharmacy benefits management (PBM) unit to rise between 8.75 percent and 10 percent this year.In presentation slides released ahead of a conference call, the company said its new PBM contracts secured this year have risen to $3 billion.  (Reporting by Phil Wahba in New York, Editing by Franklin Paul) ",2014-05-02,CVS,"Fri May 2, 2014 | 8:48am EDT",CVS Caremark sees PBM revenue growth of 8.75-10 pct,http://www.reuters.com//article/cvscarmark-results-pharm-benefits-idUSL2N0NO0I120140502?type=companyNews
28,"  May 2 CVS Caremark Corp on Friday posted a higher quarterly profit as its pharmacy benefits business won new clients and the company benefited from the introduction of new generic drugs.CVS, which operates the No. 2 U.S. drugstore chain and a major pharmacy benefits management business, earned $1.13 billion, or 95 cents per share, in its first quarter, up from $954 million, or 77 cents per share, a year earlier.  Revenue in the quarter ended March 31 rose 6.3 percent to $32.69 billion. Sales of general merchandise at stores open at least a year fell 3.8 percent as weather impeded shoppers.    (Reporting by Phil Wahba in New York; Editing by Lisa Von Ahn) ",2014-05-02,CVS,"Fri May 2, 2014 | 7:22am EDT",CVS Caremark quarterly profit rises,http://www.reuters.com//article/cvscaremark-results-idUSL2N0NN1PD20140502?type=companyNews
29,"  (Repeats Friday item)* Barclays pares back ambitions to be Wall Street powerhouse* Jenkins doesn't expect talent exodus after U.S. departures* Traders spruce up their CVs, talk to headhunters - source* Barclays to remain largest investment bank in EuropeBy Steve SlaterLONDON, May 9 Where Barclays sees a ""generational shift"", its investment bank rivals are smelling blood.The British bank, which under former chief Bob Diamond poached top staff and customers from competitors in trouble after the financial crisis, now risks suffering the same fate as it radically shrinks its investment banking business.Diamond's successor as Chief Executive, Antony Jenkins, says he does not expect a further exodus of top talent after departures from Barclays' U.S. operation, but some trading staff at least are preparing for the exit as the bank pares back its ambitions to be a Wall Street powerhouse.Barclays announced this week plans to shrink its debt trading business and axe a quarter of staff, focusing instead on U.S. and British clients and products where it ranks in the top five in business such as selling government bonds, stocks and currencies and advising on deals.Tom King, who made his career advising telecoms firms on takeover battles, is tasked with making the strategy work and hailed it as a ""step change"" that was needed in a new era of tougher regulations that have made some trades too expensive.""We're really shifting the investment bank from one that was a business run for revenue to one that is being run for return,"" King said on Thursday.The worry for Jenkins and King is that top staff and clients leave and the business slowly dies, echoing the problems of Credit Suisse First Boston when it bought Donaldson, Lufkin and Jenrette for $11 billion in 2000, only for many senior bankers there to depart.Jenkins, who previously ran Barclays' retail business and has no background in investment banking, admitted he feared a ""death spiral"" after an exodus of staff from its U.S. business last year. This prompted him controversially to raise bonuses for 2013 despite a fall in profits. King himself left Citigroup for Barclays in 2009 because the bailed out U.S. group was scaling back its investment bank while Barclays, under former debt trader Diamond, was vowing to take on Wall Street after its takeover of the U.S. division of Lehman Brothers.Even before Thursday's announcement, the atmosphere among Barclays' dealers was grim. People who feared the chop were already arriving to work late and leaving early, spending the time in-between sprucing up their CVs and talking to headhunters, said one person within the bank.""Whenever this sort of thing happens the best people will be getting a lot of inbound calls. This won't be any different,"" said a senior banker at a rival.FREEING UP THE TOP FLOORS Jenkins wants his bank to be more balanced and with lower costs to boost profitability.Cutting thousands of jobs could save the bank more than 1 billion pounds ($1.7 billion) a year based on average pay. Winding down large parts of its trading book will help to reduce the investment bank's use of capital to 30 percent by 2016 from 51 percent last year. The result will be a dismantling of much of the bond trading  powerhouse built up by Diamond in the decade prior to the 2008/09 financial crisis. Much of the former Lehman business, which includes the U.S. equities and advisory desks, will stay at the heart of the smaller firm.For Barclays, that means focusing on its strong ""home"" markets of the United States and Britain, which account for 60 percent of global market business. It will cut back hard in Asia, largely serving only big clients' needs there and Asian customers who want help on overseas deals.There have already been a series of high profile departures in the United States, including Hugh 'Skip' McGee, the head of its Americas business who was the most senior ex-Lehman banker. The bank also lost Ros Stephenson, Paul Parker and Larry Wieseneck.""I'm not concerned at all about the level of departures. What we're seeing is a something of a generational shift,"" Jenkins said on Thursday as he unveiled his plan.""We're seeing some of the senior leadership saying it's the right time for them to move on,"" he said. ""We're seeing low levels of attrition in the people that are going to be running the bank going forward, the next generation of MDs.""Senior sources at the bank concurred, and said many of the senior people had left after missing out on the top job taken by King, a U.S. native who moved to London for a couple of years in 1999 and stayed for over a decade. He is now based in New York. Industry sources said this is part of a wider trend in the industry. ""I feel that banks are in a mode to reduce the senior level,"" a source at another bank said. ""The only way to protect and promote the mid-level talent is by freeing up the top.""Barclays has said it plans to cut 7,000 investment bank jobs in the next three years, with about 2,000 of those this year.It plans to put 340 billion pounds of investment bank assets into a new ""non-core"" unit where they will be run down, so whole teams will be cut. Staff in those areas that the bank wants to keep may have bonuses based on hitting asset reduction targets - something which UBS did as it shrank its business after a bailout by the Swiss state.At Barclays, Eric Bommensath - the former fixed income boss who became co-head of the investment bank with King a year ago - is in charge of the non-core business and no longer sits on the executive committee.CUTTING COSTS Barclays faces risks in carrying out its plan. It will  ""meaningfully reduce"" the number of clients, with most focus on the top 1,000 who deliver 75 percent of the investment bank's revenues.The investment bank will also still be left with 490 billion pounds of assets. While smaller than U.S. players such as JP Morgan, it will remain the largest investment bank in Europe with more assets than the ""core"" businesses of Deutsche Bank and Credit Suisse after they also pruned operations.Barclays is exiting most commodities business and is likely to retreat from areas including emerging markets and interest rate trading products, structured products, securitisation and cross currency swaps.Areas where the bank is strong - such as rates in the G10 leading economies, foreign exchange and credit trading and debt capital markets - will be less affected. It is also sticking with its equities and advisory operations, which have expanded in the last three years, require less capital and appear set for yet stronger growth.Bankers said that while Barclays lags some rivals with its plans, it won't be the last to take radical action.""In the next year or two, more people will shrink or pull out. We've not seen anything meaningful other than UBS and RBS. Deutsche is going through some change and now Barclays, but there's still a lot more to come,"" a senior rival banker said.""It's a painful process. The key questions are where do you pick your spots, and you need to be disciplined.""   ($1 = 0.5899 British Pounds)   (Additional reporting by Clare Hutchison, So-young Kim, Lawrence White and Katharina Bart; Editing by Carmel Crimmins and David Stamp)",2014-05-12,CVS,"Mon May 12, 2014 | 3:02am EDT","RPT-Barclays sees generational shift, rivals smell blood",http://www.reuters.com//article/barclays-investmentbank-idUSL6N0NY1DV20140512?type=companyNews
30,"  SAO PAULO A formal bid by CVS Caremark Corp (CVS.N) to purchase Brazilian drugstore firm DPSP has been rejected by the company, a Brazilian news website reported on Thursday.News magazine Exame said CVS had made a formal bid to purchase DPSP for about 4.5 billion reais ($2 billion).U.S.-based CVS is being advised by local investment firm Patria Investimentos, while DPSP hired Morgan Stanley (MS.N) to help advise in the negotiations, according to Exame. Last year, CVS purchased Drogaria Onofre, Brazil's eighth-largest drugstore chain by sales, in its first international venture. Brazil's pharmacy industry has in recent years seen a surge of mergers and acquisitions as the country's middle class grew. DPSP, which includes the Drogaria Sao Paulo and Pacheco chains, is Brazil's third-largest drugstore operator by number of stores according to the Abramafa pharmacy association, with 840 stores in 80 cities. It trails Raia Drogasil and Brasil Pharma. Representatives for DPSP said the company would not confirm the report, while representatives for Patria Investimentos declined to comment. CVS's public relations director also declined to comment and Morgan Stanley in Brazil did not immediately respond to request for comment.(Reporting by Asher Levine and Alberto Alerigi Jr; Editing by G Crosse and Andrea Ricci)",2014-05-22,CVS,"Thu May 22, 2014 | 4:51pm EDT",Brazil drugstore firm rejects $2 billion offer from CVS: report,http://www.reuters.com//article/us-brazil-cvs-care-idUSBREA4L14120140522?type=companyNews
31,"  (Adds CVS declining to comment)SAO PAULO May 22 A formal bid by CVS Caremark Corp to purchase Brazilian drugstore firm DPSP has been rejected by the company, a Brazilian news website reported on Thursday.News magazine Exame said CVS had made a formal bid to purchase DPSP for about 4.5 billion reais ($2 billion). U.S.-based CVS is being advised by local investment firm Patria Investimentos, while DPSP hired Morgan Stanley to help advise in the negotiations, according to Exame.Last year, CVS purchased Drogaria Onofre, Brazil's eighth-largest drugstore chain by sales, in its first international venture. Brazil's pharmacy industry has in recent years seen a surge of mergers and acquisitions as the country's middle class grew. DPSP, which includes the Drogaria Sao Paulo and Pacheco chains, is Brazil's third-largest drugstore operator by number of stores according to the Abramafa pharmacy association, with 840 stores in 80 cities. It trails Raia Drogasil and Brasil Pharma. Representatives for DPSP said the company would not confirm the report, while representatives for Patria Investimentos declined to comment. CVS's public relations director also declined to comment and Morgan Stanley in Brazil did not immediately respond to request for comment.($1 = 2.217 Brazilian reais)   (Reporting by Asher Levine and Alberto Alerigi Jr; Editing by G Crosse and Andrea Ricci)",2014-05-22,CVS,"Thu May 22, 2014 | 4:48pm EDT",UPDATE 2-Brazil drugstore firm rejects $2 bln offer from CVS -report,http://www.reuters.com//article/brazil-cvs-care-idUSL1N0O81U620140522?type=companyNews
32,"  SAO PAULO May 22 CVS Caremark Corp made a formal bid to purchase Brazilian drugstore firm DPSP for about 4.5 billion reais ($2  billion), though the offer was rejected, a Brazilian news website reported on Thursday.DPSP, which includes the Drogaria Sao Paulo and Pacheco chains, is Brazil's third-largest drugstore operator by number of stores, the website of Brazilian news magazine Exame said.CVS is being advised by local investment firm Patria Investimentos, while DPSP hired Morgan Stanley to help advise in the negotiations, the report added. Press representatives for DPSP said the company would not confirm the report, while representatives for Patria Investimentos declined to comment. Press representatives for CVS in the United States and Morgan Stanley in Brazil did not immediately respond to requests for comment. ($1 = 2.217 Brazilian reais)   (Reporting by Asher Levine and Alberto Alerigi Jr.)",2014-05-22,CVS,"Thu May 22, 2014 | 3:16pm EDT",CVS makes $2 bln offer for Brazilian drugstore firm -report,http://www.reuters.com//article/brazil-cvs-care-idUSL1N0O81RB20140522?type=companyNews
33,"   By Verna, Gates and David Adams | BIRMINGHAM Ala.  BIRMINGHAM Ala. The Alabama Supreme Court on Friday allowed a class action lawsuit seeking more than $3 billion to go forward against CVS Health Corp and several insurance companies, affirming the ruling by a lower court which said the plaintiffs could be certified as a class.The case dates back to a 1999 class action settlement for $56 million over alleged accounting fraud at MedPartners, a physician and pharmacy benefits management corporation. CVS Health could not be reached for comment.MedPartners became Caremark and merged in 2007 with CVS, now known as CVS Health. In 2003, Alabama attorneys filed a lawsuit on behalf of a stockholder John Lauriello, alleging fraudulent insurance information was given in court by MedPartners and its insurers. The plaintiffs allege that MedPartners and its insurers hid the fact that unlimited insurance coverage was available at the time of the initial class action in 1998, enabling them to settle for $56 million, instead of $3 billion in stockholder losses, according to court documents.The 48-page opinion from the Alabama Supreme Court affirmed a Jefferson County Circuit Judge's 2013 order certifying the case as a class action.",2014-09-13,CVS,"Fri Sep 12, 2014 | 9:16pm EDT",Alabama court lets class action lawsuit against CVS Health proceed,http://www.reuters.com//article/us-cvs-health-classaction-idUSKBN0H801M20140913?type=companyNews
34,"  BIRMINGHAM, Ala., Sept 12 The Alabama Supreme Court on Friday allowed a class action lawsuit seeking more than $3 billion to go forward against CVS Health Corp and several insurance companies, affirming the ruling by a lower court which said the plaintiffs could be certified as a class.The case dates back to a 1999 class action settlement for $56 million over alleged accounting fraud at MedPartners, a physician and pharmacy benefits management corporation.CVS Health could not be reached for comment. MedPartners became Caremark and merged in 2007 with CVS, now known as CVS Health. In 2003, Alabama attorneys filed a lawsuit on behalf of a stockholder John Lauriello, alleging fraudulent insurance information was given in court by MedPartners and its insurers. The plaintiffs allege that MedPartners and its insurers hid the fact that unlimited insurance coverage was available at the time of the initial class action in 1998, enabling them to settle for $56 million, instead of $3 billion in stockholder losses, according to court documents.The 48-page opinion from the Alabama Supreme Court affirmed a Jefferson County Circuit Judge's 2013 order certifying the case as a class action.   (Reporting by Verna Gates; Writing by David Adams; Editing by Lisa Shumaker)",2014-09-13,CVS,"Fri Sep 12, 2014 | 9:02pm EDT",Alabama court lets class action lawsuit against CVS Health proceed,http://www.reuters.com//article/cvs-health-classaction-idUSL1N0RE00720140913?type=companyNews
35,"  Over the last several months there has been a 'plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000-a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed.The study, encompassing data from May through August 2014, suggests that another surge of patients will begin therapy when newer treatments of similar effectiveness and shorter duration are introduced later in the year. U.S. health regulators are due to decide by Oct. 10 whether to approve a new treatment, a pill that combines Sovaldi with the experimental therapy ledipasvir and eliminates the need for other treatments. The research revealed Sovaldi therapy discontinuation rates of 8.1 percent, approximately four times higher than those in trials, CVS said on Wednesday. Patients who were completely new to Hepatitis C treatment were also more likely to discontinue therapy, the study found. The CVS Health Research Institute analyzed discontinuation rates for nearly 2,000 patients who filled prescriptions for Sovaldi since December. The patients were managed by CVS Caremark, the CVS Health pharmacy benefit management business.Hepatitis C kills more than 15,000 Americans each year, mostly from illnesses such as cirrhosis and liver cancer, according to the U.S. Centers for Disease Control and Prevention.  (Reporting by Natalie Grover in Bangalore; Editing by Simon Jennings)",2014-09-17,CVS,"Wed Sep 17, 2014 | 8:41am EDT",Study shows downward trend in Sovaldi utilization,http://www.reuters.com//article/us-gilead-sciences-study-idUSKBN0HC19620140917?type=companyNews
36,"  Sept 17 Over the last several months there has been a 'plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000-a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed.The study, encompassing data from May through August 2014, suggests that another surge of patients will begin therapy when newer treatments of similar effectiveness and shorter duration are introduced later in the year.U.S. health regulators are due to decide by Oct. 10 whether to approve a new treatment, a pill that combines Sovaldi with the experimental therapy ledipasvir and eliminates the need for other treatments. The research revealed Sovaldi therapy discontinuation rates of 8.1 percent, approximately four times higher than those in trials, CVS said on Wednesday. Patients who were completely new to Hepatitis C treatment were also more likely to discontinue therapy, the study found. The CVS Health Research Institute analyzed discontinuation rates for nearly 2,000 patients who filled prescriptions for Sovaldi since December. The patients were managed by CVS Caremark, the CVS Health pharmacy benefit management business.Hepatitis C kills more than 15,000 Americans each year, mostly from illnesses such as cirrhosis and liver cancer, according to the U.S. Centers for Disease Control and Prevention.   (Reporting by Natalie Grover in Bangalore; Editing by Simon Jennings)",2014-09-17,CVS,"Wed Sep 17, 2014 | 8:38am EDT",Study shows downward trend in Sovaldi utilization,http://www.reuters.com//article/gilead-sciences-study-idUSL3N0RI40S20140917?type=companyNews
37,"   By Jonathan Stempel  Caremark LLC, a unit of CVS Health Corp, will pay $6 million to settle U.S. allegations that it knowingly failed to reimburse Medicaid for prescription drug costs paid on behalf of patients who were also covered by private health plans it administered.The settlement announced on Friday by the U.S. Department of Justice resolves claims that Caremark, a pharmacy benefits management company, violated the federal False Claims Act by improperly processing claims of such ""dual eligible"" patients.Donald Well, a former Caremark employee who brought the case to the government's attention, will receive $1.02 million plus interest under the law's whistleblower provisions. CVS spokeswoman Christine Cramer said the Woonsocket, Rhode Island-based company settled to avoid protracted litigation, and denied wrongdoing. She also said the accord does not involve its pharmacy or Medicare Part D businesses. Caremark is a pharmacy benefits manager for private health plans that insured some patients who also had Medicaid coverage. Medicaid can seek reimbursement from private insurers or their pharmacy benefits managers if it pays prescription drug claims of such patients in error.The government said a Caremark computer platform improperly deducted co-payments or other sums when calculating payments on some claims. It said this caused Medicaid to cover prescription drug costs for dual eligible patients that should have been borne by Caremark-administered private health plans.      (eporting by Jonathan Stempel in New York; Editing by Chizu Nomiyama. Editing by Andre Grenon)",2014-09-26,CVS,"Fri Sep 26, 2014 | 1:38pm EDT",CVS' Caremark unit settles U.S. false claims allegations,http://www.reuters.com//article/us-cvshealth-caremark-settlement-idUSKCN0HL1Z720140926?type=companyNews
38,"  (Adds allegations, whistleblower details, CVS comment, byline)By Jonathan StempelSept 26 Caremark LLC, a unit of CVS Health Corp , will pay $6 million to settle U.S. allegations that it knowingly failed to reimburse Medicaid for prescription drug costs paid on behalf of patients who were also covered by private health plans it administered. The settlement announced on Friday by the U.S. Department of Justice resolves claims that Caremark, a pharmacy benefits management company, violated the federal False Claims Act by improperly processing claims of such ""dual eligible"" patients.Donald Well, a former Caremark employee who brought the case to the government's attention, will receive $1.02 million plus interest under the law's whistleblower provisions. CVS spokeswoman Christine Cramer said the Woonsocket, Rhode Island-based company settled to avoid protracted litigation, and denied wrongdoing. She also said the accord does not involve its pharmacy or Medicare Part D businesses. Caremark is a pharmacy benefits manager for private health plans that insured some patients who also had Medicaid coverage. Medicaid can seek reimbursement from private insurers or their pharmacy benefits managers if it pays prescription drug claims of such patients in error.The government said a Caremark computer platform improperly deducted co-payments or other sums when calculating payments on some claims. It said this caused Medicaid to cover prescription drug costs for dual eligible patients that should have been borne by Caremark-administered private health plans.       (Reporting by Jonathan Stempel in New York; Editing by Chizu Nomiyama. Editing by Andre Grenon)",2014-09-26,CVS,"Fri Sep 26, 2014 | 12:55pm EDT",UPDATE 1-CVS' Caremark unit settles U.S. false claims allegations,http://www.reuters.com//article/cvshealth-caremark-settlement-idUSL2N0RR1DH20140926?type=companyNews
39,"  Sept 26 Caremark LLC, a unit of CVS Health Corp , will pay $6 million to settle U.S. allegations that it knowingly failed to reimburse Medicaid for prescription drug costs paid on behalf of Medicaid beneficiaries who were also eligible for drug benefits under private health plans it administered. The settlement was announced on Friday by the U.S. Department of Justice, and resolved allegations brought under the federal False Claims Act.   (Reporting by Jonathan Stempel in New York; Editing by Chizu Nomiyama)  ",2014-09-26,CVS,"Fri Sep 26, 2014 | 11:57am EDT",CVS' Caremark unit settles U.S. False Claims Act case,http://www.reuters.com//article/cvshealth-caremark-settlement-idUSL2N0RR1C820140926?type=companyNews
40,"  Sept 26 CVS Health Corp :  * U.S. Department of Justice says caremark to pay $6 million to resolve falseclaims act allegations  * Justice Department says caremark, now part of CVS Health Corp  settles charges stemming from alleged failure to reimburse medicaid for some prescription drug costs  * Justice Department says a whistleblower will receive $1.02 million plus interest in connection with the caremark settlement",2014-09-26,CVS,"Fri Sep 26, 2014 | 11:46am EDT",BRIEF-Caremark to pay $6 million to resolve False Claims Act case,http://www.reuters.com//article/cvshealth-brief-idUSWEN00E0320140926?type=companyNews
41,"  Drug retailer CVS Health Corp will pay $225,000 to settle allegations in California that it misled consumers about package sizes using false bottoms and sides on some of its store-branded products, a Fresno-based unit of ABC News, reported on Friday.CVS will pay the settlement to Fresno, Yolo, Sacramento, and Shasta counties after investigators found the company mislabeled 11 products under its own brand, the television station KFSN-TV reported, citing court documents. Reuters was not immediately able to confirm the report. CVS said it had reached agreements with California district attorneys to resolve the allegations and would redesign the packaging of its brands, the news channel reported on its website.The retailer has two years to comply with California state labeling laws and can continue to make the products until January, the news channel said. CVS was not immediately available for comment.  (Reporting by Ramkumar Iyer in Bangalore; Editing by Lisa Shumaker)",2014-10-04,CVS,"Fri Oct 3, 2014 | 9:22pm EDT","CVS to pay $225,000 for misleading package sizes in California: local TV",http://www.reuters.com//article/us-cvs-health-settlement-idUSKCN0HT01920141004?type=companyNews
42,"  Oct 3 Drug retailer CVS Health Corp will pay $225,000 to settle allegations in California that it misled consumers about package sizes using false bottoms and sides on some of its store-branded products, a Fresno-based unit of ABC News, reported on Friday.CVS will pay the settlement to Fresno, Yolo, Sacramento, and Shasta counties after investigators found the company mislabeled 11 products under its own brand, the television station KFSN-TV reported, citing court documents. (abc30.tv/1xMBt3X)Reuters was not immediately able to confirm the report. CVS said it had reached agreements with California district attorneys to resolve the allegations and would redesign the packaging of its brands, the news channel reported on its website. The retailer has two years to comply with California state labeling laws and can continue to make the products until January, the news channel said. CVS was not immediately available for comment.   (Reporting by Ramkumar Iyer in Bangalore; Editing by Lisa Shumaker)",2014-10-04,CVS,"Fri Oct 3, 2014 | 9:19pm EDT","CVS to pay $225,000 for misleading package sizes in California -local TV",http://www.reuters.com//article/cvs-health-settlement-idUSL3N0RZ00220141004?type=companyNews
43,"   By Nandita Bose and Nathan Layne | CHICAGO  CHICAGO Some large U.S. retailers are refusing to use Apple Inc's APPL.O new electronic payments service as they commit to developing a rival payments system that would bolster their profits by eliminating credit card transaction fees.Wal-Mart Stores Inc (WMT.N) is among the roughly 50 big retailers that have chosen not to accept Apple Pay, along with Rite Aid Corp (RAD.N) and CVS HealthCorp (CVS.N).They say they are working instead on developing their own payment system, called Current C, through the Merchants Customer Exchange (MCX) consortium.The driving force behind developing a retailer-owned mobile payment solution is to avoid paying credit card transaction fees to card companies like Visa (V.N) and Mastercard (MA.N), analysts said. Fees range between 2 percent and 3 percent of costs per transaction.""""The economics and benefits of having your own payment system is definitely one of the main reasons,"" said Hitesh Sheth, chief executive of retail technology cybersecurity firm Vectra Networks.Apple did not immediately respond to queries seeking comment. Mastercard criticized the move by CVS and Rite Aid, saying it would limit the options of consumers. ""We are disappointed that both Rite Aid and CVS have decided to block their customers from using the payment method of their choice,"" Mastercard spokesman Jim Issokson said. Apple Pay, unveiled just last month, is a mobile payment app that allows consumers to buy things by simply holding their iPhone6 and 6 Plus devices up to readers installed by store merchants.The retailers shunning Apple Pay have also refused to use mobile payment systems like Google Wallet and Softcard. Rite Aid stopped accepting Apple Pay last week at its 4,572 stores. Spokeswoman Ashley Flower said on Monday the company is continually evaluating various forms of mobile payment technologies.CVS did not respond to queries seeking comment but a visit to two CVS stores showed the NFC (Near Field Communications) reader on which Apple Pay was used has been deactivated.Wal-Mart spokesman Randy Hargrove said Wal-Mart is not participating in Apple Pay at this point. It is focused instead on MCX, as one of the heavyweights in the consortium. Target said that it supports MCX but is also allowing users to make online purchases through its mobile app using Apple Pay.Antitrust experts said CVS and Rite Aid have the right to drop a vendor if they believe they can save money by going around the credit card companies and Apple, both of which will take a piece of the action.But they could run into antitrust trouble if they coordinated on dropping Apple Pay and Google Wallet or if someone else, perhaps a person working with CurrentC, organized their decision to drop Apple and Googles payment services.""If I was a regulator, I would want to take a look at that, said Peter Carstensen, who teaches antitrust at the University of Wisconsin Law School. (Additional reporting by Diane Bartz in Washington)",2014-10-27,CVS,"Mon Oct 27, 2014 | 5:12pm EDT","Some U.S. retailers shun Apple Pay, eye rival payments system",http://www.reuters.com//article/us-rite-aid-apple-pay-idUSKBN0IG1ZD20141027?type=companyNews
44,"  Drug retailers CVS Health Corp (CVS.N) and Rite Aid Corp (RAD.N) have disabled Apple Inc's (AAPL.O) new electronic payments service Apple Pay from their stores over the weekend, the New York Times reported.Apple Pay, which was unveiled in September, is a mobile payment app that allows consumers to buy things by simply holding their iPhone6 and 6 Plus devices up to readers installed by store merchants. A Rite Aid spokeswoman told the New York Times that the company does not currently accept Apple Pay. The company is ""still in the process of evaluating our mobile payment options.""Rite Aid and CVS are not part of the group of retailers that had teamed up with Apple on its payment system. However, Apple Pay technology was working in Rite Aid and CVS stores over the week, the newspaper said. The reason for the disabling was not immediately clear, the newspaper said.According to analysts, disabling the acceptance of Apple Pay is a way to support a rival system that is being developed by Merchants Customer Exchange (MCX), a consortium of merchants that includes Rite Aid and CVS, the NYT reported. MCX is developing CurrentC, an app that scans the bar code of the product and initiates the payment transfer by connecting to the customer's debit card, according to MCX's website. CurrentC will not be available until 2015. Apple, Rite Aid and CVS could not be immediately reached for comments outside regular U.S. business hours. (Reporting by Rishika Sadam in Bangalore; Editing by Gopakumar Warrier)",2014-10-27,CVS,"Mon Oct 27, 2014 | 11:13am EDT","CVS Health, Rite Aid block Apple Pay in their stores: NYT",http://www.reuters.com//article/us-apple-cvs-health-idUSKBN0IG0J320141027?type=companyNews
45,"  Oct 27 Drug retailers CVS Health Corp  and Rite Aid Corp have disabled Apple Inc's new electronic payments service Apple Pay from their stores over the weekend, the New York Times reported.Apple Pay, which was unveiled in September, is a mobile payment app that allows consumers to buy things by simply holding their iPhone6 and 6 Plus devices up to readers installed by store merchants.A Rite Aid spokeswoman told the New York Times that the company does not currently accept Apple Pay. The company is ""still in the process of evaluating our mobile payment options."" Rite Aid and CVS are not part of the group of retailers that had teamed up with Apple on its payment system. However, Apple Pay technology was working in Rite Aid and CVS stores over the week, the newspaper said.The reason for the disabling was not immediately clear, the newspaper said. (nyti.ms/1rJ2RsA) According to analysts, disabling the acceptance of Apple Pay is a way to support a rival system that is being developed by Merchants Customer Exchange (MCX), a consortium of merchants that includes Rite Aid and CVS, the NYT reported. MCX is developing CurrentC, an app that scans the bar code of the product and initiates the payment transfer by connecting to the customer's debit card, according to MCX's website. CurrentC will not be available until 2015.Apple, Rite Aid and CVS could not be immediately reached for comments outside regular U.S. business hours.   (Reporting by Rishika Sadam in Bangalore; Editing by Gopakumar Warrier)",2014-10-27,CVS,"Mon Oct 27, 2014 | 3:34am EDT","CVS Health, Rite Aid block Apple Pay in their stores - NYT",http://www.reuters.com//article/apple-cvs-health-idUSL4N0SM25420141027?type=companyNews
46,"   By Deepa Seetharaman | LAGUNA BEACH Calif.  LAGUNA BEACH Calif. Apple Inc (AAPL.O) CEO Tim Cook fired back at CVS (CVS.N) and Rite Aid (RAD.N) on Monday after the drugstore chains blocked the iPhone maker's mobile payments service, saying there were plenty of other retailers around the world to sign up.Apple Pay launched about a week ago and saw more than a million credit cards registered over the first 72 hours. It already totes up more transactions than all other ""contact less"" payment methods combined, Cook said, citing Visa and Mastercard data. Such services, through which a user pays by holding a smartphone close to a specially designed terminal, have failed to catch on in the United States despite the backing of Google Inc (GOOG.O) and other influential players.News emerged over the weekend that the two retailers had opted out of Apple Pay in favor of a rival system that roughly 50 chains, including Wal-Mart and Best Buy, are developing for in-house use. ""We've got a lot more merchants to sign up, we've got a lot of banks to sign up and we've got the rest of the world,"" Cook told the Wall Street Journal Digital Live conference, in the company's most extensive comments on the blockade so far.In launching Apple Pay, the iPhone maker hopes to lock in more customers for its mobile devices by enhancing their overall utility. Industry experts say it stands a chance of becoming the first widely used payments feature on smartphones. CVS and Rite Aid have not explained their surprise move.     But the driving force behind developing a retailer-owned mobile payment solution is to avoid paying credit card transaction fees to card companies like Visa (V.N) and Mastercard (MA.N), analysts said. Fees range between 2 percent and 3 percent of costs per transaction.Rite Aid stopped accepting Apple Pay last week at its 4,572 stores. Spokeswoman Ashley Flower said the company was evaluating various forms of mobile payment technologies.  CVS did not respond to queries seeking comment but a visit to two of its stores showed that the NFC (Near Field Communications) reader on which Apple Pay was used had been deactivated.It remains to be seen, despite early signs of success, whether mobile payments will become widely adopted.  Cook argued on Monday that Apple Pay offered better security and privacy than competing services, and that retailers risked alienating customers by limiting choices at checkout.""It's a skirmish,"" Cook said in response to a question about the retailers' moves.""Merchants have different objectives sometimes. But in the long arc of time, you only are relevant as a retailer or merchant if your customers love you.""      (Writing by Edwin Chan; Editing by Stephen Coates)",2014-10-28,CVS,"Tue Oct 28, 2014 | 11:29am EDT",Apple CEO fires back as retailers block Pay,http://www.reuters.com//article/us-apple-payments-idUSKBN0IH0AZ20141028?type=companyNews
47,"   By Deepa Seetharaman | LAGUNA BEACH, Calif.  LAGUNA BEACH, Calif. Oct 27 Apple Inc  CEO Tim Cook fired back at CVS and Rite Aid on Monday after the drugstore chains blocked the iPhone maker's mobile payments service, saying there were plenty of other retailers around the world to sign up.Apple Pay launched about a week ago and saw more than a million credit cards registered over the first 72 hours. It already totes up more transactions than all other ""contactless"" payment methods combined, Cook said, citing Visa and Mastercard data.Such services, through which a user pays by holding a smartphone close to a specially designed terminal, have failed to catch on in the United States despite the backing of Google Inc and other influential players.News emerged over the weekend that the two retailers had opted out of Apple Pay in favor of a rival system that roughly 50 chains, including Wal-Mart and Best Buy, are developing for in-house use. ""We've got a lot more merchants to sign up, we've got a lot of banks to sign up and we've got the rest of the world,"" Cook told the Wall Street Journal Digital Live conference, in the company's most extensive comments on the blockade so far.In launching Apple Pay, the iPhone maker hopes to lock in more customers for its mobile devices by enhancing their overall utility. Industry experts say it stands a chance of becoming the first widely used payments feature on smartphones.CVS and Rite Aid have not explained their surprise move.     But the driving force behind developing a retailer-owned mobile payment solution is to avoid paying credit card transaction fees to card companies like Visa and Mastercard, analysts said. Fees range between 2 percent and 3 percent of costs per transaction. Rite Aid stopped accepting Apple Pay last week at its 4,572 stores. Spokeswoman Ashley Flower said the company was evaluating various forms of mobile payment technologies.CVS did not respond to queries seeking comment but a visit to two of its stores showed that the NFC (Near Field Communications) reader on which Apple Pay was used had been deactivated. It remains to be seen, despite early signs of success, whether mobile payments will become widely adopted.Cook argued on Monday that Apple Pay offered better security and privacy than competing services, and that retailers risked alienating customers by limiting choices at checkout.""It's a skirmish,"" Cook said in response to a question about the retailers' moves.""Merchants have different objectives sometimes. But in the long arc of time, you only are relevant as a retailer or merchant if your customers love you.""        (Writing by Edwin Chan; Editing by Stephen Coates)",2014-10-28,CVS,"Tue Oct 28, 2014 | 1:11am EDT",Apple CEO fires back as retailers block Pay,http://www.reuters.com//article/apple-payments-idUSL1N0SN08920141028?type=companyNews
48,"   By Nandita Bose | CHICAGO  CHICAGO CVS Health Corp reported slightly higher-than-expected quarterly results on Tuesday, helped by growth in sales of specialty drugs and new client additions in its pharmacy benefits business.Sales at stores open at least a year rose 2 percent during the third quarter. Same-store sales jumped 4.8 percent in the pharmacy section but fewer customers meant a 4.5 percent decline for toothpaste, snacks and other merchandise sold at the front of the stores.Chief Executive Officer Larry Merlo said on a conference call that front-end margins showed a ""solid improvement,"" one-third of which stemmed from the absence of low-margin tobacco sales.In September, 7,700 CVS stores stopped selling tobacco products after the company sought to reposition itself as a healthcare destination. Net income at CVS, which operates the No. 2 U.S. drugstore chain and a major pharmacy benefits management business, fell to $948 million, or 81 cents per share, from $1.25 billion, or $1.02 per share, a year earlier.Excluding a pre-tax loss of $521 on early retirement of debt and other items, earnings per share rose 9 percent to $1.15. Analysts on average had expected $1.13, according to Thomson Reuters I/B/E/S.Operating margins improved on the back of new generic drug additions, with operating profit for pharmacy services up 7.3 percent and retail pharmacy up 4.3 percent.    Revenue rose 9.7 percent to $35 billion, led by strong sales of specialty drugs in the pharmacy benefits business. Analysts had forecast $34.74 billion.Specialty drugs treat complex diseases such as multiple sclerosis, rheumatoid arthritis, hepatitis C and cancer. Developing this business has been one of the company's top priorities.  CVS said it expected 2014 earnings of $4.47 to $4.50 per share, compared with a prior outlook of $4.43 to $4.51.Shares of CVS were down 1.5 percent at $84.83 in early trading. (Reporting by Nandita Bose; Editing by W Simon and Lisa Von Ahn)",2014-11-04,CVS,"Tue Nov 4, 2014 | 9:55am EST",CVS posts slightly higher-than-expected quarterly results,http://www.reuters.com//article/us-cvs-health-results-idUSKBN0IO1F920141104?type=companyNews
49,"  (Adds company comments, background)By Nandita BoseCHICAGO Nov 4 CVS Health Corp reported slightly higher-than-expected quarterly results on Tuesday, helped by growth in sales of specialty drugs and new client additions in its pharmacy benefits business.Sales at stores open at least a year rose 2 percent during the third quarter. Same-store sales jumped 4.8 percent in the pharmacy section but fewer customers meant a 4.5 percent decline for toothpaste, snacks and other merchandise sold at the front of the stores.Chief Executive Officer Larry Merlo said on a conference call that front-end margins showed a ""solid improvement,"" one-third of which stemmed from the absence of low-margin tobacco sales. In September, 7,700 CVS stores stopped selling tobacco products after the company sought to reposition itself as a healthcare destination.Net income at CVS, which operates the No. 2 U.S. drugstore chain and a major pharmacy benefits management business, fell to $948 million, or 81 cents per share, from $1.25 billion, or $1.02 per share, a year earlier. Excluding a pre-tax loss of $521 on early retirement of debt and other items, earnings per share rose 9 percent to $1.15. Analysts on average had expected $1.13, according to Thomson Reuters I/B/E/S.Operating margins improved on the back of new generic drug additions, with operating profit for pharmacy services up 7.3 percent and retail pharmacy up 4.3 percent. Revenue rose 9.7 percent to $35 billion, led by strong sales of specialty drugs in the pharmacy benefits business. Analysts had forecast $34.74 billion.Specialty drugs treat complex diseases such as multiple sclerosis, rheumatoid arthritis, hepatitis C and cancer. Developing this business has been one of the company's top priorities.CVS said it expected 2014 earnings of $4.47 to $4.50 per share, compared with a prior outlook of $4.43 to $4.51.Shares of CVS were down 1.5 percent at $84.83 in early trading.   (Reporting by Nandita Bose; Editing by W Simon and Lisa Von Ahn)",2014-11-04,CVS,"Tue Nov 4, 2014 | 9:53am EST",UPDATE 2-CVS posts slightly higher-than-expected quarterly results,http://www.reuters.com//article/cvs-health-results-idUSL1N0SU0SL20141104?type=companyNews
50,"  CHICAGO Nov 4 CVS Health Corp on Tuesday posted a lower-than-expected quarterly profit hurt by a pre-tax loss on early retirement of debt.CVS, which operates the No. 2 U.S. drugstore chain and a major pharmacy benefits management business, earned $948 million, or 81 cents per share, in its third quarter, down from $1.25 billion, or $1.02 per share, a year earlier. Excluding the pre-tax loss and other items, net income rose 5 percent.  Revenue in the quarter ended Sept. 30 rose 9.7 percent to $35 billion.    (Reporting by Nandita Bose Editing by W Simon)",2014-11-04,CVS,"Tue Nov 4, 2014 | 7:11am EST",CVS Health Corp Q3 quarterly profit falls on pre-tax loss,http://www.reuters.com//article/cvs-health-results-idUSL4N0ST4SD20141104?type=companyNews
51,"  * Buyback, dividend hike, guidance lift Boeing, 3M, CVS* Indexes: Dow up 0.4 pct, S&P up 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)By Caroline ValetkevitchNEW YORK, Dec 16 The Dow and S&P 500 were holding onto small gains in volatile trading Tuesday afternoon, helped by a rebound in energy shares and investor bets the Federal Reserve will be cautious in removing support in the face of a more fragile global economy.But both indexes were well off their highs for the day, with consumer discretionary shares the biggest drag on the S&P, while the Nasdaq was lower. Shares of Amazon were down 2.5 percent.The S&P 500 moved more than 40 points from its high of the day to its low. Futures crumbled in early trading as the ruble neared 80 per U.S. dollar, down 21 percent. The Russian currency sharply pared its losses and was down about 3 percent, near 68 per dollar.Brent crude fell as much as 4.2 percent but was last down 2.3 percent at $59.65 a barrel. U.S. crude, which fell as much as 4.1 percent, was last down 31 cents at $55.60.Still the S&P energy index was up 1.6 percent, leading gains on the S&P 500, as investors snapped up beaten down shares. The index is down 15.6 percent for the year so far following a sharp selloff in oil prices since June. ""There were many, many stocks, especially in the energy sector that were just trading at absolutely ridiculous prices to their fair market valuation,"" said Paul Mendelsohn, chief investment strategist at Windham Financial Services in Charlotte, Vermont.At 1:43PM the Dow Jones industrial average rose 64.46 points, or 0.38 percent, to 17,245.3, the S&P 500 gained 5.82 points, or 0.29 percent, to 1,995.45 and the Nasdaq Composite dropped 4.18 points, or 0.09 percent, to 4,600.98. Chevron, up 2.6 percent, was leading the points advance in the sector. Chevron's forward price-to-earnings ratio was at 13.6 at the close on Monday, compared to the S&P 500's 16.1, meaning investors pay less for every dollar of Chevron's earnings than they do for the S&P 500 overall.Among the top percentage gainers, Nabors Industries, up 7.6 percent, had a forward P/E of 8.6, while Denbury Resources' P/E was 8.9. Denbury rose 8.4 percent.Market participants also said bets on the Federal Reserve's next move were giving stocks support. Fed officials will decide this week whether to make a critical change to their policy statement that would widen the door for interest rate hikes next year. In October, The Fed repeated that benchmark rates were unlikely to rise for a ""considerable time.""CVS Health Corp rose 3.8 percent to $94.14 after issuing a strong 2015 forecast. 3M lifted its dividend and was the top points gainer on the Dow industrials with a 2.2 percent advance. Boeing, up 2.3 percent, was among the best performers after it raised its dividend and perked up its buyback program.Advancing issues outnumbered declining ones on the NYSE by 1,841 to 1,188, for a 1.55-to-1 ratio; on the Nasdaq, 1,601 issues rose and 1,081 fell for a 1.48-to-1 ratio.   (Additional reporting by Rodrigo Campos and Chuck Mikolajczak; editing by Chizu Nomiyama, Nick Zieminski and Meredith Mazzilli)",2014-12-16,CVS,"Tue Dec 16, 2014 | 2:15pm EST","US STOCKS-Dow, S&P 500 edge up as energy shares rebound; Nasdaq slips",http://www.reuters.com//article/markets-stocks-usa-idUSL1N0U01QN20141216?type=companyNews
52,"  * Buyback, dividend hike, guidance lift Boeing, 3M, CVS* Indexes up: Dow 0.7 pct, S&P 0.6 pct, Nasdaq 0.3 pct   (Updates prices)By Rodrigo CamposNEW YORK, Dec 16 U.S. stocks rose in a volatile Tuesday session as energy shares rallied and investors bet the Federal Reserve will be cautious in removing support in the face of a more fragile global economy.Futures had crumbled in early trading as the ruble  neared 80 per U.S. dollar, down 21 percent. The Russian currency sharply pared its losses and was down about 3 percent, near 68 per dollar.Brent crude fell as much as 4.2 percent but was last down 1.2 percent at $60.36 a barrel. U.S. crude, which fell as much as 4.1 percent, was recently up 0.2 percent at $56.04 a barrel after gaining as much as 2.2 percent.Energy shares, up 2.9 percent, were the largest gainers on the S&P 500. ""There were many, many stocks, especially in the energy sector that were just trading at absolutely ridiculous prices to their fair market valuation,"" said Paul Mendelsohn, chief investment strategist at Windham Financial Services in Charlotte, Vermont.""That is really what started the rally, when investors really started to come into the energy stocks.""Chevron, up 2.6 percent, was leading the points advance in the sector. Chevron's forward price-to-earnings ratio was at 13.6 at the close on Monday, compared to the S&P 500's 16.1, meaning investors pay less for every dollar of Chevron's earnings than they do for the S&P 500 overall.Among the top percentage gainers, Nabors Industries, up 7.6 percent, had a forward P/E of 8.6, while Denbury Resources' P/E was 8.9. Denbury rose 8.4 percent. The 43 components of the S&P 500 energy sector were in positive territory.At 12:57 p.m. EST (1757 GMT) the Dow Jones industrial average rose 118.86 points, or 0.69 percent, to 17,299.7, the S&P 500 gained 12.12 points, or 0.61 percent, to 2,001.75 and the Nasdaq Composite added 11.51 points, or 0.25 percent, to 4,616.67.Market participants also said bets on the Federal Reserve's next move were giving stocks support. Fed officials will decide this week whether to make a critical change to their policy statement that would widen the door for interest rate hikes next year. In October, The Fed repeated that benchmark rates were unlikely to rise for a ""considerable time."" ""Perhaps markets think the Fed will not be as on-schedule on taking out that language,"" said Quincy Krosby, market strategist at Prudential Financial in Newark, New Jersey.She said the market is betting the Fed will give consideration to rapidly changing financial conditions. A Fed statement and news conference are expected on Wednesday.CVS Health Corp, rose 3.8 percent to $94.14 after a strong 2015 forecast. 3M lifted its dividend and was the top points gainer on the Dow industrials with a 2.2 percent advance.Boeing, up 2.4 percent at $124.95, was among the best performers after it raised its dividend and perked up its buyback program.NYSE advancing issues outnumbered decliners 2,018 to 996, for a 2.03-to-1 ratio; on the Nasdaq, 1,714 issues rose and 945 fell for a 1.81-to-1 ratio.The S&P 500 was posting 10 new 52-week highs and 39 lows; the Nasdaq Composite was recording 22 new highs and 154 lows.     (Additional reporting by Chuck Mikolajczak; editing by Chizu Nomiyama, Nick Zieminski and Meredith Mazzilli)",2014-12-16,CVS,"Tue Dec 16, 2014 | 1:10pm EST",US STOCKS-Energy rally boosts Wall St despite global growth woes,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0U01KY20141216?type=companyNews
53,"  * Buyback, dividend hike, guidance lift Boeing, 3M, CVS* Indexes up: Dow 0.9 pct, S&P 0.8 pct, Nasdaq 0.4 pct   (Updates to midday)By Rodrigo CamposNEW YORK, Dec 16 U.S. stocks rose in a volatile Tuesday session as energy shares rallied and investors bet the Federal Reserve will be cautious in removing support in the face of a more fragile global economy.Futures had crumbled in early trading as the ruble  neared 80 per U.S. dollar, down 21 percent for the session. The Russian currency sharply pared its losses and was down about 3 percent, near 68 per dollar.Market participants cited bets on the Federal Reserve's next move as giving stocks support. Fed officials will decide this week whether to make a critical change to their policy statement that would widen the door for interest rate hikes next year. In October, The Fed repeated that benchmark rates were unlikely to rise for a ""considerable time."" ""Perhaps markets think the Fed will not be as on-schedule on taking out that language,"" said Quincy Krosby, market strategist at Prudential Financial in Newark, New Jersey.She said the market is betting the Fed will give consideration to rapidly changing financial conditions. A Fed statement and news conference are expected on Wednesday.At 12:08 p.m. EST (1708 GMT) the Dow Jones industrial average rose 156.37 points, or 0.91 percent, to 17,337.21, the S&P 500 gained 16.42 points, or 0.83 percent, to 2,006.05 and the Nasdaq Composite added 19.09 points, or 0.41 percent, to 4,624.24. Brent crude fell as much as 4.2 percent but was last down 1.2 percent at $60.36 a barrel. U.S. crude, which fell as much as 4.1 percent, was recently up 0.2 percent at $56.04 a barrel after gaining as much as 2.2 percent.Energy sector stocks, up 2.9 percent, were the largest gainers on the S&P 500. ""There were many, many stocks, especially in the energy sector that were just trading at absolutely ridiculous prices to their fair market valuation,"" said Paul Mendelsohn, chief investment strategist at Windham Financial Services in Charlotte, Vermont.""That is really what started the rally, when investors really started to come into the energy stocks.""CVS Health Corp, up 4.8 percent to $94.14, led gains on the S&P 500 after a strong 2015 forecast. 3M lifted its dividend and was the top gainer on the Dow industrials with a 2.5 percent advance.Boeing, up 2.6 percent at $125.20, was among the best performers on the day after it raised its dividend and perked up its buyback program.(Editing by Chizu Nomiyama, Nick Zieminski and Meredith Mazzilli)",2014-12-16,CVS,"Tue Dec 16, 2014 | 12:23pm EST",US STOCKS-Energy rally boosts Wall St despite global growth woes,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0U01G320141216?type=companyNews
54,"   By Bill Berkrot and Caroline Humer  CVS Health Corp, one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from AbbVie Inc only as an exception.The latest salvo in the battle to grab market share for new all-oral treatments for the liver-destroying hepatitis C virus follows a move last month by CVS rival Express Scripts Holding that favored AbbVie's regimen after negotiating a price discount below what Gilead had been charging its commercial customers.Express Scripts, the nation's largest pharmacy benefit manager, said it would cover AbbVie's Viekira Pak and exclude Gilead's Sovaldi and combination drug Harvoni. The decision had sent Gilead shares sharply lower at the time.On Monday, Gilead shares were up 2.5 percent following the CVS announcement, while AbbVie shares were down 2.2 percent.Gilead has come under intense criticism for the high price of its first-to-market all-oral treatment; Sovaldi costs about $1,000 per pill. Harvoni combines Sovaldi with another drug into a one-pill, once-a-day treatment with cure rates well above 90 percent. A 12-week course of treatment with Harvoni costs about $93,500, although some patients may need just eights weeks of therapy costing about $63,000.It was not yet known whether Gilead agreed to a substantially discounted price to secure CVS coverage. Gilead did not immediately return a call seeking comment.Express Scripts said it is still negotiating with Gilead on behalf of its plans. ""Our actions have changed how pharmaceutical innovation will be rewarded in the future,""  spokesman Brian Henry said.  RBC Capital Markets analyst Michael Yee said the CVS move ""removes near-term uncertainty for many investors who feared CVS would also strike a deal with AbbVie and put more pressure on Gilead.""AbbVie declined to say whether it was still in talks with CVS.CVS said the Gilead drugs would be exclusive on its standard commercial formulary, as well as those for exchanges created under the Affordable Care Act, Medicare Part D and Medicaid. ""Our goal was to create the lowest net-cost solution for the entire population of patients with all genotypes of hepatitis C,"" CVS spokeswoman Christine Cramer said in a statement.The recently approved AbbVie regimen has similarly high cure rates, but involves more drugs and pills per day. Many patients must also take the older drug ribavirin, which can cause anemia and other side effects.Gilead shares were up $2.28 at $97.19, while AbbVie shares were down $1.45 at $64.44. (Reporting by Caroline Humer and Bill Berkrot in New York; Editing by Jeffrey Benkoe and Leslie Adler)",2015-01-05,CVS,"Mon Jan 5, 2015 | 2:28pm EST",CVS to cover Gilead hepatitis C treatment over AbbVie regimen,http://www.reuters.com//article/us-gilead-cvs-idUSKBN0KE1FK20150105?type=companyNews
55,"  (Recasts with attribution from CVS; adds Express Scripts, analyst comment, background)By Bill Berkrot and Caroline HumerJan 5 CVS Health Corp, one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from AbbVie Inc only as an exception.The latest salvo in the battle to grab market share for new all-oral treatments for the liver-destroying hepatitis C virus follows a move last month by CVS rival Express Scripts Holding  that favored AbbVie's regimen after negotiating a price discount below what Gilead had been charging its commercial customers.Express Scripts, the nation's largest pharmacy benefit manager, said it would cover AbbVie's Viekira Pak and exclude Gilead's Sovaldi and combination drug Harvoni. The decision had sent Gilead shares sharply lower at the time.On Monday, Gilead shares were up 2.5 percent following the CVS announcement, while AbbVie shares were down 2.2 percent. Gilead has come under intense criticism for the high price of its first-to-market all-oral treatment; Sovaldi costs about $1,000 per pill. Harvoni combines Sovaldi with another drug into a one-pill, once-a-day treatment with cure rates well above 90 percent.A 12-week course of treatment with Harvoni costs about $93,500, although some patients may need just eights weeks of therapy costing about $63,000.It was not yet known whether Gilead agreed to a substantially discounted price to secure CVS coverage. Gilead did not immediately return a call seeking comment. Express Scripts said it is still negotiating with Gilead on behalf of its plans. ""Our actions have changed how pharmaceutical innovation will be rewarded in the future,""  spokesman Brian Henry said.RBC Capital Markets analyst Michael Yee said the CVS move ""removes near-term uncertainty for many investors who feared CVS would also strike a deal with AbbVie and put more pressure on Gilead."" AbbVie declined to say whether it was still in talks with CVS.CVS said the Gilead drugs would be exclusive on its standard commercial formulary, as well as those for exchanges created under the Affordable Care Act, Medicare Part D and Medicaid.""Our goal was to create the lowest net-cost solution for the entire population of patients with all genotypes of hepatitis C,"" CVS spokeswoman Christine Cramer said in a statement.The recently approved AbbVie regimen has similarly high cure rates, but involves more drugs and pills per day. Many patients must also take the older drug ribavirin, which can cause anemia and other side effects.Gilead shares were up $2.28 at $97.19, while AbbVie shares were down $1.45 at $64.44.   (Reporting by Caroline Humer and Bill Berkrot in New York; Editing by Jeffrey Benkoe and Leslie Adler)",2015-01-05,CVS,"Mon Jan 5, 2015 | 2:07pm EST",UPDATE 1-CVS to cover Gilead hepatitis C treatment over AbbVie regimen,http://www.reuters.com//article/gilead-cvs-idUSL1N0UK1B920150105?type=companyNews
56,"   By Nandita Bose and Shailaja Sharma  CVS Health Corp (CVS.N) reported a better-than-expected quarterly net revenue, boosted by growth in its Medicaid business and strength in specialty drug sales.Pharmacy sales at stores open at least a year rose 5.5 percent during the fourth quarter but fewer customers and the decision to stop selling cigarettes meant a 7.2 percent decline for toothpaste, snacks and other merchandise sold at the front of the stores. The company said an increase in items purchased per customer helped stem the decline.The company estimated that front-end same store sales would have been approximately 800 basis points higher if the impact of the loss of tobacco was removed.Shares of the No. 2 U.S. drugstore operator were down 0.3 percent at $99.24 in early trading. Chief Executive Larry Merlo said the impact of tobacco sales on other product categories has been less than expected.CVS became the first national drugstore chain in the United States to take cigarettes off its shelves from Oct. 1. The company had warned that the decision would hurt profits initially, along with a $2 billion hit to annual sales.Revenue in the pharmacy services division jumped 21.7 percent to $23.9 billion, driven by growth in specialty pharmacy business, the company said.CVS Health has focused on developing its specialty pharmacy business, which sells drugs to treat complex diseases such as multiple sclerosis, rheumatoid arthritis, hepatitis C and cancer.  The medium-term outlook for the pharmacy services segment remains highly favorable due to government policy and the continued opening of healthcare clinics, said Neil Saunders, chief executive of retail research and consulting firm Conlumino.CVS on Tuesday reaffirmed its current-quarter earnings forecast of $1.06-$1.09 per share. Analysts on average are expecting a profit of $1.08 per share, according to Thomson Reuters I/B/E/S.Net revenue rose nearly 13 percent to $37.06 billion. The company, which also operates a major pharmacy benefits management business, said net income rose to $1.32 billion, or $1.14 per share, from $1.27 billion, or $1.05 per share.Excluding items, CVS earned $1.21 per share, at the top end of the $1.18-$1.21 per share it forecast in November.Analysts on average had expected a profit of $1.20 per share on revenue of $36.08 billion. (Reporting by Nandita Bose in Chicago and Shailaja Sharma in Bengaluru; Editing by Savio D'Souza, Sriraj Kalluvila and Meredith Mazzilli)",2015-02-10,CVS,"Tue Feb 10, 2015 | 9:52am EST",CVS Health revenue beats as pharmacy services sales rise,http://www.reuters.com//article/us-cvs-health-results-idUSKBN0LE1B720150210?type=companyNews
57,"  (Adds comments, details)By Nandita Bose and Shailaja SharmaFeb 10 CVS Health Corp reported a better-than-expected quarterly net revenue, boosted by growth in its Medicaid business and strength in specialty drug sales.Pharmacy sales at stores open at least a year rose 5.5 percent during the fourth quarter but fewer customers and the decision to stop selling cigarettes meant a 7.2 percent decline for toothpaste, snacks and other merchandise sold at the front of the stores. The company said an increase in items purchased per customer helped stem the decline.The company estimated that front-end same store sales would have been approximately 800 basis points higher if the impact of the loss of tobacco was removed.Shares of the No. 2 U.S. drugstore operator were down 0.3 percent at $99.24 in early trading. Chief Executive Larry Merlo said the impact of tobacco sales on other product categories has been less than expected.CVS became the first national drugstore chain in the United States to take cigarettes off its shelves from Oct. 1.The company had warned that the decision would hurt profits initially, along with a $2 billion hit to annual sales. Revenue in the pharmacy services division jumped 21.7 percent to $23.9 billion, driven by growth in specialty pharmacy business, the company said.CVS Health has focused on developing its specialty pharmacy business, which sells drugs to treat complex diseases such as multiple sclerosis, rheumatoid arthritis, hepatitis C and cancer.The medium-term outlook for the pharmacy services segment remains highly favorable due to government policy and the continued opening of healthcare clinics, said Neil Saunders, chief executive of retail research and consulting firm Conlumino. CVS on Tuesday reaffirmed its current-quarter earnings forecast of $1.06-$1.09 per share. Analysts on average are expecting a profit of $1.08 per share, according to Thomson Reuters I/B/E/S.Net revenue rose nearly 13 percent to $37.06 billion.The company, which also operates a major pharmacy benefits management business, said net income rose to $1.32 billion, or $1.14 per share, from $1.27 billion, or $1.05 per share.Excluding items, CVS earned $1.21 per share, at the top end of the $1.18-$1.21 per share it forecast in November.Analysts on average had expected a profit of $1.20 per share on revenue of $36.08 billion.   (Reporting by Nandita Bose in Chicago and Shailaja Sharma in Bengaluru; Editing by Savio D'Souza, Sriraj Kalluvila and Meredith Mazzilli)",2015-02-10,CVS,"Tue Feb 10, 2015 | 9:47am EST",UPDATE 2-CVS Health revenue beats as pharmacy services sales rise,http://www.reuters.com//article/cvs-health-results-idUSL4N0VK59S20150210?type=companyNews
58,"  Feb 10 CVS Health Corp, the No. 2 U.S. drugstore operator, reported a near 13 percent rise in quarterly net revenue, helped by an increase in pharmacy same-store sales.CVS said net revenue rose to $37.06 billion in the fourth quarter ended Dec. 31 from $32.83 billion a year earlier. Pharmacy same-store sales rose 5.5 percent, CVS said.  The company, which also operates a major pharmacy benefits management business, said net income rose to $1.32 billion, or $1.14 per share, from $1.27 billion, or $1.05 per share.   (Reporting by Shailaja Sharma in Bengaluru; Editing by Savio D'Souza)",2015-02-10,CVS,"Tue Feb 10, 2015 | 7:16am EST",CVS Health revenue rises nearly 13 pct,http://www.reuters.com//article/cvs-health-results-idUSL4N0VK57F20150210?type=companyNews
59,"   By Ransdell Pierson  CVS Health warned on Tuesday that the costs of a potent new class of cholesterol treatments could eclipse those of other expensive medicines and overwhelm the U.S. healthcare system ""if rigid cost control mechanisms are not put in place.""Two of the new injectable cholesterol treatments, called PCSK9 inhibitors, could gain U.S. approval this summer. CVS said they could eventually be used by as many as 15 million patients at an annual cost of up to $150 billion a year if priced at $7,000 to $12,000 a year, making it the highest-selling class of drugs in history.""The resilience and ability of our health care system to absorb such high costs will be tested if rigid cost control mechanisms are not put in place,"" William Shrank, chief scientific officer for CVS, said in a statement.CVS, the second-largest U.S. pharmacy benefit manager (PBM), negotiates drug prices for 65 million people through contracts with employers and health plans.The CVS call for cost controls follows sharp criticism from insurers, other payers and politicians over the high cost of new, highly effective treatments for hepatitis C, especially two medicines from Gilead Science Inc that have retail prices of up to $94,500 per patient for a course of treatment. Unlike those drugs, which are typically taken for about 12 weeks, the PCSK9s would be used for a lifetime.Express Scripts, the largest U.S. PBM, which has waged a campaign against Gilead's hepatitis C drugs and is now scrutinizing costly cancer medications, provided a slightly different view of the new cholesterol drug market.Express Scripts also expects annual costs of around $10,000 per year per patient. But it sees a patient population that will start small before it ever reaches a possible high of 10 million people and a potential annual cost of $100 billion. Express Scripts Chief Medical Officer Steve Miller said in an interview that limits set by regulators and the fact that the first wave of drugs are injections may slow their uptake. ""We are going to work to get these products at the best price possible, but they also deserve to get value in the marketplace,"" Miller said.Amgen Inc and a partnership of Sanofi and Regeneron Pharmaceuticals Inc are awaiting approval of rival PCSK9 inhibitors.  They are expected to be used first by patients who are genetically prone to extreme high cholesterol - a population that CVS and Express peg at 620,000 Americans. They also are likely to be used by those who cannot tolerate standard statin treatments, like Pfizer Inc's Lipitor. Amgen declined to comment on the pricing issue and Regeneron did not respond to a request for comment.Shares of Amgen closed up 0.5 percent at $154.24, while Regeneron's stock gained 0.4 percent to $404.18. Sanofi's shares slipped 0.2 percent to 85.53 euros in trading in Paris. (Additional reporing by Bill Berkrot and Caroline Humer in New York and Vidya L Nathan in Bengaluru; Editing by Simon Jennings, Paul Simao and Matthew Lewis)",2015-02-17,CVS,"Tue Feb 17, 2015 | 5:57pm EST",CVS urges cost controls for new cholesterol drugs,http://www.reuters.com//article/us-cvs-health-cholesterol-idUSKBN0LL1CQ20150217?type=companyNews
60,"  (Adds comment from CVS rival Express Scripts, other background)By Ransdell PiersonFeb 17 CVS Health warned on Tuesday that the costs of a potent new class of cholesterol treatments could eclipse those of other expensive medicines and overwhelm the U.S. healthcare system ""if rigid cost control mechanisms are not put in place.""Two of the new injectable cholesterol treatments, called PCSK9 inhibitors, could gain U.S. approval this summer. CVS said they could eventually be used by as many as 15 million patients at an annual cost of up to $150 billion a year if priced at $7,000 to $12,000 a year, making it the highest-selling class of drugs in history.""The resilience and ability of our health care system to absorb such high costs will be tested if rigid cost control mechanisms are not put in place,"" William Shrank, chief scientific officer for CVS, said in a statement.CVS, the second-largest U.S. pharmacy benefit manager (PBM), negotiates drug prices for 65 million people through contracts with employers and health plans. The CVS call for cost controls follows sharp criticism from insurers, other payers and politicians over the high cost of new, highly effective treatments for hepatitis C, especially two medicines from Gilead Science Inc that have retail prices of up to $94,500 per patient for a course of treatment.Unlike those drugs, which are typically taken for about 12 weeks, the PCSK9s would be used for a lifetime.Express Scripts, the largest U.S. PBM, which has waged a campaign against Gilead's hepatitis C drugs and is now scrutinizing costly cancer medications, provided a slightly different view of the new cholesterol drug market. Express Scripts also expects annual costs of around $10,000 per year per patient. But it sees a patient population that will start small before it ever reaches a possible high of 10 million people and a potential annual cost of $100 billion.Express Scripts Chief Medical Officer Steve Miller said in an interview that limits set by regulators and the fact that the first wave of drugs are injections may slow their uptake. ""We are going to work to get these products at the best price possible, but they also deserve to get value in the marketplace,"" Miller said.Amgen Inc and a partnership of Sanofi and Regeneron Pharmaceuticals Inc are awaiting approval of rival PCSK9 inhibitors.They are expected to be used first by patients who are genetically prone to extreme high cholesterol - a population that CVS and Express peg at 620,000 Americans. They also are likely to be used by those who cannot tolerate standard statin treatments, like Pfizer Inc's Lipitor.Amgen declined to comment on the pricing issue and Regeneron did not respond to a request for comment.Shares of Amgen closed up 0.5 percent at $154.24, while Regeneron's stock gained 0.4 percent to $404.18. Sanofi's shares slipped 0.2 percent to 85.53 euros in trading in Paris.   (Additional reporing by Bill Berkrot and Caroline Humer in New York and Vidya L Nathan in Bengaluru; Editing by Simon Jennings, Paul Simao and Matthew Lewis)",2015-02-17,CVS,"Tue Feb 17, 2015 | 5:55pm EST",UPDATE 2-CVS urges cost controls for new cholesterol drugs,http://www.reuters.com//article/cvs-health-cholesterol-idUSL1N0VR1OH20150217?type=companyNews
61,"  (Corrects first paragraph to show that CVS move was on Tuesday, not Monday)By Ransdell PiersonFeb 17 CVS Health on Tuesday warned that costs of a potent new class of cholesterol treatments and other specialty drugs in development could eclipse those of expensive new medicines and overwhelm the healthcare system ""if rigid cost control mechanisms are not put in place.""CVS, the second largest U.S. pharmacy benefit manager which negotiates drug prices for 65 million people through contracts with employers and health plans, noted that two of the new injectable cholesterol fighters - called PCSK9 inhibitors - could be approved by mid-2015 and likely each cost $7,000 to $12,000 a year.All told, PCSK9 inhibitors could eventually cost the healthcare system as much as $150 billion a year and become the highest-selling class of drugs in history, CVS said. ""The resilience and ability of our health care system to absorb such high costs will be tested if rigid cost control mechanisms are not put in place,"" William Shrank, chief scientific officer for CVS, said in a statement.The company added that the sky-high prices of the new cholesterol drugs could pave the way for other very costly specialty drugs.CVS' call for cost controls follows sharp criticism from insurers, other payers and politicians of the high costs of recently approved oral treatments for hepatitis C, especially two brands from Gilead Science Inc that have retail prices of up to $94,500. Those drugs wipe out the liver virus in more than 90 percent of patients and don't need to be used beyond 12 weeks for most patients. By contrast, CVS warned that the new cholesterol drugs might be needed ""for the duration of patients' lives"" and eventually be deemed appropriate for as many as 15 million Americans.Amgen Inc and a partnership of Sanofi and Regeneron Pharmaceuticals Inc are awaiting U.S. approval of their rival PCSK9 inhibitors. They are expected to be approved for patients who are genetically prone to high levels of cholesterol - a population that CVS pegs at 620,000 Americans. They also are likely to be used for those who cannot tolerate standard statin treatments, like Pfizer Inc's  Lipitor. The experimental treatments, in combination with statins,  knocked down their levels of ""bad"" LDL cholesterol by as much as 60 percent more than statins alone.Gilead's Harvoni, which combines Sovaldi with another of its  anti-viral medicines into a daily pill, won U.S. approval late last year and has a retail price of $94,500. By itself, Sovaldi's list price is $84,000 per treatment.Gilead has acknowledged negotiating price discounts with payers of more than 40 percent for the two hepatitis C brands, as it vies for market share with a newer rival therapy from AbbVie called Viekira Pak.Shares of Amgen were up 0.8 percent on Tuesday on the Nasdaq, while Regeneron's stock gained 2.2 percent. Sanofi's shares slipped 0.3 percent in trading in Paris.   (Additional reporing by Bill Berkrot in New York and Vidya L Nathan in Bengaluru, Editing by Simon Jennings and Paul Simao)",2015-02-17,CVS,"Tue Feb 17, 2015 | 2:58pm EST","CORRECTED-UPDATE 1-CVS urges cost controls for new cholesterol, specialty drugs",http://www.reuters.com//article/cvs-health-cholesterol-idUSL4N0VR47620150217?type=companyNews
62,"  Feb 17 CVS Health Corp, the second-largest U.S. pharmacy chain operator, has warned that a new class of drugs being developed to lower ""bad"" cholesterol could cost the U.S. healthcare system as much as $150 billion per year.The new class of cholesterol drugs called PCSK9 inhibitors could be priced in the range of $7,000-$12,000 per year, CVS said. The company's statement follows resistance to ""high-priced"" treatments for hepatitis C, notably Gilead Sciences Inc's  Sovaldi and combination treatment Harvoni.  CVS Health has focused on developing its specialty pharmacy business, which sells drugs to treat complex diseases such as multiple sclerosis, rheumatoid arthritis, hepatitis C and cancer.   (Reporting by Vidya L Nathan in Bengaluru, Editing by Simon Jennings)",2015-02-17,CVS,"Tue Feb 17, 2015 | 9:54am EST",CVS says new cholesterol drugs could cost U.S. $150 bln/year,http://www.reuters.com//article/cvs-health-cholesterol-idUSL4N0VR42220150217?type=companyNews
63,"   By Caroline Humer | WASHINGTON  WASHINGTON The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters.CVS is one of the largest U.S. pharmacy benefit managers and, along with rival Express Scripts, has put unprecedented pressure on global pharmaceutical makers to lower prices for its clients.The comments by CVS Health Chief Medical Officer Troyen Brennan suggest U.S. drug benefit managers will be pressing for much steeper discounts on new biosimilar drugs than the 20 percent to 30 percent widely expected by Wall Street.Depending on how similar treatments are, and on demand from doctors and patients, biosimilar pricing could more closely track the face-off among branded drugs, Brennan said in an interview on Wednesday.Generic versions of traditional pharmaceuticals can usher in discounts of as much as 98 percent. Biosimilars retain a much higher margin due to their more complicated manufacturing process, which can create a new version of a biotechnology drug but not an exact copy.As a result of that, with these new ones coming on we are probably going to be seeing something that looks like more of a situation where there are multiple brands,"" Brennan said. ""In the past that didnt give you 98 percent discounts. In the past, that would give you 40 to 50 percent discounts.""  The U.S. Food and Drug Administration approved on Friday the first biosimilar drug for use in the country, a copy of Amgen Inc's Neupogen cancer treatment that was made by Novartis. Pricing on the biosimilar has yet to be determined.Drugmakers that are racing to develop biosimilars include Pfizer Inc and Hospira Inc. In Europe, Hospira already sells copycat versions of Neupogen and Merck & Co's and Johnson & Johnson Inc's arthritis drug Remicade. Other biosimilar players include Amgen, Biogen Idec, Teva Pharmaceuticals Industries and Mylan Inc.Biologic drugs have already been approved in Europe, but pricing varies as each country has a role in negotiating drug costs. Earlier this year, Express Scripts and CVS pitted two novel treatments for hepatitis C against each other to wrest large price cuts from their manufacturers, Gilead Sciences Inc and AbbVie Inc. Brennan said they are likely to use similar tactics as more biosimilars enter the marketplace. That could mean excluding one of the drugs from their reimbursement list for most patients, requiring patients to try the less expensive treatment first or insisting they give prior approval before a patient begins the medication based on their specific medical history, he explained.Brennan sees competitive pressure ahead for drugs that treat auto-immune disorders like rheumatoid arthritis, Crohn's disease and colitis. AbbVies Humira for arthritis and Remicade are billion-dollar biotech franchises that are close to facing biosimilar versions made by others. Express Scripts estimates that about $250 billion could be saved in the next decade if biosimilars for 11 different biological drugs are approved in the United States as expected. ""Whenever you are engaging in greater competition, we should be able to take advantage of that to get a lower price,"" Brennan said. (Reporting by Caroline Humer; Editing by Michele Gershberg and Alden Bentley)",2015-03-11,CVS,"Wed Mar 11, 2015 | 4:48pm EDT",Exclusive: CVS says biotech drug copies may bring price cuts of 40-50 percent,http://www.reuters.com//article/us-cvs-health-biosimilars-idUSKBN0M72GK20150311?type=companyNews
64,"  Pharmacy service provider Omnicare Inc OCR.N is getting buyout interest from potential buyers, including Express Scripts Holding Co (ESRX.O) and CVS Health Corp (CVS.N), Bloomberg reported, citing people with knowledge of the matter.Omnicare is working with Bank of America Corp and Centerview Partners to explore options including a sale, the report said. Shares of Omnicare, which has a market value of about $8.4 billion, rose 2 percent to $88.19 in late afternoon trading on the New York Stock Exchange on Thursday.The report also named Walgreens Boots Alliance Inc (WBA.O) and McKesson Corp (MCK.N) as potential bidders. Initial bids for the top U.S. provider of pharmacy services to the elderly are due in May, the report said. Pharmacy benefit managers and pharmacy chain operators are consolidating to negotiate better prices with drugmakers.Bloomberg reported last week that Omnicare was looking to sell itself.  (Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila)",2015-04-30,CVS,"Thu Apr 30, 2015 | 2:58pm EDT","Omnicare draws buyout interest from CVS, Express Scripts: Bloomberg",http://www.reuters.com//article/us-omnicare-sale-idUSKBN0NL2FY20150430?type=companyNews
65,"  April 30 Pharmacy service provider Omnicare Inc  is getting buyout interest from potential buyers, including Express Scripts Holding Co and CVS Health Corp, Bloomberg reported, citing people with knowledge of the matter.Omnicare is working with Bank of America Corp and Centerview Partners to explore options including a sale, the report said. (bloom.bg/1JV83Dj)Shares of Omnicare, which has a market value of about $8.4 billion, rose 2 percent to $88.19 in late afternoon trading on the New York Stock Exchange on Thursday. The report also named Walgreens Boots Alliance Inc  and McKesson Corp as potential bidders.Initial bids for the top U.S. provider of pharmacy services to the elderly are due in May, the report said. Pharmacy benefit managers and pharmacy chain operators are consolidating to negotiate better prices with drugmakers. Bloomberg reported last week that Omnicare was looking to sell itself.(Reporting by Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila)",2015-04-30,CVS,"Thu Apr 30, 2015 | 2:56pm EDT","Omnicare draws buyout interest from CVS, Express Scripts - Bloomberg",http://www.reuters.com//article/omnicare-sale-idUSL4N0XR7FS20150430?type=companyNews
66,"   By Nandita Bose and Sruthi Ramakrishnan  CVS Health Corp (CVS.N) reported higher-than-expected quarterly results on Friday, helped by increased revenue from its specialty pharmacy services and increased claim processing.General merchandise sales at drugstores open at least a year were down, however. The company blamed its decision in October to stop selling tobacco products.CVS, the No. 2 U.S. drugstore operator, also raised the low end of its 2015 profit forecast to $5.08 a share from $5.05 before special items, while keeping the high end at 5.19. Its shares rose 1 percent to $100.24 in morning trading.One of CVS's top priorities has been to develop its specialty pharmacy business, which provides medication and services for complex diseases such as multiple sclerosis, hepatitis C and cancer.Chief Executive Officer Larry Merlo said on a conference call that specialty pharmacy revenue increased in the quarter because of volume, new products, inflation and a prescription services program called Specialty Connect. Overall pharmacy services revenue rose 18.2 percent to $23.9 billion. Total net revenue increased 11 percent to $36.33 billion. Analysts on average had expected $35.93 billion, according to Thomson Reuters I/B/E/S.The number of pharmacy network claims CVS processed increased 11 percent to 230.8 million, with growth from its Medicaid management business and public exchanges. Same-store sales increased 1.2 percent, double analysts' expectations of a 0.6 percent rise. On that basis, pharmacy sales increased 4.2 percent, helped by more flu cases, but general merchandise fell 6.1 percent.The impact of the tobacco exit was around 800 basis points, about 100 basis points less than what the company originally anticipated when it became the first national U.S. drugstore chain to take cigarettes off its shelves. Stephen Ward, commercial director of research firm Conlumino, said CVS needed to put more effort into boosting its retail sales.  ""There are factors wider than just tobacco that are at play,"" Ward said. ""Areas such as range assortment, visual merchandising and the general shopping experience are all in need of improvement.""    First-quarter net income rose 8.1 percent to $1.22 billion, or $1.07 per share. Excluding intangible asset amortization related to acquisition activity, CVS earned $1.14 per share. Analysts on average had expected $1.08. (Reporting by Nandita Bose in Chicago and Sruthi Ramakrishnan in Bengaluru; Editing by Maju Samuel, Savio D'Souza and Lisa Von Ahn)",2015-05-01,CVS,"Fri May 1, 2015 | 10:51am EDT",CVS profit beats estimates on pharmacy services strength,http://www.reuters.com//article/us-cvshealth-results-idUSKBN0NM3NR20150501?type=companyNews
67,"  (Adds company comments, analyst comment, details on specialty pharmacy, tobacco exit)By Nandita Bose and Sruthi RamakrishnanMay 1 CVS Health Corp reported higher-than-expected quarterly results on Friday, helped by increased revenue from its specialty pharmacy services and increased claim processing.General merchandise sales at drugstores open at least a year were down, however. The company blamed its decision in October to stop selling tobacco products.CVS, the No. 2 U.S. drugstore operator, also raised the low end of its 2015 profit forecast to $5.08 a share from $5.05 before special items, while keeping the high end at 5.19 . Its shares rose 1 percent to $100.24 in morning trading.One of CVS's top priorities has been to develop its specialty pharmacy business, which provides medication and services for complex diseases such as multiple sclerosis, hepatitis C and cancer. Chief Executive Officer Larry Merlo said on a conference call that specialty pharmacy revenue increased in the quarter because of volume, new products, inflation and a prescription services program called Specialty Connect.Overall pharmacy services revenue rose 18.2 percent to $23.9 billion.Total net revenue increased 11 percent to $36.33 billion. Analysts on average had expected $35.93 billion, according to Thomson Reuters I/B/E/S. The number of pharmacy network claims CVS processed increased 11 percent to 230.8 million, with growth from its Medicaid management business and public exchanges.Same-store sales increased 1.2 percent, double analysts' expectations of a 0.6 percent rise. On that basis, pharmacy sales increased 4.2 percent, helped by more flu cases, but general merchandise fell 6.1 percent. The impact of the tobacco exit was around 800 basis points, about 100 basis points less than what the company originally anticipated when it became the first national U.S. drugstore chain to take cigarettes off its shelves.Stephen Ward, commercial director of research firm Conlumino, said CVS needed to put more effort into boosting its retail sales.""There are factors wider than just tobacco that are at play,"" Ward said. ""Areas such as range assortment, visual merchandising and the general shopping experience are all in need of improvement.""First-quarter net income rose 8.1 percent to $1.22 billion, or $1.07 per share.Excluding intangible asset amortization related to acquisition activity, CVS earned $1.14 per share. Analysts on average had expected $1.08.   (Reporting by Nandita Bose in Chicago and Sruthi Ramakrishnan in Bengaluru; Editing by Maju Samuel, Savio D'Souza and Lisa Von Ahn)",2015-05-01,CVS,"Fri May 1, 2015 | 10:50am EDT",UPDATE 2-CVS profit beats estimates on pharmacy services strength,http://www.reuters.com//article/cvshealth-results-idUSL4N0XS31520150501?type=companyNews
68,"  May 1 CVS Health Corp, the No.2 U.S drugstore operator, reported an 11 percent rise in quarterly net revenue, helped by higher revenue from specialty pharmacy services and an increase in pharmacy network claims.The company's net income rose to $1.22 billion, or $1.07 per share, in the first quarter ended March 31, from $1.13 billion, or 95 cents per share, a year earlier.  Net revenue rose to $36.33 billion from $32.69 billion. Same-store sales increased 1.2 percent.    (Reporting by Nandita Bose in Chicago and Sruthi Ramakrishnan in Bengaluru; Editing by Maju Samuel) ",2015-05-01,CVS,"Fri May 1, 2015 | 7:16am EDT",Drugstore operator CVS reports 11 pct rise in revenue,http://www.reuters.com//article/cvshealth-results-idUSL4N0XS2T420150501?type=companyNews
69,"   By Jonathan Stempel  CVS Health Corp, the second-largest U.S. drugstore operator, will pay $22 million to resolve a federal probe into whether two of its pharmacies in central Florida sold powerful, potentially addictive painkillers that were not prescribed for legitimate medical purposes.The settlement was announced on Wednesday by U.S. Attorney A. Lee Bentley in Tampa, nearly three years after U.S. Drug Enforcement Administration licenses were revoked for the two pharmacies in Sanford, Florida, about 25 miles (40 km) northeast of Orlando. These revocations were part of a crackdown in Florida on illegal sales of controlled substances, at the height of what Bentley called the state's ""pill mill crisis."" DEA agents had found that the two pharmacies ordered roughly 3 million oxycodone pills in 2011, ranking 23rd and 37th nationwide among pharmacies in the distribution of such pills, and ignored red flags that the prescriptions they were filling were not legitimate. In a regulatory filing, CVS said the settlement resolves all civil matters between the company, which is based in Woonsocket, Rhode Island, and the DEA in Florida. It also said it set aside enough money in prior fiscal periods to cover the accord.CVS shares fell 43 cents to $99.81 in Wednesday trading.",2015-05-13,CVS,"Wed May 13, 2015 | 7:23pm EDT",CVS pays $22 million to resolve Florida painkiller probe,http://www.reuters.com//article/us-cvs-health-settlement-idUSKBN0NY2O720150513?type=companyNews
70,"   By Jonathan Stempel  CVS Health Corp, the second-largest U.S. drugstore operator, will pay $22 million to resolve a federal probe into whether two of its pharmacies in central Florida sold powerful, potentially addictive painkillers that were not prescribed for legitimate medical purposes.The settlement was announced on Wednesday by U.S. Attorney A. Lee Bentley in Tampa, nearly three years after U.S. Drug Enforcement Administration licenses were revoked for the two pharmacies in Sanford, Florida, about 25 miles (40 km) northeast of Orlando.These revocations were part of a crackdown in Florida on illegal sales of controlled substances, at the height of what Bentley called the state's ""pill mill crisis."" DEA agents had found that the two pharmacies ordered roughly 3 million oxycodone pills in 2011, ranking 23rd and 37th nationwide among pharmacies in the distribution of such pills, and ignored red flags that the prescriptions they were filling were not legitimate. In a regulatory filing, CVS said the settlement resolves all civil matters between the company, which is based in Woonsocket, Rhode Island, and the DEA in Florida. It also said it set aside enough money in prior fiscal periods to cover the accord.CVS shares fell 43 cents to $99.81 in Wednesday trading.  (Editing by Ted Botha)",2015-05-13,CVS,"Wed May 13, 2015 | 6:15pm EDT",CVS pays $22 million to resolve Florida painkiller probe,http://www.reuters.com//article/us-cvs-health-settlement-idUSKBN0NY2O920150513?type=companyNews
71,"   By Jonathan Stempel  CVS Health Corp, the second-largest U.S. drugstore operator, will pay $22 million to resolve a federal probe into whether two of its pharmacies in central Florida sold powerful, potentially addictive painkillers that were not prescribed for legitimate medical purposes.The settlement was announced on Wednesday by U.S. Attorney A. Lee Bentley in Tampa, nearly three years after U.S. Drug Enforcement Administration licenses were revoked for the two pharmacies in Sanford, Florida, about 25 miles (40 km) northeast of Orlando. These revocations were part of a crackdown in Florida on illegal sales of controlled substances, at the height of what Bentley called the state's ""pill mill crisis."" DEA agents had found that the two pharmacies ordered roughly 3 million oxycodone pills in 2011, ranking 23rd and 37th nationwide among pharmacies in the distribution of such pills, and ignored red flags that the prescriptions they were filling were not legitimate. In a regulatory filing, CVS said the settlement resolves all civil matters between the company, which is based in Woonsocket, Rhode Island, and the DEA in Florida. It also said it set aside enough money in prior fiscal periods to cover the accord.CVS shares fell 43 cents to $99.81 in Wednesday trading.",2015-05-13,CVS,"Wed May 13, 2015 | 6:13pm EDT",CVS pays $22 mln to resolve Florida painkiller probe,http://www.reuters.com//article/cvs-health-settlement-idUSL1N0Y434C20150513?type=companyNews
72,"   By Jonathan Stempel  May 13 CVS Health Corp, the second-largest U.S. drugstore operator, will pay $22 million to resolve a federal probe into whether two of its pharmacies in central Florida sold powerful, potentially addictive painkillers that were not prescribed for legitimate medical purposes.The settlement was announced on Wednesday by U.S. Attorney A. Lee Bentley in Tampa, nearly three years after U.S. Drug Enforcement Administration licenses were revoked for the two pharmacies in Sanford, Florida, about 25 miles (40 km) northeast of Orlando. These revocations were part of a crackdown in Florida on illegal sales of controlled substances, at the height of what Bentley called the state's ""pill mill crisis."" DEA agents had found that the two pharmacies ordered roughly 3 million oxycodone pills in 2011, ranking 23rd and 37th nationwide among pharmacies in the distribution of such pills, and ignored red flags that the prescriptions they were filling were not legitimate. In a regulatory filing, CVS said the settlement resolves all civil matters between the company, which is based in Woonsocket, Rhode Island, and the DEA in Florida. It also said it set aside enough money in prior fiscal periods to cover the accord.CVS shares fell 43 cents to $99.81 in Wednesday trading.   (Editing by Ted Botha)",2015-05-13,CVS,"Wed May 13, 2015 | 6:08pm EDT",CVS pays $22 mln to resolve Florida painkiller probe,http://www.reuters.com//article/cvs-health-settlement-idUSL1N0Y431120150513?type=companyNews
73,"   By Greg Roumeliotis  CVS Health Corp (CVS.N), the second-largest U.S. drugstore operator, is nearing a deal to buy pharmacy service provider Omnicare Inc OCR.N for more than $12 billion, according to two people familiar with the matter.A deal between the two companies could be announced as early as Thursday, one of the people said. Representatives at CVS Health and Omnicare were not immediately available for comment.Shares of Omnicare, the top U.S. provider of pharmacy services to the elderly, rose as much as 6.7 percent at $101 in after-hours trading on Wednesday. The deal between CVS and Omnicare was first reported by Bloomberg News. The news comes at a time when most pharmacy benefit managers and pharmacy chain operators are consolidating to get better prices on drugs.  (Reporting by Greg Roumeliotis in New York; Editing by Lisa Shumaker)",2015-05-20,CVS,"Wed May 20, 2015 | 7:45pm EDT",CVS nears deal to buy Omnicare for more than $12 billion: sources,http://www.reuters.com//article/us-omnicre-m-a-cvs-health-idUSKBN0O52TA20150520?type=companyNews
74,"  (Changes sourcing)By Greg RoumeliotisMay 20 CVS Health Corp, the second-largest U.S. drugstore operator, is nearing a deal to buy pharmacy service provider Omnicare Inc for more than $12 billion, according to two people familiar with the matter. A deal between the two companies could be announced as early as Thursday, one of the people said. Representatives at CVS Health and Omnicare were not immediately available for comment. Shares of Omnicare, the top U.S. provider of pharmacy services to the elderly, rose as much as 6.7 percent at $101 in after-hours trading on Wednesday. The deal between CVS and Omnicare was first reported by Bloomberg News.The news comes at a time when most pharmacy benefit managers and pharmacy chain operators are consolidating to get better prices on drugs.   (Reporting by Greg Roumeliotis in New York; Editing by Lisa Shumaker)",2015-05-20,CVS,"Wed May 20, 2015 | 7:39pm EDT",UPDATE 1-CVS nears deal to buy Omnicare for more than $12 bln -sources,http://www.reuters.com//article/omnicre-ma-cvs-health-idUSL1N0YB2RM20150520?type=companyNews
75,"  May 20 CVS Health Corp, the second-largest U.S. drugstore operator, is in advanced talks to buy pharmacy service provider Omnicare Inc, Bloomberg reported, citing people with knowledge of the matter.The deal with Omnicare, which has a market value of about $9.2 billion, could be announced as soon as this week, according to the report. (bloom.bg/1KkTgWe)Shares of Omnicare, the top U.S. provider of pharmacy services to the elderly, rose as much as 6.7 percent at $101 in after-hours trading on Wednesday following the Bloomberg report. Both the companies are still finalising the terms of the deal, and no agreement is certain, Bloomberg said citing the people. The news comes at a time when most pharmacy benefit managers and pharmacy chain operators are consolidating to get better prices on drugs. Representatives at CVS Health and Omnicare were not immediately available for comment.Bloomberg had earlier reported in April that Omnicare was looking to sell itself.    (Reporting by Aurindom Mukherjee in Bengaluru; Editing by Lisa Shumaker)",2015-05-20,CVS,"Wed May 20, 2015 | 6:47pm EDT",CVS Health in advanced talks to buy pharmacy service provider Omnicare -Bloomberg,http://www.reuters.com//article/omnicre-ma-cvs-health-idUSL3N0YB5NL20150520?type=companyNews
76,"  (Adds Exor, Emirates National Oil, Dogan, Potash Corp, TAP)May 21 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:** CVS Health Corp, the second-largest U.S. drugstore operator, said on Thursday it will buy pharmacy services provider Omnicare Inc for $10.1 billion to expand in the growing market serving the senior patient population.** Oil producer Pacific Rubiales Energy Corp said it has agreed to the C$6.50 per share cash offer from Mexico's Alfa Sab de CV and investment firm Harbour Energy Ltd.** Permira Advisers LLC, the buyout firm that owns most of Ancestry.com LLC, the world's largest family history website helping users trace their heritage, is exploring a sale that could value the genealogy website at $2.5-$3.0 billion, including debt, according to people familiar with the matter.** Italian investment holding company Exor said on Thursday it would not raise its $6.8 billion takeover offer for PartnerRe but was willing to negotiate with the reinsurer if its board declared its offer superior to that of rival suitor Axis Capital Holdings.** Emirates National Oil Co (ENOC) went public with an offer to buy out minority shareholders in Dragon Oil, saying talks with a committee set up by the Turkmenistan-focused oil explorer had not yet produced the endorsement it believed its ""full and fair"" bid warranted.** Turkish conglomerate Dogan Holding said on Thursday one of its units had placed a non-binding bid for the Turkish fuel distribution business of French oil producer Total .** Potash Corporation of Saskatchewan Inc Chief Executive Jochen Tilk said on Thursday that he views the company's stakes in fertilizer companies Sinofert Holdings  and Arab Potash Company as ""strategic,"" but continues to review whether to keep its shares in ICL  and SQM.** The Portuguese government on Thursday picked bids by two Brazil-based aviation tycoons for the next phase of privatisation of the indebted flag carrier TAP, discarding the only offer by a local competitor.** The Canada Pension Plan Investment Board (CPPIB), one of the world's biggest dealmakers, is looking at deals in the energy sector as a selloff in the price of oil makes valuations more appealing, its top executive said on Thursday.** U.S. private equity firm Cerberus Capital Management LP on Thursday launched a selldown of up to $878 million in railway firm Seibu Holdings, IFR reported, citing a term sheet of the transaction. ** U.S. private equity firm Bain Capital will cut its 70 percent stake in Japanese restaurant chain Skylark Co Ltd  to less than 50 percent.** Germany's premium automakers Mercedes, Audi  and BMW have teamed up with private equity firm General Atlantic to raise their chances of clinching Nokia's map unit HERE, two people familiar with the matter said.A separate source said that each of the three carmakers was prepared to chip in up to 700 million euros ($780 million).** Cadila Healthcare Ltd, among India's top ten drugmakers, is in late-stage talks to buy smaller rival Claris Lifesciences Ltd for about 34 billion rupees ($534 million), the Economic Times newspaper reported, citing sources aware of the talks.** Indian drugmaker Strides Arcolab Ltd has agreed to buy businesses in Australia and Mauritius from South Africa's Aspen Pharmacare Holdings Ltd, paying $300 million to expand its footprint in markets set for brisk growth. ** GE, which announced plans last month to sell $200 billion in GE Capital finance assets, now expects to be largely done with the process by 2016 instead of finishing in 2017.** Bermuda-based reinsurer PartnerRe said on Wednesday it was ready to talk to Italian holding company Exor  to see if there was room to improve its $6.8 billion takeover bid.AXIS Capital Holdings Ltd Chief Executive Officer Albert Benchimol told employees on Wednesday that a merger with PartnerRe Ltd was still in the best interests of both reinsurance companies, according to a memo seen by Reuters.** Oman's United Finance said National Bank of Oman had confirmed interest in participating in a bidding process for a possible acquisition of the company.** Brazilian investment bank BTG Pactual SA and its partners P2Brasil and GMR Energia jointly sold 100 percent of renewable energy company Latin America Power (LAP) to SunEdison, BTG and P2 said. ** German lender HSH Nordbank could split off a ""bad bank"" for non-performing shipping loans as part of a plan to create a sustainable business model, according to a person familiar with the matter.** Israeli defence electronics firm Elbit Systems  has agreed to buy Nice Systems' cyber and intelligence division for $157.9 million as it seeks to boost its presence in this fast-growing market.** Kuwait's Al Ahli Bank will pay $150 million for a 98.5 percent stake in the Egyptian unit of Greece's Piraeus Bank, using its own cash resources to support a regional expansion drive, it said on Thursday.** South Korean media company Jcontentree Corp  said it would buy the 50 percent stake that it does not already own in the country's third-largest movie theatre chain Megabox Inc for 152 billion won ($139 million).** Dubai's Amanat Holdings said it has bought a 4.14 percent stake in London-listed UAE healthcare firm Al Noor Hospitals from Deutsche Bank for 250 million dirhams ($68.1 million).** Booker Group Plc, Britain's biggest cash-and-carry wholesaler, has agreed to buy the Londis and Budgens chains 40 million pounds ($62.2 million) to expand its network of grocery and convenience stores and tap into changing consumer habits.** Indian vehicle maker Mahindra and Mahindra Ltd  said it would buy a 33 percent voting stake in the agricultural machinery-making unit of Mitsubishi Heavy Industries Ltd  for $25 million.** The investment arm of Rwanda's ruling party is selling its 20 percent stake in MTN Rwandacell, a unit of the South African telecoms group.** South Africa's biggest insurer Sanlam Ltd will buy a 40 percent stake in a Zimbabwean insurance firm, it said on Thursday, betting on the industry's growth in a country facing a liquidity crunch and weak domestic savings. Sanlam will pay $11.6 million for the stake in Masawara Investments Mauritius Limited (MIM).($1 = 63.71 Indian rupees)  ($1 = C$1.21)  ($1 = 1,092.51 won)  ($1 = 3.67 UAE dirham)  ($1 = 0.64 pounds)  ($1 = 0.89 euros)   (Compiled by Ankit Ajmera and Amrutha Penumudi in Bengaluru)",2015-05-21,CVS,"Thu May 21, 2015 | 4:18pm EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0YC4GY20150521?type=companyNews
77,"  Drugstore operator CVS Health Corp (CVS.N) said Thursday it will spend $10.1 billion to buy Omnicare Inc OCR.N, a company that supplies prescription medicines to nursing, assisted living and other healthcare facilities.The move gives CVS, the second-largest U.S. drugstore operator, access to the older, sicker U.S. population and builds on its specialty pharmacy, which provides drugs to people with expensive chronic conditions such as rheumatoid arthritis.CVS said it expects the deal to add about 20 cents to adjusted earnings per share in 2016. The deal also includes debt of about $2.3 billion, the companies said.        The pharmaceutical sector has been consolidating as companies look to beef up and bargain for lower prices from both drug manufacturers and the three largest U.S. drug distributors. ""There's a lot of purchasing scale. There's a lot more volume. They could renegotiate their supply contracts given the volume,"" said FBR analyst Steven Halper.In addition to its drugstore chain and mail-order sales, CVS is the second-largest pharmacy benefit manager in the United States, securing pricing for big employers and government plans.CVS offered $98 per Omnicare share, representing a premium of 4 percent to the closing price Wednesday of Omnicare, the top U.S. provider of pharmacy services to the elderly. The offer is at a nearly 21 percent premium to Omnicare's April 21 close, a day before Bloomberg reported that the company was exploring a sale.Shares of Omnicare,  rose 1.5 percent to $96 while CVS was up 2.8 percent at $104.08. FOLLOWS OTHER DEALS Bloomberg first reported Wednesday that CVS was nearing a deal to buy Omnicare. Speculation has mounted of more pharmacy-industry consolidation as others have tied up, and the field of companies involved in drug distribution, sales or management has shrunk. Health insurer UnitedHealth Group Inc (UNH.N) agreed to buy Catamaran Corp CTRX.O CCT.TO for about $12.8 billion in March. Rite Aid Corp (RAD.N) bought pharmacy benefit manager EnvisionRx for about $2 billion in February. Last year, pharmacy Walgreen tied up with European pharmacy and drug distribution company Boots Alliance.CVS said it secured $13 billion in financing from Barclays for the deal, which is expected to close near the end of 2015. Barclays and Evercore are CVS's financial advisers, while Bank of America Merrill Lynch and Centerview Partners advised Omnicare. CVS's legal adviser is Sullivan & Cromwell LLP, while White & Case LLP served as Omnicare's legal counsel.  (Reporting by Caroline Humer in New York and Sruthi Ramakrishnan and Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila and Bernadette Baum)",2015-05-21,CVS,"Thu May 21, 2015 | 1:28pm EDT",CVS to expand pharmacy business with $10.1 billion Omnicare buy,http://www.reuters.com//article/us-omnicare-m-a-cvs-health-idUSKBN0O619T20150521?type=companyNews
78,"  * Deal values Omnicare at $12.7 bln, including $2.3B debt* Offer of $98/share at 4 pct premium to Wednesday close* Deal to add $0.20/share to CVS adjusted earnings in 2016   (Adds analyst comments, updates trading)May 21 Drugstore operator CVS Health Corp  said Thursday it will spend $10.1 billion to buy Omnicare Inc, a company that supplies prescription medicines to nursing, assisted living and other healthcare facilities.The move gives CVS, the second-largest U.S. drugstore operator, access to the older, sicker U.S. population and builds on its specialty pharmacy, which provides drugs to people with expensive chronic conditions such as rheumatoid arthritis.CVS said it expects the deal to add about 20 cents to adjusted earnings per share in 2016. The deal also includes debt of about $2.3 billion, the companies said.The pharmaceutical sector has been consolidating as companies look to beef up and bargain for lower prices from both drug manufacturers and the three largest U.S. drug distributors. ""There's a lot of purchasing scale. There's a lot more volume. They could renegotiate their supply contracts given the volume,"" said FBR analyst Steven Halper.In addition to its drugstore chain and mail-order sales, CVS is the second-largest pharmacy benefit manager in the United States, securing pricing for big employers and government plans.CVS offered $98 per Omnicare share, representing a premium of 4 percent to the closing price Wednesday of Omnicare, the top U.S. provider of pharmacy services to the elderly. The offer is at a nearly 21 percent premium to Omnicare's April 21 close, a day before Bloomberg reported that the company was exploring a sale.Shares of Omnicare,  rose 1.5 percent to $96 while CVS was up 2.8 percent at $104.08. FOLLOWS OTHER DEALS Bloomberg first reported Wednesday that CVS was nearing a deal to buy Omnicare.Speculation has mounted of more pharmacy-industry consolidation as others have tied up, and the field of companies involved in drug distribution, sales or management has shrunk.Health insurer UnitedHealth Group Inc agreed to buy Catamaran Corp  for about $12.8 billion in March. Rite Aid Corp bought pharmacy benefit manager EnvisionRx for about $2 billion in February. Last year, pharmacy Walgreen tied up with European pharmacy and drug distribution company Boots Alliance.CVS said it secured $13 billion in financing from Barclays for the deal, which is expected to close near the end of 2015.Barclays and Evercore are CVS's financial advisers, while Bank of America Merrill Lynch and Centerview Partners advised Omnicare. CVS's legal adviser is Sullivan & Cromwell LLP, while White & Case LLP served as Omnicare's legal counsel.    (Reporting by Caroline Humer in New York and Sruthi Ramakrishnan and Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila and Bernadette Baum)",2015-05-21,CVS,"Thu May 21, 2015 | 11:17am EDT",UPDATE 3-CVS to expand pharmacy business with $10.1 billion Omnicare buy,http://www.reuters.com//article/omnicare-ma-cvs-health-idUSL3N0YC4MY20150521?type=companyNews
79,"  * Jobless claims, factory data weaker-than expected* April home resales unexpectedly decline* Lumber Liquidators plunges after CEO resigns* CVS up on $10.1 bln Omnicare deal* Indexes up: Dow 0.02 pct, S&P 0.1 pct, Nasdaq 0.2 pct   (Updates to open)By Tanya AgrawalMay 21 U.S. stocks moved higher in morning trading on Thursday as investors shrugged of fresh batch of weaker-than-expected data, which came a day after the Federal Reserve all but ruled out an interest rate hike in June.The central bank's officials believed it would be premature to raise rates next month even though most felt the economy was set to rebound from a dismal start to the year, according to minutes from their April policy meeting.However, data on Thursday showed that the number of Americans filing new claims for unemployment benefits rose slightly more than expected last week, while growth in the manufacturing sector slowed for a second straight month during May. That was followed by data that showed home resales unexpectedly fell in April as tight inventories pushed prices higher.Still, the underlying trend in last week's jobless claims suggested the jobs market was strengthening despite a sluggish economy.""There is a malaise in the market as investors re-adjust their expectations of a Fed hike,"" said Andrew Barber, chief market strategist at Eagleview Capital in Delaware.""The consensus is probably for a tightening in September, though an increasing number of people think there will be no hike in 2015 as economic data remains weak."" At 10:13 a.m. ET (1413 GMT) the Dow Jones industrial average  was up 4.51 points, or 0.02 percent, at 18,289.91, the S&P 500 was up 2.76 points, or 0.13 percent, at 2,128.61 and the Nasdaq Composite was up 7.37 points, or 0.15 percent, at 5,079.12.Eight of the 10 major S&P 500 sectors were higher, with the energy index rising 0.7 percent as oil prices rose for a second day.The Fed has kept interest rates at near zero for almost a decade, which has made funds cheaper and helped the stock market reach record highs.The S&P 500 hit a record intraday high on Wednesday. The Dow, which had closed at record highs in the previous two sessions, was also briefly on track for another all-time high close. Salesforce.com shares rose 5.4 percent to $73.98 trading after the cloud software company, the subject of takeover speculation for the past few weeks, reported a profit for the first time in seven quarters. [ID:nL3N0YB57DLumber Liquidators shares plunged 14.8 percent to $21.55 after the hardwood flooring retailer's chief executive resigned unexpectedly.NetApp fell 11.8 percent to $31.15 after the data storage equipment maker reported lower-than-expected quarterly results and cut about 500 jobs.Best Buy jumped 5.2 percent to $35.54 after the consumer electronics chain reported better-than-expected quarterly profit and sales.CVS Health was up 2.8 percent at $104.14 after it said it would buy pharmacy service provider Omnicare for $10.1 billion. Omnicare shares rose 1.3 percent to $95.92.Advancing issues outnumbered decliners on the NYSE by 1,685 to 1,112, for a 1.52-to-1 ratio on the upside. On the Nasdaq, 1,213 issues rose and 1,189 fell for a 1.02-to-1 ratio favoring advancers.The S&P 500 showed nine new 52-week highs and two new lows, while the Nasdaq recorded 38 new highs and 18 new lows.   (Editing by Savio D'Souza)",2015-05-21,CVS,"Thu May 21, 2015 | 10:22am EDT",US STOCKS-Wall St shrugs off weak data to inch higher,http://www.reuters.com//article/markets-stocks-usa-idUSL3N0YC4MT20150521?type=companyNews
80,"  (Corrects to ""people aged between 55 and 64"" from ""people aged between 50-75"" in paragraph 2)* Deal values Omnicare at $12.7 bln, including $2.3 bln debt* Offer of $98/share at 4 pct premium to Wednesday close* Deal to add $0.20/share to CVS's adjusted earnings in 2016* Omnicare shares rise to $95.75 premarket; CVS up 1.6 pctMay 21 CVS Health Corp, the second-largest U.S. drugstore operator, said on Thursday it will buy pharmacy services provider Omnicare Inc for $10.1 billion to expand in the growing market serving the senior patient population.The number of people aged between 55 and 64, commonly called baby boomers, having two or more chronic conditions that require medication grew 39.2 percent in the last decade, according to the Centers for Disease Control and Prevention's latest report.Baby Boomers surpassed all other age groups as the highest-cost medication users in 2014, according to a report from Express Scripts, the largest U.S. pharmacy benefit manager. CVS offered $98 per Omnicare share, representing a premium of 4 percent to Omnicare's closing price on Wednesday.The offer is at a nearly 21 percent premium to Omnicare's April 21 close, the day before Bloomberg reported that the company was exploring a sale.Shares of Omnicare, the top U.S. provider of pharmacy services to the elderly, rose 1.2 percent to $95.75 in premarket trading. CVS's stock was up 1.6 percent at $102.90 in light trading on Thursday.The deal comes at a time when pharmacy benefit managers and pharmacy chain operators are consolidating to negotiate better prices with drugmakers. Rite Aid Corp bought pharmacy benefit manager EnvisionRx for about $2 billion in February, while health insurer UnitedHealth Group Inc agreed to buy Catamaran Corp  for about $12.8 billion in March.""Both (CVS and Omnicare) are big Part D players and there could be some scale benefits in negotiating with other payors,"" Cowen & Co analyst Charles Rhyee wrote in a note on Wednesday.Bloomberg first reported on Wednesday that CVS was nearing a deal to buy Omnicare.CVS said the deal will also help expand its presence in the rapidly growing specialty pharmacy business, which sells high-cost drugs to treat complex or rare conditions. CVS said it expects the deal to add about 20 cents to adjusted earnings per share in 2016.The deal values Omnicare at about $12.7 billion, including debt of about $2.3 billion, the companies said.CVS said it had secured $13 billion in financing from Barclays for the deal, which is expected to close near the end of 2015.Barclays and Evercore are CVS's financial advisers, while Bank of America Merrill Lynch and Centerview Partners advised Omnicare.CVS's legal adviser is Sullivan & Cromwell LLP, while White & Case LLP served as Omnicare's legal counsel.(Reporting by Sruthi Ramakrishnan and Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila)",2015-05-21,CVS,"Thu May 21, 2015 | 9:19am EDT",CORRECTED-UPDATE 2-CVS to buy pharmacy services provider Omnicare for $10.1 bln,http://www.reuters.com//article/omnicare-ma-cvs-health-idUSL3N0YC3WR20150521?type=companyNews
81,"  * 4-week jobless claims at lowest since April 2000* Lumber Liquidators plunges after CEO resigns unexpectedly* Best Buy rises; NetApp falls after results* CVS up on $10.1 bln Omnicare deal* Futures down: Dow 23 pts, S&P 2.75 pts, Nasdaq 10.50 pts   (Adds details, comment, updates prices)By Tanya AgrawalMay 21 U.S. stocks were set to open slightly lower on Thursday after weekly U.S. jobless claims rose more than expected, and a day after minutes from the Federal Reserve meeting bolstered the view that rates would stay near zero until later this year.While the number of Americans filing new claims for unemployment benefits rose slightly more than expected last week, the four-week moving average was the lowest since April 2000, continuing to suggest the labor market was tightening. That gives weight to the opinion of most central bank officials who agreed that economic growth would climb to a healthier pace and the labor market would strengthen, according to minutes from the Fed's April 28-29 meeting.Fed officials believed it would be premature to raise rates in June, even though most felt the U.S. economy was set to rebound from a dismal start to the year.Data measuring the growth in the U.S. manufacturing sector in May is due at 9:45 a.m. ET (1345 GMT) and 15 minutes later the National Association of Realtors data is expected to show that sales of used homes increased last month.""There is a malaise in the market as investors re-adjust their expectations of a Fed hike,"" said Andrew Barber, chief market strategist at Eagleview Capital in Delaware. S&P 500 e-mini futures were down 2.75 points and their fair value - a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract - indicated a lower open.Dow Jones industrial average e-mini futures fell 23 points and Nasdaq 100 e-mini futures lost 10.50 points.""The consensus is probably for a tightening in September, though an increasing number of people think there will be no hike in 2015 as economic data remains weak,"" said Barber.The Fed has kept interest rates at near zero for almost a decade, which has made funds cheaper and helped the stock market reach record highs. The S&P 500 hit a record intraday high on Wednesday. The Dow, which had closed at record highs in the previous two sessions, was also briefly on track for another all-time high close.Salesforce.com shares rose 3.7 percent to $72.77 in premarket trading after the cloud software company, the subject of takeover speculation for the past few weeks, reported a profit for the first time in seven quarters. [ID:nL3N0YB57DLumber Liquidators shares plunged 16.1 percent to $21.21 after the hardwood flooring retailer's chief executive resigned unexpectedly.NetApp fell 12.26 percent to $31 after the data storage equipment maker reported lower-than-expected quarterly results and cut about 500 jobs.Best Buy jumped 5.5 percent to $35.64 after the consumer electronics chain reported better-than-expected quarterly profit and sales.CVS Health was up 1.6 percent at $102.90 after it said it would buy pharmacy service provider Omnicare for $10.1 billion. Omnicare shares rose 1.1 percent to $95.71.Hewlett-Packard, Intuit and Gap are scheduled to report results after the close.   (Editing by Savio D'Souza)",2015-05-21,CVS,"Thu May 21, 2015 | 9:10am EDT",US STOCKS-Wall St set to open lower as weekly jobless claims rise,http://www.reuters.com//article/markets-stocks-usa-idUSL3N0YC4EB20150521?type=companyNews
82,  May 21 Drugstore operator CVS Health Corp  said it will acquire pharmacy service provider Omnicare Inc for an enterprise value of about $12.7 billion.The $98 per share offer represents a premium of 4 percent over Omnicare's closing price on Wednesday. The deal includes debt of about $2.3 billion.  (Reporting by Sruthi Ramakrishnan in Bengaluru; Editing by Sriraj Kalluvila),2015-05-21,CVS,"Thu May 21, 2015 | 7:10am EDT",CVS Health to buy Omnicare in $12.7 billion deal,http://www.reuters.com//article/omnicare-ma-cvs-health-idUSL3N0YC3W320150521?type=companyNews
83,"  May 21 The following bids, mergers, acquisitions and disposals were reported by 1030 GMT on Thursday:** CVS Health Corp, the second-largest U.S. drugstore operator, is nearing a deal to buy pharmacy service provider Omnicare Inc for more than $12 billion, according to two people familiar with the matter.** Oil producer Pacific Rubiales Energy Corp said it has agreed to the C$6.50 per share cash offer from Mexico's Alfa Sab de CV and investment firm Harbour Energy Ltd.** Permira Advisers LLC, the buyout firm that owns most of Ancestry.com LLC, the world's largest family history website helping users trace their heritage, is exploring a sale that could value the genealogy website at $2.5-$3.0 billion, including debt, according to people familiar with the matter.** U.S. private equity firm Cerberus Capital Management LP on Thursday launched a selldown of up to $878 million in railway firm Seibu Holdings, IFR reported, citing a term sheet of the transaction.** U.S. private equity firm Bain Capital will cut its 70 percent stake in Japanese restaurant chain Skylark Co Ltd  to less than 50 percent.** Cadila Healthcare Ltd, among India's top ten drugmakers, is in late-stage talks to buy smaller rival Claris Lifesciences Ltd for about 34 billion rupees ($534 million), the Economic Times newspaper reported, citing sources aware of the talks. ** Indian drugmaker Strides Arcolab Ltd has agreed to buy businesses in Australia and Mauritius from South Africa's Aspen Pharmacare Holdings Ltd, paying $300 million to expand its footprint in markets set for brisk growth.** GE, which announced plans last month to sell $200 billion in GE Capital finance assets, now expects to be largely done with the process by 2016 instead of finishing in 2017.** Bermuda-based reinsurer PartnerRe said on Wednesday it was ready to talk to Italian holding company Exor  to see if there was room to improve its $6.8 billion takeover bid.AXIS Capital Holdings Ltd Chief Executive Officer Albert Benchimol told employees on Wednesday that a merger with PartnerRe Ltd was still in the best interests of both reinsurance companies, according to a memo seen by Reuters. ** Oman's United Finance said National Bank of Oman had confirmed interest in participating in a bidding process for a possible acquisition of the company.** Brazilian investment bank BTG Pactual SA and its partners P2Brasil and GMR Energia jointly sold 100 percent of renewable energy company Latin America Power (LAP) to SunEdison, BTG and P2 said.** German lender HSH Nordbank could split off a ""bad bank"" for non-performing shipping loans as part of a plan to create a sustainable business model, according to a person familiar with the matter. ** Israeli defence electronics firm Elbit Systems  has agreed to buy Nice Systems' cyber and intelligence division for $157.9 million as it seeks to boost its presence in this fast-growing market.** South Korean media company Jcontentree Corp  said it would buy the 50 percent stake that it does not already own in the country's third-largest movie theatre chain Megabox Inc for 152 billion won ($139 million).** Dubai's Amanat Holdings said it has bought a 4.14 percent stake in London-listed UAE healthcare firm Al Noor Hospitals from Deutsche Bank for 250 million dirhams ($68.1 million).** Booker Group Plc, Britain's biggest cash-and-carry wholesaler, has agreed to buy the Londis and Budgens chains 40 million pounds ($62.2 million) to expand its network of grocery and convenience stores and tap into changing consumer habits.** Indian vehicle maker Mahindra and Mahindra Ltd  said it would buy a 33 percent voting stake in the agricultural machinery-making unit of Mitsubishi Heavy Industries Ltd  for $25 million.($1 = 63.7100 Indian rupees)  ($1 = C$1.2081)  ($1 = 1,092.5100 won)  ($1 = 3.6730 UAE dirham)  ($1 = 0.6436 pounds)   (Compiled by Ankit Ajmera in Bengaluru)",2015-05-21,CVS,"Thu May 21, 2015 | 6:36am EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL3N0YC3BT20150521?type=companyNews
84,"   By Nandita Bose and Nathan Layne | CHICAGO  CHICAGO Target Corp's (TGT.N) sale of its in-store pharmacies to CVS Health Corp (CVS.N) may encourage large supermarket chains with struggling pharmacies to look for professional drug store partners of their own.More than 1,660 Target pharmacies will become CVS units in the $1.9 billion deal, the first time a drugstore chain has expanded its pharmacy business within a third party retail store, pharmacy consultants and analysts said.Drug stores in recent years have focused on opening new stores, an effort which has slowed recently.Target pharmacies helped drive overall sales at the chain but lost money, as the government health care program known as Obamacare expanded ranks of insured and increased pressure on costs.""Grocery store chains must be taking the news today and thinking hard about it. Pharmacy is not really a core competence,"" said Todd Huseby, partner, AT Kearney said, citing Safeway and Albertsons as two companies that might consider it. Neither responded to a request for comment. Some supermarkets may have the scale and buying power to make their own pharmacies work, said Neil Stern, senior partner at retail consulting firm McMillan Doolittle. They may see the store-in-store format as an opening for a competitor, he said.However, margins are eroding, said Adam Fein, president of advisory and research firm Pembroke Consulting.  ""The future of pharmacy is really about being a low cost buyer of generic drugs and capability to dispense specialty drugs and that is an area of challenge for several supermarket operators,"" he said.Supermarkets with pharmacies such as Kroger (KR.N), Safeway and Stop & Shop saw a 0.6 percent increase in the number of prescriptions filled, but a 0.17 percent decline in prescription market share in 2014 from a year earlier, data from Fein's blog Drug Channels showed.Last year, prescriptions filled at chain drugstores like CVS, Walgreens WBA.N, Rite Aid (RAD.N) rose 5.1 percent, with 1.41 percent growth in prescription market share, while mass merchant chains like Wal-Mart Stores Inc (WMT.N) increased market share by 0.32 percent. Wal-Mart's health and wellness business has been performing very well, and it sees no need to have pharmacies handled by another company, spokeswoman Sarah McKinney said.Drug store chains could look to stores-in-stores as a way to get ""immediate access to new markets at a much lower cost,"" than building their own stores, said Tom Charland, chief executive at consulting firm Merchant Medicine. (Reporting by Nandita Bose in Chicago; Editing by Richard Chang)",2015-06-15,CVS,"Mon Jun 15, 2015 | 7:46pm EDT",CVS-Target deal could spur supermarkets to find pharmacy partners,http://www.reuters.com//article/us-targetpharmacy-m-a-cvs-health-competi-idUSKBN0OV2XI20150615?type=companyNews
85,"   By Sruthi Ramakrishnan and Nathan Layne  Drugstore operator CVS Health Corp (CVS.N) will buy Target Corp's (TGT.N) pharmacies and clinics in a $1.9 billion deal that should help it bargain with drug makers for lower prices, while freeing Target from a costly business where it struggled to make a profit. CVS, the second-largest U.S. drugstore operator with 7,800 stores, said on Monday it will acquire Target's more than 1,660 pharmacies in 47 states with about $4 billion in annual sales. It will also acquire Target's nearly 80 clinics.The pharmacies will continue to be located within Target stores but carry the CVS brand. The move was the CVS' second large acquisition in as many months, coming on the heels of its $10.1 billion deal for healthcare services firm Omnicare Inc OCR.N in May.  The transaction will significantly expand the drugstore chain's retail presence and should bolster its bargaining power with pharmaceutical companies. ""The healthcare industry is evolving rapidly,"" CVS Chief Executive Larry Merlo said on a conference call. ""In this environment, success is all about effectively managing costs, quality and access.""  For Target, the deal divests a business that was ""modestly negative"" in terms of profits. While Target will lose revenue, its sales, general and administrative costs will drop by $1 billion. Target Chief Executive Brian Cornell said the move fits with the company's focus on a handful of categories where it believes it can be most competitive including apparel, items for children and health and wellness-related goods. Target will continue to handle the sale of over-the-counter drugs.Cornell, who has been remaking the retailer's strategy since taking the helm in August, said the deal will allow it to focus resources on reviving its food business, for instance. He also said it should bring more customers into Target stores. The companies hope CVS' price advantages, including in generic drugs, will attract more customers to the pharmacies who then buy other items from Target. ""They bring scale, cost efficiency; they bring expertise that we just could not bring to a space that we were operating as a subscale player,"" Cornell said of CVS. CVS shares were up 0.7 percent at $102.88, while Target shares rose 1.3 percent to $80.51 in morning trading.The two companies said the 80 Target clinics will be rebranded as MinuteClinics, as will the 20 additional clinics they plan to open within three years of the deal closing, expected near the end of 2015..Target and CVS also said they plan to co-develop five to 10 small-format stores, potentially accelerating Target's strategy of finding growth through smaller outlets in urban areas.The deal will also affect both companies' plans for share buybacks. Target said it would likely use some of the expected $1.2 billion in after-tax proceeds for shares repurchases. It doubled its share buyback program to $10 billion last week.In contrast, CVS cut its 2015 share repurchase program by $1 billion to $5 billion as a result of the transaction, which it will finance with debt. The move adds to the strain on its finances, already under pressure from the Omnicare deal.CVS' reduced buyback target led it to lower its 2015 and 2016 adjusted earnings forecast. Barclays is CVS' financial adviser, while Target's is Goldman Sachs.CVS' legal adviser is Fried Frank and regulatory adviser is Dechert LLP. Target's legal advisers are Faegre Baker Daniels LLP, Wachtell, Lipton, Rosen & Katz, and Dorsey & Whitney. (Reporting by Sruthi Ramakrishnan in Bengaluru and Nathan Layne in Chicago; Editing by Savio D'Souza and Cynthia Osterman)",2015-06-15,CVS,"Mon Jun 15, 2015 | 6:29pm EDT",CVS Health to buy Target's pharmacy business for $1.9 billion,http://www.reuters.com//article/us-targetpharmacy-m-a-cvs-health-idUSKBN0OV1C620150615?type=companyNews
86,"  * Deal to boost CVS' bargaining power, narrow Target's focus* All new Target stores with pharmacies to include CVS pharmacy* CVS cuts 2015 share repurchase program to $5 bln from $6 bln* Target to use $1.2 bln proceeds for share repurchase* CVS shares up 0.7 pct, Target up 1.3 pct   (Adds CEO comments, details)By Sruthi Ramakrishnan and Nathan LayneJune 15 Drugstore operator CVS Health Corp  will buy Target Corp's pharmacies and clinics in a $1.9 billion deal that should help it bargain with drug makers for lower prices, while freeing Target from a costly business where it struggled to make a profit.CVS, the second-largest U.S. drugstore operator with 7,800 stores, said on Monday it will acquire Target's more than 1,660 pharmacies in 47 states with about $4 billion in annual sales. It will also acquire Target's nearly 80 clinics.The pharmacies will continue to be located within Target stores but carry the CVS brand. The move was the CVS' second large acquisition in as many months, coming on the heels of its $10.1 billion deal for healthcare services firm Omnicare Inc in May.The transaction will significantly expand the drugstore chain's retail presence and should bolster its bargaining power with pharmaceutical companies.""The healthcare industry is evolving rapidly,"" CVS Chief Executive Larry Merlo said on a conference call. ""In this environment, success is all about effectively managing costs, quality and access.""For Target, the deal divests a business that was ""modestly negative"" in terms of profits. While Target will lose revenue, its sales, general and administrative costs will drop by $1 billion.Target Chief Executive Brian Cornell said the move fits with the company's focus on a handful of categories where it believes it can be most competitive including apparel, items for children and health and wellness-related goods. Target will continue to handle the sale of over-the-counter drugs. Cornell, who has been remaking the retailer's strategy since taking the helm in August, said the deal will allow it to focus resources on reviving its food business, for instance.He also said it should bring more customers into Target stores. The companies hope CVS' price advantages, including in generic drugs, will attract more customers to the pharmacies who then buy other items from Target.""They bring scale, cost efficiency; they bring expertise that we just could not bring to a space that we were operating as a subscale player,"" Cornell said of CVS.CVS shares were up 0.7 percent at $102.88, while Target shares rose 1.3 percent to $80.51 in morning trading. The two companies said the 80 Target clinics will be rebranded as MinuteClinics, as will the 20 additional clinics they plan to open within three years of the deal closing, expected near the end of 2015..Target and CVS also said they plan to co-develop five to 10 small-format stores, potentially accelerating Target's strategy of finding growth through smaller outlets in urban areas.The deal will also affect both companies' plans for share buybacks.Target said it would likely use some of the expected $1.2 billion in after-tax proceeds for shares repurchases. It doubled its share buyback program to $10 billion last week.In contrast, CVS cut its 2015 share repurchase program by $1 billion to $5 billion as a result of the transaction, which it will finance with debt. The move adds to the strain on its finances, already under pressure from the Omnicare deal.CVS' reduced buyback target led it to lower its 2015 and 2016 adjusted earnings forecast.Barclays is CVS' financial adviser, while Target's is Goldman Sachs.CVS' legal adviser is Fried Frank and regulatory adviser is Dechert LLP. Target's legal advisers are Faegre Baker Daniels LLP, Wachtell, Lipton, Rosen & Katz, and Dorsey & Whitney.   (Reporting by Sruthi Ramakrishnan in Bengaluru and Nathan Layne in Chicago; Editing by Savio D'Souza and Cynthia Osterman)",2015-06-15,CVS,"Mon Jun 15, 2015 | 2:12pm EDT",UPDATE 4-CVS Health to buy Target's pharmacy business for $1.9 bln,http://www.reuters.com//article/targetpharmacy-ma-cvs-health-idUSL3N0Z13VO20150615?type=companyNews
87,"  (The following statement was released by the rating agency) NEW YORK, June 15 (Fitch) Fitch Ratings does not expect any rating implications  from Target Corporation's (Target) announcement that it has signed a definitive  agreement to sell its pharmacy and clinic businesses to CVS Health (CVS) for  pretax proceeds of $1.9 billion. Target's long-term Issuer Default Rating (IDR)  is 'A-' and short-term IDR is 'F2'. The Rating Outlook is Stable. A full list of  ratings follows at the end of this release. Target expects to deploy the after-tax net proceeds of approximately $1.2  billion to support its long-term capital priorities, including share  repurchases.  The transaction is subject to customary closing conditions,  including regulatory clearance, with timing of closing currently uncertain.  Fitch does not expect Target's financial leverage to increase. The transaction  should benefit operating margins, enhance the customer experience around  healthcare, strengthen Target's focus on wellness as a signature category, and  potentially help drive traffic and sales at its stores.  Target could also  benefit over time by co-developing its smaller Target Express stores in  conjunction with CVS, potentially creating a stronger convenience format.   Target's ratings reflect its strong competitive position in the discount retail  sector, improving performance in its U.S. business, and exit from Canada,  closing its remaining stores during April 2015. Cash costs associated with  exiting Canada are expected to total $500 million-$600 million. However, the  disposition results in the elimination of significant operating losses and  capital lease obligations.   Target's U.S. comparable store sales (comps) were up 2.3% in the first quarter  of 2015 (1Q15) following a modest 1.3% increase in 2014 and a 0.4% decline in  2013. The improvement underscores progress Target is making as the company  focuses on merchandise offerings in the apparel, home, baby, kids and wellness  categories.  Transactions rose 0.9% during1Q15, after declining 0.2% in 2014,  and 2.7% in 2013. Fitch expects comp sales growth can improve to the 2% range in  2015 from 1.3% in 2014. This includes the effect of digital sales, which Fitch  estimates at 2%-3% of total sales and expects to grow at 30% or more annually.  For the continuing U.S. segment, the EBITDA margin increased 110 basis points  (bps) to 10.5% for the 1Q15 versus 9.4% in the comparable period last year. The  expansion was due to primarily to lower promotional activity and cost savings  initiatives. Target's margin had declined by 30 bps in 2014 due to heavier  promotional and clearance activity.  Fitch believes there is upside to Target's consolidated margin to above 10% from  9.3% at the fiscal year ended Jan. 31, 2015 and 9.7% for the latest 12 months  (LTM) period ended May 2, 2015. Expansion will be driven by comp sales growth  and $2 billion of targeted cost reductions over the next two years, offset in  part by investments to drive growth. Margins should also benefit from the sale  of its pharmacy and clinics business to CVS as Target expects the transaction to  be immediately accretive to earnings following deal close.  Adjusted leverage was 2.0x at May 2, 2015, compared with 2.4x at Feb. 1, 2014.  Fitch expects leverage is expected to track at or modestly above 2.0x over the  next few years as EBITDA grows and debt is used to partially finance share  repurchases. Fitch currently expects free cash flow (FCF) excluding  restructuring costs to range from $1.5 billion to $2 billion annually, and along  with incremental borrowings, be directed to share repurchases. RATING SENSITIVITIES The following factors, individually or collectively, could lead to a positive  rating action: improved operating momentum in the domestic business, including  consistent comp sales growth of 2%-3%; an improvement in EBITDA margin toward  its historical level of 10% or greater; and adjusted financial leverage of  around 2.0x. The following factors, individually or collectively, could lead to a negative  rating action: operating shortfalls and more aggressive share repurchase  activity that drive adjusted leverage above the mid-2x range for an extended  period. Fitch currently rates Target as follows: --Long-term IDR 'A-'; --Senior unsecured debt 'A-'; --Bank credit facility 'A-'; --Short-term IDR 'F2'; --Commercial paper 'F2'. The Rating Outlook is Stable. Contact: Primary Analyst Carla Norfleet Taylor, CFA Senior Director +1-312-368-3195 Fitch Ratings, Inc. 70 W. Madison Street Chicago, IL 60602 Secondary Analyst Monica Aggarwal, CFA Senior Director +1-212-908-0282 Committee Chairperson Michael Weaver Managing Director +1-312-368-3156 Media Relations: Alyssa Castelli, New York, Tel: +1 (212) 908 0540, Email:  alyssa.castelli@fitchratings.com. Additional information is available at 'www.fitchratings.com'. ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2015-06-15,CVS,"Mon Jun 15, 2015 | 1:30pm EDT",Fitch: No Rating Implications from Target's Announcement of Pharmacy Sale to CVS,http://www.reuters.com//article/idUSFit92598520150615?type=companyNews
88,"  June 15 Drugstore operator CVS Health Corp  said it will acquire Target Corp's pharmacy and clinic businesses for about $1.9 billion.CVS will acquire more than 1,660 Target pharmacies across 47 states in the United States and operate them through a store-within-a-store format, the companies said in a statement.  (Reporting by Sruthi Ramakrishnan in Bengaluru; Editing by Sriraj Kalluvila) ",2015-06-15,CVS,"Mon Jun 15, 2015 | 7:09am EDT","CVS to buy Target's pharmacy, clinic businesses for $1.9 bln",http://www.reuters.com//article/targetpharmacy-ma-cvs-health-idUSL3N0Z13U820150615?type=companyNews
89,"   By Barbara Grzincic  CVS Caremark's ""ExtraBucks Rewards"" program was too widely publicized to be the basis for a customer's whistleblower action, a federal judge in Chicago has ruled. The ruling in U.S. District Court for the Northern District of Illinois on Friday dismissed two False Claims Act lawsuits brought by Richard Carmel, a retired real estate broker and Medicare recipient.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1C69jVw",2015-06-30,CVS,"Tue Jun 30, 2015 | 4:31pm EDT",Judge tosses whistleblower suits over CVS ExtraBucks program,http://www.reuters.com//article/health-cvs-whistleblower-idUSL1N0ZG2O020150630?type=companyNews
90,"  (Adds details on CVS deal, updates prices)     * Greek deal reduces safe-haven bond buying     * Focus on Fed after hawkish Yellen speech     * Large CVS bond deal weighs on market      By Karen Brettell     NEW YORK, July 13 U.S. Treasury yields rose on Monday after Greek and euro zone leaders reached a deal that is likely to keep Greece in the single currency and as a large corporate bond deal weighed on the market.     Euro zone leaders made Greece surrender much of its sovereignty to outside supervision in return for talks on an 86-billion-euro bailout to keep the near-bankrupt country within the single currency union.      The news reduced safe-haven buying of U.S. debt and boosted riskier assets including equities.     Drugstore chain CVS Health also came to market with a bond sale of up to $15 billion to finance its acquisitions of Omnicare and Target Pharmacies, according to IFR, a Thomson Reuters service.     The CVS deal ""definitely put some pressure on the market,"" said Dan Mulholland, head of Treasuries trading at Credit Agricole in New York.     Benchmark 10-year notes were last down 10/32 in price to yield 2.43 percent, up from 2.38 percent before the Greek deal was announced earlier on Monday. The yields have risen from a low of 2.18 percent on Thursday as hopes for a resolution increased.     Yields also increased as investors anticipated the Federal Reserve is closer to raising interest rates for the first time in nearly ten years, after Fed Chair Janet Yellen said on Friday she expects a rate hike at some point this year.      ""Everyone is waiting for Yellen's remarks after her comments on Friday, which were fairly hawkish,"" said Gennadiy Goldberg, an interest rate strategist at TD Securities in New York.     Yellen is due to give her Humphrey-Hawkins testimony to Congress on Wednesday and Thursday.     Investors now expect that the Fed is likely to begin raising rates at its September meeting.     ""I think they are very close to hiking rates and the market is now finally starting to understand that,"" said Goldberg.     U.S. economic data will be closely evaluated for signs that growth is improving at a pace that will allow the Fed to begin raising rates.     The next major economic report will be retail sales data for June, due out on Tuesday.   (Editing by Bernadette Baum and Meredith Mazzilli)   ",2015-07-13,CVS,"Mon Jul 13, 2015 | 2:41pm EDT","TREASURIES-Yields rise on Greek deal, corporate bond sale weighs",http://www.reuters.com//article/markets-bonds-usa-idUSL2N0ZT1L320150713?type=companyNews
91,"  University of California (UCLA) Health, which runs four hospitals in the university's campuses, and drug retailer CVS Health Corp's (CVS.N) CVSphoto.com became the latest victims of cyber attacks.UCLA Health said on Friday that data on as many as 4.5 million individuals was at potentially at risk, although it added it had not yet found evidence that individuals' personal or medical information was actually accessed or acquired during the breach.The Federal Bureau of Investigation and private computer forensic experts are looking into the attack, UCLA Health said.Meanwhile, CVSphoto.com, CVS's online photo service, temporarily shut down access to online and related mobile photo services after falling victim to a similar breach. ""Customer credit card information collected by the independent vendor who manages and hosts CVSPhoto.com may have been compromised,"" CVSphoto.com said on its website. (bit.ly/1fb7NGT) It was not immediately clear if the two attacks were related.Anthem Inc (ANTM.N), the No. 2 U.S. health insurer, disclosed in February that it fell victim to a massive data breach, prompting state and federal investigations. The Anthem hack followed a breach at hospital operator Community Health Systems (CYH.N) last year, which compromised about 4.5 million records.  (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Saumyadeb Chakrabarty and Simon Jennings)",2015-07-17,CVS,"Fri Jul 17, 2015 | 4:39pm EDT","CVS Health's photo service, UCLA Health get hacked",http://www.reuters.com//article/us-ucla-health-cyberattack-idUSKCN0PR1ZW20150717?type=companyNews
92,"  (Adds CVSphoto.com hacking, details)July 17 University of California (UCLA) Health, which runs four hospitals in the university's campuses, and drug retailer CVS Health Corp's CVSphoto.com became the latest victims of cyber attacks.UCLA Health said on Friday that data on as many as 4.5 million individuals was at potentially at risk, although it added it had not yet found evidence that individuals' personal or medical information was actually accessed or acquired during the breach. The Federal Bureau of Investigation and private computer forensic experts are looking into the attack, UCLA Health said.Meanwhile, CVSphoto.com, CVS's online photo service, temporarily shut down access to online and related mobile photo services after falling victim to a similar breach. ""Customer credit card information collected by the independent vendor who manages and hosts CVSPhoto.com may have been compromised,"" CVSphoto.com said on its website. (bit.ly/1fb7NGT) It was not immediately clear if the two attacks were related.Anthem Inc, the No. 2 U.S. health insurer, disclosed in February that it fell victim to a massive data breach, prompting state and federal investigations. The Anthem hack followed a breach at hospital operator Community Health Systems last year, which compromised about 4.5 million records.   (Reporting by Anjali Rao Koppala in Bengaluru; Editing by Saumyadeb Chakrabarty and Simon Jennings)",2015-07-17,CVS,"Fri Jul 17, 2015 | 2:24pm EDT","UPDATE 1-CVS Health's photo service, UCLA Health get hacked",http://www.reuters.com//article/ucla-health-cyberattack-idUSL4N0ZX4MF20150717?type=companyNews
93,"   By Noel Randewich  Wall Street ended lower on Tuesday for a third straight session as investors worried about a rise in interest rates while Apple's shares hit their lowest in over six months.The iPhone maker's shares fell 3.21 percent to $114.64, firmly below their 200-day daily moving average, a key technical level closely watched by traders. The stock was the biggest drag on the three major U.S. indexes.A slowdown in China and skepticism over demand for iPhones were contributing to pressure on Apple's shares, traders said.""Apple has been the weak sister in the market today,"" said Alan Gayle, senior investment strategist and director of asset allocation at RidgeWorth Investments in Atlanta, Georgia. ""But if you look at the sectors, most everything is down with the exception of materials."" Stocks extended losses after Atlanta Federal Reserve President Dennis Lockhart told the Wall Street Journal that September may be the right time for Fed to lift interest rates.The Dow Jones industrial average .DJI fell 0.27 percent to end at 17,550.69 and the S&P 500 .SPX lost 0.22 percent to 2,093.32. The Nasdaq Composite .IXIC dropped 0.19 percent finish at 5,105.55. Eight of the 10 major S&P sectors fell, with the utilities index's .SPLRCU 1.64 percent decline leading the losers. The Fed has said it needs to see a sustained economic recovery before it raises interest rates for the first time in nearly a decade.Soft economic data had prompted some investors to argue that the Fed might hold off on raising rates until December. After the Fed meeting last week, investors expected a rate increase in September. ""The market is getting such a mixed bag of rhetoric from the Fed, it seems like the Fed isn't sure what it's going to do,"" said Jack Ablin, chief investment officer at BMO Private Bank in Chicago.After the bell, shares of crafts website Etsy (ETSY.O) fell 9 percent and Walt Disney (DIS.N) lost 1.4 percent after the companies posted quarterly results that disappointed Wall Street. First Solar (FSLR.O) posted better-than-expected quarterly results and guidance and its stock was up 10 percent.During the session, American International Group (AIG.N) fell 2.82 percent after the insurer's underwriting income fell in almost all of its units, while home and auto insurer Allstate (ALL.N) fell 10.15 percent after its profit missed expectations. Declining issues outnumbered advancing ones on the NYSE by 1.23 to 1. On the Nasdaq, 1,414 issues fell and 1,376 advanced for a 1.03-to-1 ratio favoring decliners.The benchmark S&P 500 index was posting 32 new 52-week highs and 26 new lows; the Nasdaq Composite was recording 91 new highs and 127 new lows. Some 6.4 billion shares changed hands on U.S. exchanges, below the five-day average of 7.0 billion this month, according to BATS Global Markets.  (Additional reporting by Tanya Agrawal; Editing by Saumyadeb Chakrabarty and Meredith Mazzilli)",2015-08-04,CVS,"Tue Aug 4, 2015 | 6:13pm EDT","Wall Street moves lower on Apple, interest rate worries",http://www.reuters.com//article/us-markets-stocks-idUSKCN0Q916Y20150804?type=companyNews
94,"  U.S. drugstore chain operator CVS Health Corp estimated current-quarter profit below analysts' expectations, hurt by pressure from reimbursement rates and lower customer traffic after the company stopped selling tobacco products. CVS shares fell as much as 5.5 percent on Tuesday.  The company is also being hurt by introduction of new generic drugs, which offer lower margins.CVS said its front store same-store sales declined 7.8 percent in the second quarter, the biggest decline in two years. Analysts on average had expected a 5.8 percent drop, according to research firm Consensus Metrix.CVS sells over-the-counter drugs, general consumer items and snacks at the front of its stores.  The company forecast adjusted profit of $1.27-$1.30 per share for the third quarter. Analysts on average were expecting $1.37 per share, according to Thomson Reuters I/B/E/S.The company also raised the lower end of its 2015 adjusted profit forecast range to $5.11 per share and cut the higher end to $5.18. CVS had earlier forecast an adjusted profit of $5.08-$5.19 per share. CVS's net income rose 2.1 percent to $1.27 billion, or $1.12 per share, in the second quarter ended June 30. Net revenue rose 7.4 percent to $37.17 billion.Excluding items, the company earned $1.22 per share. Analysts on average had expected earnings of $1.20 per share  and revenue of $37.18 billion.CVS shares were down 3 percent at $109.50 in late morning trading on the New York Stock Exchange.  (Reporting by Ramkumar Iyer in Bengaluru; Editing by Saumyadeb Chakrabarty and Kirti Pandey)",2015-08-04,CVS,"Tue Aug 4, 2015 | 1:34pm EDT",Drugstore chain operator CVS forecasts profit below estimates,http://www.reuters.com//article/us-cvs-health-results-idUSKCN0Q91F220150804?type=companyNews
95,"  (Adds forecast, details, shares)Aug 4 U.S. drugstore chain operator CVS Health Corp estimated current-quarter profit below analysts' expectations, hurt by pressure from reimbursement rates and lower customer traffic after the company stopped selling tobacco products.CVS shares fell as much as 5.5 percent on Tuesday.The company is also being hurt by introduction of new generic drugs, which offer lower margins.CVS said its front store same-store sales declined 7.8 percent in the second quarter, the biggest decline in two years. Analysts on average had expected a 5.8 percent drop, according to research firm Consensus Metrix. CVS sells over-the-counter drugs, general consumer items and snacks at the front of its stores.The company forecast adjusted profit of $1.27-$1.30 per share for the third quarter. Analysts on average were expecting $1.37 per share, according to Thomson Reuters I/B/E/S. The company also raised the lower end of its 2015 adjusted profit forecast range to $5.11 per share and cut the higher end to $5.18. CVS had earlier forecast an adjusted profit of $5.08-$5.19 per share.CVS's net income rose 2.1 percent to $1.27 billion, or $1.12 per share, in the second quarter ended June 30. Net revenue rose 7.4 percent to $37.17 billion. Excluding items, the company earned $1.22 per share.Analysts on average had expected earnings of $1.20 per share  and revenue of $37.18 billion.CVS shares were down 3 percent at $109.50 in late morning trading on the New York Stock Exchange.    (Reporting by Ramkumar Iyer in Bengaluru; Editing by Saumyadeb Chakrabarty and Kirti Pandey)",2015-08-04,CVS,"Tue Aug 4, 2015 | 10:50am EDT",UPDATE 2-Drugstore chain operator CVS forecasts profit below estimates,http://www.reuters.com//article/cvs-health-results-idUSL3N10F43Q20150804?type=companyNews
96,"  * Baxalta soars after $30-billion Shire offer* Coach jumps after results beat expectations* Walt Disney, Genworth to report after the bell* Indexes up: Dow 0.02 pct, S&P 0.04 pct, Nasdaq 0.05 pct   (Updates to open)By Tanya AgrawalAug 4 Wall Street was little changed on Tuesday amid a burst of earnings reports from companies ranging from drugstore operator CVS Health to handbag maker Coach, while Apple's shares remained under pressure for a second day.The iPhone maker's shares fell 2.1 percent to $115.99, moving firmly below their 200-day daily moving average, a key technical level closely watched by traders. The stock was also the biggest drag on the three major U.S. indexes.The main S&P sectors were split in half in terms of gainers and losers - energy stocks led the gainers as oil bounced back, while utilities were the biggest losers.Among other companies scheduled to release results are Dow component Walt Disney, Devon Energy and Genworth Financial. With a bulk of the S&P 500 companies having reported results, investors are taking to the sidelines ahead of Friday's monthly jobs data.The report is shaping up to be critical for the market as it can provide clues on the timing of a rate hike. The U.S. economy created 225,000 new jobs in July, according to economists polled by Reuters.Wall Street ended lower on Monday as tumbling oil prices dragged energy shares to a three-year low and factory data from China raised concerns about the world's second-biggest economy.In the United States, consumer spending recorded its smallest gain in four months, while the pace of growth in the manufacturing sector slowed in July. Soft data has prompted some investors to argue that the U.S. Federal Reserve might hold off on raising rates until December. After the Fed meeting last week, investors expected a rate increase in September.The Fed, which has kept interest rates near zero for nearly a decade, has said it will raise rates only when it sees a sustained recovery in the economy.Oil prices steadied but have fallen more than 20 percent over the last month, while copper - seen as a bellwether of global growth - nudged off a six-year low.At 9:47 a.m. ET (1347 GMT) the Dow Jones industrial average  was up 3.94 points, or 0.02 percent, at 17,602.14, the S&P 500 was up 0.81 points, or 0.04 percent, at 2,098.85 and the Nasdaq Composite was up 2.78 points, or 0.05 percent, at 5,118.16. Valuations remain a concern. The S&P 500 is trading near 16.8 times forward 12-month earnings, above the 10-year median of 14.7 times, according to StarMine data.Baxalta shares soared 14.2 percent to $37.84 after Shire  said it was seeking to buy the company in a $30 billion all-share deal. U.S.-listed shares of Shire fell 3.3 percent to $259.CVS Health fell 4.4 percent to $107.73 afters its revenue narrowly missed estimates.Coach was up 5.9 percent at $32.27 after the handbag-maker's results beat expectations.Regeneron Pharmaceuticals rose 8.1 percent to $599.98 after the biotechnology company reported a 50 percent rise in quarterly revenue.Advancing issues outnumbered decliners on the NYSE by 1,664 to 1,009. On the Nasdaq, 1,397 issues rose and 831 fell.The S&P 500 index showed 14 new 52-week highs and six new lows, while the Nasdaq recorded 39 new highs and 38 new lows.   (Reporting by Tanya Agrawal; Editing by Saumyadeb Chakrabarty)",2015-08-04,CVS,"Tue Aug 4, 2015 | 10:12am EDT","US STOCKS-Wall St flat amid slew of earnings, Apple weighs",http://www.reuters.com//article/markets-stocks-usa-idUSL3N10F4U620150804?type=companyNews
97,"  * Baxalta soars after $30-billion Shire offer* Coach jumps after results beat expectations* CVS Health falls after revenue narrowly misses estimates* Futures: Dow up 13 pts, S&P little changed, Nasdaq down 4 pts   (Adds details, comment, updates prices)By Tanya AgrawalAug 4 Wall Street was set to open little changed on Tuesday as investors digest earnings reports from a slew of consumer products companies, including Kellogg, Coach and CVS Health.Among other companies scheduled to release results are Dow component Walt Disney, Devon Energy and Genworth Financial.Investors are taking to the sidelines ahead of Friday's monthly jobs data, which is shaping up to be critical for market as it can provide clues on the timing of a rate hike. The U.S. economy created 225,000 new jobs in July, according to economists polled by Reuters. Wall Street ended lower on Monday as tumbling oil prices dragged energy shares to a three-year low and factory data from China raised concerns about the world's second-biggest economy.In the United States, consumer spending recorded its smallest gain in four months, while the pace of growth in the manufacturing sector slowed in July.Soft data has prompted some investors to argue that the U.S. Federal Reserve might hold off on raising rates until December. After the Fed meeting last week, investors expected a rate increase in September. The Fed, which has kept interest rates near zero for nearly a decade, has said it will raise rates only when it sees a sustained recovery in the economy.""If we get some certainty about the strength of the U.S. economy and the likelihood of policy normalization by the Fed, and if a rate hike seems justifiable, that is positive for sentiment ... because a lot of people have been bracing for this,"" said Stefan Worrall, director of cash equities at Credit Suisse.Oil prices steadied but have fallen more than 20 percent over the last month, while copper - seen as a bellwether of global growth - nudged off a six-year low.S&P 500 e-minis were up 0.25 points, or 0.01 percent, with 144,784 contracts traded at 9:02 a.m. ET (1302 GMT). Nasdaq 100 e-minis were down 4 points, or 0.09 percent, on volume of 27,781 contracts while Dow e-minis  were up 13 points, or 0.07 percent, with 20,164 contracts changing hands. With more than half of the S&P 500 companies having reported their second-quarter results, analysts expect overall earnings to edge up 0.9 percent and revenue to decline 3.3 percent, according to Thomson Reuters data.Valuations remain a concern. The S&P 500 is trading near 16.8 times forward 12-month earnings, above the 10-year median of 14.7 times, according to StarMine data.Baxalta shares soared 21.3 percent to $40.21 in premarket trading after Shire  said it was seeking to buy the company in a $30 billion all-share deal. U.S.-listed shares of Shire fell 2.8 percent to $260.38.Sprint rose 5.4 percent to $3.52 after the telecom carrier reported a lower-than-expected quarterly loss while CVS Health fell 2.5 percent to $110 afters its revenue narrowly missed estimates.Coach was up 5.5 percent at $32.10 after the handbag-maker's results beat expectations.Regeneron Pharmaceuticals rose 4.8 percent to $581 after the biotechnology company reported a 50 percent rise in quarterly revenue, boosted by increasing demand for its blockbuster eye drug, Eylea.    (Reporting by Tanya Agrawal; Editing by Saumyadeb Chakrabarty)",2015-08-04,CVS,"Tue Aug 4, 2015 | 9:07am EDT",US STOCKS-Wall St set to open little changed amid earnings,http://www.reuters.com//article/markets-stocks-usa-idUSL3N10F4KT20150804?type=companyNews
98,"  (Corrects revenue to $37.17 billion from $37.16 billion in paragraph 3)Aug 4 Drugstore operator CVS Health Corp  reported a 7.4 percent rise in quarterly sales as demand for its specialty pharmacy services increased and pharmacy claims rose. The company's net income rose to $1.27 billion, or $1.12 per share, in the second quarter ended June 30, from $1.25 billion, or $1.06 per share, a year earlier.  Net revenue rose to $37.17 billion from $34.60 billion a year earlier.   (Reporting by Ramkumar Iyer in Bengaluru; Editing by Saumyadeb Chakrabarty)",2015-08-04,CVS,"Tue Aug 4, 2015 | 7:19am EDT",CORRECTED-CVS Health's sales rise 7.4 percent,http://www.reuters.com//article/cvs-health-results-idUSL3N10E5BG20150804?type=companyNews
99,"  (Adds J&J comment)By Ransdell Pierson and Bill BerkrotAug 5 CVS Health Corp, which operates the nation's second-biggest pharmacy benefit manager, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including Viagra and widely used treatments for diabetes and multiple sclerosis.The 2016 excluded drugs, disclosed on Wednesday, also include Vivus Inc's weight loss treatment Qsymia, which last week was excluded from the 2016 formulary of rival PBM Express Scripts Holding Co. Vivus officials could not immediately be reached for comment.Pharmacy benefit managers, or PBMs, which administer drug benefits for employers and health plans and also run large mail-order pharmacies, have been challenging the rising cost of new medications. When drugs are knocked off their formularies, patients may have to pay full price for them. PBMs often keep or dump a product depending on whether they can obtain favorable pricing.Viagra, the world's first approved pill for erectile dysfunction, has annual sales of $1.8 billion, including $1.3 billion in the United States. Cheaper generic versions are expected to be launched by December 2017. ""Pfizer is committed to ensuring patient access to our medicines,"" the drugmaker said in an emailed statement.The CVS formulary, however, does include Eli Lilly and Co's  rival Cialis anti-impotence treatment.Next year's formulary will also exclude two interferon-based multiple sclerosis treatments from Biogen, big-selling Avonex and its new longer-acting Plegridy. Avonex, Biogen's second-biggest product, has annual sales of almost $2.5 billion. ""Avonex and Plegridy have broad insurance coverage,"" Biogen said in an emailed statement. ""We are confident that patients will continue to have access to our medicines.""Johnson & Johnson's two-year-old diabetes treatment, Invokana, and a related combination treatment called Invokamet, will also be stripped from CVS coverage. Combined sales of the medicines have been growing by leaps and bounds, reaching $318 million in the second quarter.""We are disappointed in this decision because it affects patients who are currently taking Invokana and are experiencing success with it,"" J&J said in a statement. ""Despite this decision, Invokana will continue to have broad access for patients with Medicare with more than 70 percent preferred access for patients with private insurance and more than 90 percent preferred access for patients with Medicare, Part D coverage.""Another diabetes drug to be excluded from the CVS formulary is Bydureon, a once-weekly treatment from AstraZeneca Plc . CVS will favor instead similar treatments from Lilly and Novo Nordisk.""Bydureon continues to have excellent access across commercial and non-commercial plans, including (Medicare) Part D,"" AstraZeneca said.Express Scripts, the nation's biggest PBM, last week said it would boot about 20 additional medicines from its formulary in 2016 <ID:nL1N10B2JM>.Express Scripts said it can negotiate lower drug prices through its ability to exclude drugs from its coverage list. The formulary determines whether tens of millions of people with private insurance can easily use an insurance co-pay to buy  prescription drugs.   (Reporting by Ransdell Pierson and Bill Berkrot; Editing by Jonathan Oatis, Toni Reinhold)",2015-08-05,CVS,"Wed Aug 5, 2015 | 6:15pm EDT","UPDATE 1-CVS strips Viagra, other top drugs, from insurance coverage",http://www.reuters.com//article/cvs-health-coverage-idUSL1N10G3S620150805?type=companyNews
100,"   By Ransdell Pierson and Bill Berkrot  Aug 5 CVS Health Corp, which operates the nation's second-biggest pharmacy benefit manager, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including Viagra and widely used treatments for diabetes and multiple sclerosis.The 2016 excluded drugs, disclosed on Wednesday, also include Vivus Inc's weight loss treatment Qsymia, which last week was excluded from the 2016 formulary of rival PBM Express Scripts Holding Co. Vivus officials could not immediately be reached for comment.Pharmacy benefit managers, or PBMs, which administer drug benefits for employers and health plans and also run large mail-order pharmacies, have been challenging the rising cost of new medications. When drugs are knocked off their formularies, patients may have to pay full price for them. PBMs often keep or dump a product depending on whether they can obtain favorable pricing.Viagra, the world's first approved pill for erectile dysfunction, has annual sales of $1.8 billion, including $1.3 billion in the United States. Cheaper generic versions are expected to be launched by December 2017. ""Pfizer is committed to ensuring patient access to our medicines,"" the drugmaker said in an emailed statement.The CVS formulary, however, does include Eli Lilly and Co's  rival Cialis anti-impotence treatment.Next year's formulary will also exclude two interferon-based multiple sclerosis treatments from Biogen, big-selling Avonex and its new longer-acting Plegridy. Avonex, Biogen's second-biggest product, has annual sales of almost $2.5 billion. ""Avonex and Plegridy have broad insurance coverage,"" Biogen said in an emailed statement. ""We are confident that patients will continue to have access to our medicines.""Johnson & Johnson's two-year-old diabetes treatment, Invokana, and a related combination treatment called Invokamet, will also be stripped from CVS coverage. Combined sales of the medicines have been growing by leaps and bounds, reaching $318 million in the second quarter. J&J did not have an immediate comment. Another diabetes drug to be excluded from the CVS formulary is Bydureon, a once-weekly treatment from AstraZeneca Plc . CVS will favor instead similar treatments from Lilly and Novo Nordisk.""Bydureon continues to have excellent access across commercial and non-commercial plans, including (Medicare) Part D,"" AstraZeneca said.Express Scripts, the nation's biggest PBM, last week said it would boot about 20 additional medicines from its formulary in 2016 <ID:nL1N10B2JM>.Express Scripts said it can negotiate lower drug prices through its ability to exclude drugs from its coverage list. The formulary determines whether tens of millions of people with private insurance can easily use an insurance co-pay to buy  prescription drugs.   (Reporting by Ransdell Pierson and Bill Berkrot; Editing by Jonathan Oatis)",2015-08-05,CVS,"Wed Aug 5, 2015 | 5:37pm EDT","CVS strips Viagra, other top drugs, from insurance coverage",http://www.reuters.com//article/cvs-health-coverage-idUSL1N10G3HE20150805?type=companyNews
101,"  Aug 5 Orexo* Zubsolv market access update on agreement with cvs caremark and announcement of new exclusive agreement in managed medicaid * Orexo ab says in PBM, CVS Caremark 2016 standard formulary list of excluded drugs for their commercial clients, effective from january 1 Zubsolv has been removed from preferred position * Orexo ab says at this time orexo estimates direct impact today would effect approximately 10-15 percent of zubsolv gross sales (0.6 - 0.8 share points) * Orexo says signed exclusive agreement with a PBM in managed medicaid, with potential to exceed market share loss that may develop due to  change in cvs caremark commercial plans  Source text for Eikon:  Further company coverage:",2015-08-05,CVS,"Wed Aug 5, 2015 | 12:51am EDT",BRIEF-Orexo says Zubsolv removed from preferred position on CVS Caremark list,http://www.reuters.com//article/idUSFWN10F01R20150805?type=companyNews
102,"   By Deena Beasley  CVS Health Corp, the No 2 manager of drug benefit plans for U.S. employers and insurers, will wait until a second new cholesterol-lowering drug is approved by regulators before negotiating for price discounts or adding either of the much pricer new drugs to its list of covered medications.The U.S. Food and Drug Administration in July approved Regeneron Pharmaceuticals Inc and Sanofi SA's  Praluent, which works by blocking a protein called PCSK9 that helps ""bad"" LDL cholesterol stay in the bloodstream. An FDA decision on a second PCSK9 inhibitor, Amgen Inc's Repatha, is expected later this month.CVS and other pharmacy benefit managers are concerned about the cost of the PCSK9s compared to older cholesterol fighters such as statins, which are available as generics for less than $50 a month. Praluent, given by injection, has a list price of almost $15,000 a year.""It's smart to wait and see what the competitor medication looks like in terms of what the FDA label is,"" Dr Troyen Brennan, chief medical officer at CVS, told Reuters, referring to the type of patients who should be given the drug. Brennan added that ""all bets are off"" in negotiations between CVS and the PCSK9 drugmakers in terms of which, if either, of the drugs would be added to its formulary, or list of covered medications.Currently, doctors seeking to prescribe Praluent have to go through a ""formulary exception process,"" to secure CVS coverage.Brennan said an exclusive agreement for one of the new drugs would be ""a tried and true method"" for obtaining the best pricing, but CVS could have deals to place both drugs on its formulary. He said CVS will institute a ""utilization management program,"" taking into account issues such as patient history of heart disease or diabetes, as well as overall risk for cardiovascular disease. ""We expect patients to first use statins,"" Brennan said. ""If they can't use statins, or can't make (LDL) targets, then they would use PCSK9 inhibitors.""CVS estimates that about 73 million Americans have elevated cholesterol. Brennan forecast that less than 1 percent of current statin users will be switched to PCSK9s in the first year they are on the market. ""That could change as new data comes in on outcome measures,"" he said. Brennan said Praluent will first be used by the small number of people who are genetically predisposed to high cholesterol. ""For those patients, the use of this drug is less expensive than the drugs they were on,"" he said. (Reporting By Deena Beasley; Editing by Richard Pullin)",2015-08-10,CVS,"Sun Aug 9, 2015 | 10:43pm EDT",CVS: 'all bets are off' for new cholesterol drug contracts,http://www.reuters.com//article/us-health-cholesterol-costs-idUSKCN0QF05120150810?type=companyNews
103,  Sept 2 Orexo AB* Letter to orexo shareholders from CEO Nikolaj Srensen * Ceo says in letter to shareholders is encouraged by zubsolv market share gains in the last two month * Says CVS Caremark decision to exclude zubsolv from standard formulary for 2016 affects a minority of clients from next year * Says could potentially impact up to about 10-15 percent of current Zubsolv sales if new standard formulary is implemented by all CVS Caremark's clients  Source text: www.orexo.com/Global/2.%20IR%20sida%20-%20puffar%20%5b240x122%5d/Letter%20to%20Shareholders%20Sep%202015.pdf?epslanguage=en Further company coverage:,2015-09-02,CVS,"Wed Sep 2, 2015 | 11:50am EDT",BRIEF-Orexo says encouraged by zubsolv market share gains in past 2 mos,http://www.reuters.com//article/idUSASM000C0Z20150902?type=companyNews
104,"  CHICAGO CVS Health Corp said on Thursday its decision to stop selling tobacco products last year led to a 1 percent decrease in cigarette sales in some states where the drugstore chain has a sizeable presence.The September 2014 decision hurt sales, with general merchandise revenue at CVS pharmacies open at least a year falling 7.8 percent in the second quarter from a year earlier, the company said.However, CVS said it benefited in others ways. In the eight months since the decision, nicotine patch purchases rose 4 percent from a year earlier in the 26 states where it had a market share of 15 percent or greater. The company also said the average number of visits to its retail clinics for smoking cessation counseling nearly doubled.The 1 percent reduction in sales of cigarette packs occurred in 13 of the states where CVS's market share was at least 15 percent. The company said the decline equated to the average smoker in those states buying five fewer packs of cigarettes, or a total of 95 million. The company estimated it held 1.5 percent to 2 percent of the U.S. tobacco market before it stopped selling the products, which accounted for about $2 billion in annual sales.For the analysis, CVS said it compared cigarette pack purchases in markets where it had a presence with those where it did not. Researchers looked at sales in drug, food, big box, dollar, convenience and gas station retailers. Chief Medical Officer Troyen Brennan said many people thought that smokers would go elsewhere to buy cigarettes once the chain stopped selling them. ""The data shows that our decision to not sell cigarettes did have an impact,"" he said. CVS has 7,800 retail pharmacies and is the second-largest manager of prescription-drug benefits in the United States.  (Reporting by Nandita Bose in Chicago; Editing by Lisa Von Ahn)",2015-09-03,CVS,"Thu Sep 3, 2015 | 8:17am EDT",CVS says its ban on cigarette sales has reduced smoking,http://www.reuters.com//article/us-cvs-tobacco-idUSKCN0R31A420150903?type=companyNews
105,"  CHICAGO, Sept 3 CVS Health Corp said on Thursday its decision to stop selling tobacco products last year led to a 1 percent decrease in cigarette sales in some states where the drugstore chain has a sizeable presence.The September 2014 decision hurt sales, with general merchandise revenue at CVS pharmacies open at least a year falling 7.8 percent in the second quarter from a year earlier, the company said.However, CVS said it benefited in others ways. In the eight months since the decision, nicotine patch purchases rose 4 percent from a year earlier in the 26 states where it had a market share of 15 percent or greater. The company also said the average number of visits to its retail clinics for smoking cessation counseling nearly doubled.The 1 percent reduction in sales of cigarette packs occurred in 13 of the states where CVS's market share was at least 15 percent. The company said the decline equated to the average smoker in those states buying five fewer packs of cigarettes, or a total of 95 million. The company estimated it held 1.5 percent to 2 percent of the U.S. tobacco market before it stopped selling the products, which accounted for about $2 billion in annual sales. For the analysis, CVS said it compared cigarette pack purchases in markets where it had a presence with those where it did not. Researchers looked at sales in drug, food, big box, dollar, convenience and gas station retailers.Chief Medical Officer Troyen Brennan said many people thought that smokers would go elsewhere to buy cigarettes once the chain stopped selling them. ""The data shows that our decision to not sell cigarettes did have an impact,"" he said.CVS has 7,800 retail pharmacies and is the second-largest manager of prescription-drug benefits in the United States.    (Reporting by Nandita Bose in Chicago; Editing by Lisa Von Ahn)",2015-09-03,CVS,"Thu Sep 3, 2015 | 8:07am EDT",CVS says its ban on cigarette sales has reduced smoking,http://www.reuters.com//article/cvs-tobacco-idUSL1N1190JS20150903?type=companyNews
106,"   By Jonathan Stempel  CVS Health Corp reached a $48 million settlement of a lawsuit accusing the U.S. drugstore operator of fraudulently concealing a big loss of revenue in its pharmacy benefits manager business, culminating in a plunge in its stock price.The all-cash settlement with investors led by three Massachusetts public pension funds was disclosed in a Monday filing with the federal court in Providence, Rhode Island.CVS' share price tumbled 20.1 percent on Nov. 5, 2009, after the company, then known as CVS Caremark, revealed the loss of contracts representing about $4.5 billion of annual revenue.Shareholders said this disclosure blindsided them, after CVS officials had repeatedly assured them that the company was doing an excellent job integrating the former Caremark Rx Inc and retaining clients. CVS bought Caremark in March 2007 and changed its name to CVS Health last September.The settlement requires court approval and awaits class-action certification for shareholders from Oct. 30, 2008, to Nov. 4, 2009. CVS denied wrongdoing.CVS spokeswoman Carolyn Castel said the payment will be covered by insurance and that the Woonsocket, Rhode Island-based company settled to avoid the ""burden, uncertainty and expense of continuing litigation."" In April 2014, CVS agreed to pay $20 million to settle U.S. Securities and Exchange Commission civil charges related to the PBM business, and its accounting for an unrelated acquisition.The $48 million is just 1 percent of CVS' annual profit, but the plaintiffs' lawyers in court papers called the accord ""a very good recovery,"" given the risks of continued litigation. They estimated the sum at 5.33 percent of the potential $900 million of ""recoverable damages"" in the litigation.The lead plaintiffs are the City of Brockton Retirement System, Norfolk County Retirement System and Plymouth County Retirement System.Their lawyers, led by Robbins Geller Rudman & Dowd and Labaton Sucharow, plan to seek legal fees of up to 30 percent of the settlement amount, court papers show.The case, which has a different named plaintiff and defendant, is Medoff v. CVS Caremark Corp et al, U.S. District Court, District of Rhode Island, No. 09-00554.",2015-09-16,CVS,"Wed Sep 16, 2015 | 12:07pm EDT",CVS Health in $48 million settlement of lawsuit over hiding loss,http://www.reuters.com//article/cvs-health-settlement-idUSL1N11M12K20150916?type=companyNews
107,"   By Jonathan Stempel  CVS Health Corp (CVS.N) reached a $48 million settlement of a lawsuit accusing the U.S. drugstore operator of fraudulently concealing a big loss of revenue in its pharmacy benefits manager business, culminating in a plunge in its stock price.The all-cash settlement with investors led by three Massachusetts public pension funds was disclosed in a Monday filing with the federal court in Providence, Rhode Island.CVS' share price tumbled 20.1 percent on Nov. 5, 2009, after the company, then known as CVS Caremark, revealed the loss of contracts representing about $4.5 billion of annual revenue.Shareholders said this disclosure blindsided them, after CVS officials had repeatedly assured them that the company was doing an excellent job integrating the former Caremark Rx Inc and retaining clients.CVS bought Caremark in March 2007 and changed its name to CVS Health last September. The settlement requires court approval and awaits class-action certification for shareholders from Oct. 30, 2008, to Nov. 4, 2009. CVS denied wrongdoing.CVS spokeswoman Carolyn Castel said the payment will be covered by insurance and that the Woonsocket, Rhode Island-based company settled to avoid the ""burden, uncertainty and expense of continuing litigation.""In April 2014, CVS agreed to pay $20 million to settle U.S. Securities and Exchange Commission civil charges related to the PBM business, and its accounting for an unrelated acquisition. The $48 million is just 1 percent of CVS' annual profit, but the plaintiffs' lawyers in court papers called the accord ""a very good recovery,"" given the risks of continued litigation.They estimated the sum at 5.33 percent of the potential $900 million of ""recoverable damages"" in the litigation. The lead plaintiffs are the City of Brockton Retirement System, Norfolk County Retirement System and Plymouth County Retirement System.Their lawyers, led by Robbins Geller Rudman & Dowd and Labaton Sucharow, plan to seek legal fees of up to 30 percent of the settlement amount, court papers show.The case, which has a different named plaintiff and defendant, is Medoff v. CVS Caremark Corp et al, U.S. District Court, District of Rhode Island, No. 09-00554. (Reporting by Jonathan Stempel in New York; Editing by Lisa Von Ahn and Alan Crosby)",2015-09-16,CVS,"Wed Sep 16, 2015 | 11:55am EDT",CVS Health in $48 million settlement of lawsuit over hiding loss,http://www.reuters.com//article/us-cvs-health-settlement-idUSKCN0RG1XP20150916?type=companyNews
108,"  (Adds CVS comment)By Jonathan StempelSept 16 CVS Health Corp reached a $48 million settlement of a lawsuit accusing the U.S. drugstore operator of fraudulently concealing a big loss of revenue in its pharmacy benefits manager business, culminating in a plunge in its stock price.The all-cash settlement with investors led by three Massachusetts public pension funds was disclosed in a Monday filing with the federal court in Providence, Rhode Island.CVS' share price tumbled 20.1 percent on Nov. 5, 2009, after the company, then known as CVS Caremark, revealed the loss of contracts representing about $4.5 billion of annual revenue.Shareholders said this disclosure blindsided them, after CVS officials had repeatedly assured them that the company was doing an excellent job integrating the former Caremark Rx Inc and retaining clients. CVS bought Caremark in March 2007 and changed its name to CVS Health last September.The settlement requires court approval and awaits class-action certification for shareholders from Oct. 30, 2008, to Nov. 4, 2009. CVS denied wrongdoing. CVS spokeswoman Carolyn Castel said the payment will be covered by insurance and that the Woonsocket, Rhode Island-based company settled to avoid the ""burden, uncertainty and expense of continuing litigation.""In April 2014, CVS agreed to pay $20 million to settle U.S. Securities and Exchange Commission civil charges related to the PBM business, and its accounting for an unrelated acquisition.The $48 million is just 1 percent of CVS' annual profit, but the plaintiffs' lawyers in court papers called the accord ""a very good recovery,"" given the risks of continued litigation. They estimated the sum at 5.33 percent of the potential $900 million of ""recoverable damages"" in the litigation.The lead plaintiffs are the City of Brockton Retirement System, Norfolk County Retirement System and Plymouth County Retirement System.Their lawyers, led by Robbins Geller Rudman & Dowd and Labaton Sucharow, plan to seek legal fees of up to 30 percent of the settlement amount, court papers show.The case, which has a different named plaintiff and defendant, is Medoff v. CVS Caremark Corp et al, U.S. District Court, District of Rhode Island, No. 09-00554.   (Reporting by Jonathan Stempel in New York; Editing by Lisa Von Ahn and Alan Crosby)",2015-09-16,CVS,"Wed Sep 16, 2015 | 11:55am EDT",UPDATE 1-CVS Health in $48 million settlement of lawsuit over hiding loss,http://www.reuters.com//article/cvs-health-settlement-idUSL1N11M1DK20150916?type=companyNews
109,"  Sept 16 CVS Health Corp reached a $48 million settlement of a lawsuit accusing the U.S. drugstore operator of fraudulently concealing a big loss of revenue in its pharmacy benefits manager business, culminating in a plunge in its stock price.The all-cash settlement with investors led by three Massachusetts public pension funds was disclosed in a Monday filing with the federal court in Providence, Rhode Island.CVS' share price tumbled 20.1 percent on Nov. 5, 2009, after the company, then known as CVS Caremark, revealed the loss of contracts representing about $4.5 billion of annual revenue.Shareholders said this disclosure blindsided them, after CVS officials had repeatedly assured them that the company was doing an excellent job integrating the former Caremark Rx Inc and retaining clients.CVS bought Caremark in March 2007. The Woonsocket, Rhode Island-based company changed its name to CVS Health last September. The settlement requires court approval and awaits class-action certification for shareholders from Oct. 30, 2008, to Nov. 4, 2009. CVS denied wrongdoing.CVS spokeswoman Carolyn Castel was not immediately available on Wednesday to comment. In April 2014, CVS agreed to pay $20 million to settle U.S. Securities and Exchange Commission civil charges related to the PBM business, and its accounting for an unrelated acquisition.The $48 million is just 1 percent of CVS' annual profit, but the plaintiffs' lawyers in court papers called the accord ""a very good recovery,"" given the risks of continued litigation. They estimated the sum at 5.33 percent of the potential $900 million of ""recoverable damages"" in the litigation.The lead plaintiffs are the City of Brockton Retirement System, Norfolk County Retirement System and Plymouth County Retirement System.Their lawyers, led by Robbins Geller Rudman & Dowd and Labaton Sucharow, plan to seek legal fees of up to 30 percent of the settlement amount, court papers show.The case, which has a different named plaintiff and defendant, is Medoff v. CVS Caremark Corp et al, U.S. District Court, District of Rhode Island, No. 09-00554.     (Reporting by Jonathan Stempel in New York; Editing by Lisa Von Ahn)",2015-09-16,CVS,"Wed Sep 16, 2015 | 10:09am EDT",CVS Health in $48 million settlement of lawsuit over stock plunge,http://www.reuters.com//article/cvs-health-settlement-idUSL1N11M0WH20150916?type=companyNews
110,"   By Brendan Pierson  CVS Health Corp's pharmacy benefit management unit has dodged a whistleblower lawsuit accusing it of multiple violations of the federal Medicare law, including approving claims for drugs without proper physician identification or necessary authorization. U.S. District Judge Ronald Buckwalter of the Eastern District of Pennsylvania ruled Tuesday that while CVS Caremark, a division of Rhode Island-based CVS, may have made errors in processing Medicare claims, it did not deliberately defraud the government.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1JqJqfF",2015-09-23,CVS,"Wed Sep 23, 2015 | 7:54pm EDT",CVS dodges Medicare fraud whistleblower lawsuit,http://www.reuters.com//article/health-cvs-idUSL1N11T2OJ20150923?type=companyNews
111,"   By Michael Flaherty and Caroline Humer  Valeant Pharmaceuticals Inc. sustained hits on several fronts on Thursday after CVS Health Corp and Express Scripts dropped Philidor from their networks in a sign the fallout from the drugmaker's connection with the specialty pharmacy is spreading.The moves by the nation's two largest pharmacy benefit managers whacked Valeant shares before the market close, and pushed them 10 percent lower to $99 after hours.After coming under pressure this summer, Valeant's stock plunged last week after short-seller Citron Research said that the company was using its drug distributor, Philidor Rx, to inflate revenue numbers.About a dozen Valeant officials held a conference call on Monday to address the accusations, which helped ease pressure on the company's stock. Valeant said it properly accounts for sales through its pharmacy partners and only books revenue once one of its medicines reaches a patient.Valeant's stock recovered throughout the week than sank on the CVS and Express Scripts news. CVS, late on Thursday, said its Caremark program was dropping Philidor. CVS took the step following an audit of Philidor, citing ""noncompliance"" with its provider agreement, the company said.Shortly after the market close, Express Scripts said it too was ending its ties to Philidor.  CVS did not explain the ""noncompliance"" further when contacted by Reuters. Bloomberg on Thursday said Philidor has altered doctors orders to wring more payment out of insurers, according to former employees and an internal document, which details how to proceed with a prescription for certain Valeant drugs after they have been rejected.""Valeants drugs are provided to patients through many channels, including traditional retail pharmacies, specialty pharmacies, and directly from health care providers,"" said Valeant Spokeswoman Laurie Little in an emailed statement. Philidor declined to comment on Thursday.  CVS and Express Scripts Holdings manage most of the prescriptions filled under health plans run by the nation's largest insurers. Express Scripts manages prescription benefits for 85 million people.  The move by CVS and Express Scripts will have a direct impact on Valeant, though Philidor accounts for a small portion of the Canadian company's revenues.In Valeant's detailed presentation on Monday that spelled out its dealings with Philidor, the company said that the pharmacy accounted for about 5.9 percent of its total sales so far this year.The stock was trading as high as $260 per share in August. The next month, U.S. Democratic politicians singled out Valeant for hiking drug prices on consumers, and a federal subpoena followed. With the stock under pressure, the Citron report last Wednesday sent it into a tailspin.TOP SHAREHOLDER SPEAKS  The CVS announcement came after mutual fund manager Ruane, Cunniff & Goldfarb Inc., sent a letter to its own investors about the Valeant saga. The Sequoia Fund, which the mutual fund manages, owns 9.93 percent of Valeant and is the company's largest shareholder.While the letter is largely a defense of Valeant's practices, it says that the company needs to move faster with paying down its debt. It also points out that Valeant's aggressive business practices have ""pushed boundaries,"" and that the company needs to better manage its image.""We would stress the importance of taking a more systemic approach to managing business practices with an eye on the company's long-term corporate reputation,"" said the letter dated Oct. 28 and signed by Ruane, Cunniff & Goldfarb President Robert Goldfarb and Executive Vice President David Poppe.Separately, two of the five independent directors of the Sequoia Fund resigned over the weekend, the Wall Street Journal reported on Thursday, citing the boards chairman. A person who answered the phone at Ruane, Cunniff & Goldfarb said the chairman, Roger Lowenstein, could not be reached. ACTIVISTS HIT Valeant's abrupt slide from a hedge fund darling to a drug company under fire has weighed heavily on two of the best known U.S. activist funds: ValueAct Partners and Pershing Square.ValueAct has been an investor in Valeant since 2006, and played a significant role in instituting the company's strategy and its current CEO, Michael Pearson. Pearson took over in 2008 and built Valeant into a more than $40 billion company with over 100 transactions. ValueAct, with $19 billion under management, now has two directors on the company's board, and was the fourth largest shareholder as of June 30.William Ackman's Pershing Square, Valeant's third-largest shareholder, has scheduled a call on Friday at 9 am EDT to address the drug company's issues. Pershing owned 5.7 percent of Valeant as of June 30, and faced a paper loss of more than $800 million at one point last week. (Additional reporting by Vidya L Nathan; Editing by Cynthia Osterman, Nick Zieminski and Andrew Hay)",2015-10-29,CVS,"Thu Oct 29, 2015 | 7:27pm EDT","CVS, Express Scripts drop Valeant's Philidor; stock dives",http://www.reuters.com//article/us-valeant-pharmacies-shareholders-idUSKCN0SN28U20151029?type=companyNews
112,"  (Adds CVS, Express Scripts dropping Philidor, share drop)By Michael Flaherty and Caroline HumerOct 29 Shares of Valeant Pharmaceuticals Inc. fell further on Thursday after CVS Health Corp and Express Scripts dropped Philidor Rx from their networks in a sign the fall-out from the drugmaker's connection with the specialty pharmacy is spreading.Philidor Rx, the speciality pharmacy used by Valeant, is at the center of accusations lodged by a short-seller last week that Valeant inflated revenues - allegations that sent Valeant shares into a tailspin.The stock recovered some of its losses, and was trading higher through most of Thursday until CVS, late in the trading session, said its Caremark program was dropping Philidor. CVS took the step following an audit of Philidor, citing ""noncompliance"" with its provider agreement, the company said.Valeant's New York traded shares fell 4.7 percent to $111.50 at the close. The stock was trading as high as $260 per share in August. Express Scripts, later on Thursday, said it too was ending its ties to Philidor.The CVS announcement came after mutual fund manager Ruane, Cunniff & Goldfarb Inc., sent a letter to its own investors about the Valeant saga. The Sequioa Fund, which the mutual fund manages, owns 9.93 percent of Valeant and is the company's largest shareholder. While the letter is largely a defense of Valeant's practices, it says that the company needs to move faster with paying down its debt. It also points out that Valeant's aggressive business practices have ""pushed boundaries,"" and that the company needs to better manage its reputation.""We would stress the importance of taking a more systemic approach to managing business practices with an eye on the company's long-term corporate reputation,"" said the letter dated Oct. 28 and signed by Ruane, Cunniff & Goldfarb President Robert Goldfarb and Executive Vice President David Poppe.Separately, two of the five independent directors of the Sequioa Fund resigned over the weekend, the Wall Street Journal reported on Thursday, citing the board's chairman. Reuters could not immediately reach the chairman, Roger Lowenstein. After coming under pressure this summer, Valeant's stock plunged after short-seller Citron Research said last week that the company was using its drug distributor, Philidor, to inflate revenue numbers.(Additional reporting by Vidya Nathan; Editing by Cynthia Osterman, Nick Zieminski and Andrew Hay)",2015-10-29,CVS,"Thu Oct 29, 2015 | 5:22pm EDT","UPDATE 4-CVS, Express Scripts drop Valeant's Philidor; stock dives",http://www.reuters.com//article/valeant-pharmacies-shareholders-idUSL3N12T5VA20151029?type=companyNews
113,"  Drugstore chain CVS Health Corp (CVS.N) said it had dropped Philidor Rx, a specialty pharmacy associated with Valeant Pharmaceuticals Inc (VRX.TO) (VRX.N), from its Caremark program.Valeant's shares tumbled last week after influential short-seller Citron Research said the company was using specialty pharmacies to inflate revenue.  CVS took the step following an audit of Philidor, citing  ""noncompliance"" with its provider agreement.     (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva)",2015-10-29,CVS,"Thu Oct 29, 2015 | 4:12pm EDT","CVS Health drops Philidor, adds to Valeant's woes",http://www.reuters.com//article/us-valeant-pharmacies-cvs-health-idUSKCN0SN2QY20151029?type=companyNews
114,"  Oct 29 Drugstore chain CVS Health Corp  said it had dropped Philidor Rx, a specialty pharmacy associated with Valeant Pharmaceuticals Inc , from its Caremark program.Valeant's shares tumbled last week after influential short-seller Citron Research said the company was using specialty pharmacies to inflate revenue.  CVS took the step following an audit of Philidor, citing  ""noncompliance"" with its provider agreement.     (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva) ",2015-10-29,CVS,"Thu Oct 29, 2015 | 4:08pm EDT","CVS Health drops Philidor, adds to Valeant's woes",http://www.reuters.com//article/valeant-pharmacies-cvs-health-idUSL3N12T68520151029?type=companyNews
115,"   By Ramkumar Iyer and Natalie Grover  Vertex Pharmaceuticals Inc said it received a subpoena from the U.S. Department of Justice in the third quarter, seeking documents related primarily to its ""good laboratory practices"" in a bioanalytical lab.Good laboratory practices are rules that govern non-clinical safety studies, ensuring quality, integrity and reliability of data. Shares of the cystic fibrosis drugmaker, which said it was in the process of responding to the subpoena, fell about 2 percent after-hours.Separately, drugmaker Mylan NV and drugstore chain CVS Health Corp said in their quarterly filings that they had also received subpoenas from federal agencies. CVS said the Drug Enforcement Administration in September sought documents related to controlled substance policies, procedures, and practices at eight pharmacy locations since May 2012. Mylan said the U.S. Securities and Exchange Commission was seeking documents with regard to certain ""related party matters"".CVS and Mylan's shares were little changed after the bell.",2015-10-30,CVS,"Fri Oct 30, 2015 | 6:04pm EDT","Vertex, Mylan, CVS subpoenaed by federal agencies",http://www.reuters.com//article/healthcare-subpeona-idUSL1N12U31520151030?type=companyNews
116,"  Vertex Pharmaceuticals Inc said it received a subpoena from the U.S. Department of Justice in the third quarter, seeking documents related primarily to its ""good laboratory practices"" in a bioanalytical lab.Good laboratory practices are rules that govern non-clinical safety studies, ensuring quality, integrity and reliability of data. Shares of the cystic fibrosis drugmaker, which said it was in the process of responding to the subpoena, fell about 2 percent after-hours. Separately, drugmaker Mylan NV and drugstore chain CVS Health Corp said in their quarterly filings that they had also received subpoenas from federal agencies. CVS said the Drug Enforcement Administration in September sought documents related to controlled substance policies, procedures, and practices at eight pharmacy locations since May 2012. Mylan said the U.S. Securities and Exchange Commission was seeking documents with regard to certain ""related party matters"".CVS and Mylan's shares were little changed after the bell.  (Reporting by Natalie Grover and Ramkumar Iyer in Bengaluru; Editing by Anil D'Silva)",2015-10-30,CVS,"Fri Oct 30, 2015 | 6:01pm EDT","Vertex, Mylan, CVS subpoenaed by federal agencies",http://www.reuters.com//article/us-healthcare-subpeona-idUSKCN0SO2SS20151030?type=companyNews
117,"  Oct 30 Vertex Pharmaceuticals Inc said it received a subpoena from the U.S. Department of Justice in the third quarter, seeking documents related primarily to its ""good laboratory practices"" in a bioanalytical lab.Good laboratory practices are rules that govern non-clinical safety studies, ensuring quality, integrity and reliability of data.Shares of the cystic fibrosis drugmaker, which said it was in the process of responding to the subpoena, fell about 2 percent after-hours. Separately, drugmaker Mylan NV and drugstore chain CVS Health Corp said in their quarterly filings that they had also received subpoenas from federal agencies. CVS said the Drug Enforcement Administration in September sought documents related to controlled substance policies, procedures, and practices at eight pharmacy locations since May 2012. Mylan said the U.S. Securities and Exchange Commission was seeking documents with regard to certain ""related party matters"".CVS and Mylan's shares were little changed after the bell.   (Reporting by Natalie Grover and Ramkumar Iyer in Bengaluru; Editing by Anil D'Silva)",2015-10-30,CVS,"Fri Oct 30, 2015 | 6:00pm EDT","Vertex, Mylan, CVS subpoenaed by federal agencies",http://www.reuters.com//article/healthcare-subpeona-idUSL3N12U6IX20151030?type=companyNews
118,"   By Sruthi Ramakrishnan  CVS Health Corp (CVS.N) gave a disappointing profit forecast for 2016, hurt by costs related to the acquisition of Target Corp's pharmacies and as its own pharmacy benefits management (PBM) business expands in low-margin Medicare and Medicaid plans.The drugstore operator's profit missed analysts' estimates for the first time in six quarters, as its $10-billion Omnicare acquisition failed to offset pressure from lower reimbursement rates and new low-margin generic drugs.CVS shares were down 4.6 percent at $98.98 in heavy trading on Friday, among the top decliners on the S&P 500 .SPX. They fell as much as 7 percent earlier.The weak forecast from CVS, the No.2 U.S. drugstore chain by store count, comes in the same week that larger rival Walgreens Boots Alliance Inc (WBA.O) said it would buy No.3 Rite Aid Corp (RAD.N) for $9.4 billion.CVS forecast 2016 adjusted earnings of $5.68-$5.88 per share, including a $4 billion stock buyback plan and a 6 cents per share impact related to the acquisition of Target's (TGT.N) pharmacies in June. Analysts on average were expecting a profit of $6.02 per share, according to Thomson Reuters I/B/E/S.""While no one can complain about a $100 billion behemoth growing EPS 10-14 percent in a challenging environment, expects were clearly somewhat higher given the M&A activity in 2015,"" Evercore ISI analyst Ross Muken wrote in a note.CVS said sales at its drugstores were hurt in the third quarter by the introduction of low-margin generic drugs, lower reimbursement rates and its move to stop selling tobacco products last year. ""Reimbursement pressure has not changed but ... Medicare and Medicaid are big areas of growth in this (PBM) business. And they carry a lower margin rate,"" Chief Executive Larry Merlo said on a conference call.Rising generic drug prices are hurting drugstore operators as insurers and PBMs have been slow in raising reimbursement rates for those drugs.Margins in CVS's PBM business, which accounted for 66 percent of net revenue in the quarter ended Sept. 30, fell 45 basis points. Net income attributable to CVS rose 31.4 percent to $1.25 billion, or $1.11 per share. Excluding items, it earned $1.28 per share. Net revenue rose 10.3 percent to $38.64 billion.Analysts had expected earnings of $1.29 per share on revenue of $37.89 billion.About 9.2 million CVS shares were traded by 11 a.m ET, with the stock' turnover topping $900 million, the third highest among S&P 500 companies. (Reporting by Sruthi Ramakrishnan in Bengaluru; Editing by Savio D'Souza)",2015-10-30,CVS,"Fri Oct 30, 2015 | 11:05am EDT","CVS 2016 profit forecast hurt by healthcare plans, Target deal",http://www.reuters.com//article/us-cvs-health-results-idUSKCN0SO1BR20151030?type=companyNews
119,"  * Q3 adjusted profit of $1.28/share vs est $1.29* To buy back $4 bln of shares in 2016* Revenue of $38.64 bln beats est. of $37.89 bln* Sees 2016 adjusted EPS $5.68-$5.88 vs est $6.02* Shares fall as much as 7 pct in heavy trading   (Adds details from conference call, analyst comment; updates shares)By Sruthi RamakrishnanOct 30 CVS Health Corp gave a disappointing profit forecast for 2016, hurt by costs related to the acquisition of Target Corp's pharmacies and as its own pharmacy benefits management (PBM) business expands in low-margin Medicare and Medicaid plans. The drugstore operator's profit missed analysts' estimates for the first time in six quarters, as its $10-billion Omnicare acquisition failed to offset pressure from lower reimbursement rates and new low-margin generic drugs.CVS shares were down 4.6 percent at $98.98 in heavy trading on Friday, among the top decliners on the S&P 500. They fell as much as 7 percent earlier.The weak forecast from CVS, the No.2 U.S. drugstore chain by store count, comes in the same week that larger rival Walgreens Boots Alliance Inc said it would buy No.3 Rite Aid Corp  for $9.4 billion.CVS forecast 2016 adjusted earnings of $5.68-$5.88 per share, including a $4 billion stock buyback plan and a 6 cents per share impact related to the acquisition of Target's  pharmacies in June. Analysts on average were expecting a profit of $6.02 per share, according to Thomson Reuters I/B/E/S.""While no one can complain about a $100 billion behemoth growing EPS 10-14 percent in a challenging environment, expects were clearly somewhat higher given the M&A activity in 2015,"" Evercore ISI analyst Ross Muken wrote in a note.CVS said sales at its drugstores were hurt in the third quarter by the introduction of low-margin generic drugs, lower reimbursement rates and its move to stop selling tobacco products last year. ""Reimbursement pressure has not changed but ... Medicare and Medicaid are big areas of growth in this (PBM) business. And they carry a lower margin rate,"" Chief Executive Larry Merlo said on a conference call.Rising generic drug prices are hurting drugstore operators as insurers and PBMs have been slow in raising reimbursement rates for those drugs.Margins in CVS's PBM business, which accounted for 66 percent of net revenue in the quarter ended Sept. 30, fell 45 basis points.Net income attributable to CVS rose 31.4 percent to $1.25 billion, or $1.11 per share. Excluding items, it earned $1.28 per share. Net revenue rose 10.3 percent to $38.64 billion.Analysts had expected earnings of $1.29 per share on revenue of $37.89 billion.About 9.2 million CVS shares were traded by 11 a.m ET, with the stock' turnover topping $900 million, the third highest among S&P 500 companies.   (Reporting by Sruthi Ramakrishnan in Bengaluru; Editing by Savio D'Souza)",2015-10-30,CVS,"Fri Oct 30, 2015 | 11:05am EDT","UPDATE 3-CVS 2016 profit forecast hurt by healthcare plans, Target deal",http://www.reuters.com//article/cvs-health-results-idUSL3N12U4OC20151030?type=companyNews
120,"  Oct 30 CVS Health Corp, the second-largest U.S. drugstore chain, reported a 10.3 percent rise in quarterly net revenue, helped by strong demand for its pharmacy benefit management services.Net income attributable to the company rose to $1.25 billion, or $1.11 per share, in the third quarter ended Sept. 30, from $948 million, or 81 cents per share, a year earlier.  Net revenue rose to $38.64 billion from $35.02 billion.   (Reporting by Sruthi Ramakrishnan in Bengaluru; Editing by Savio D'Souza) ",2015-10-30,CVS,"Fri Oct 30, 2015 | 6:56am EDT",CVS Health quarterly revenue increases 10 pct,http://www.reuters.com//article/cvs-health-results-idUSL3N12T4AF20151030?type=companyNews
121,"  (Adds Vertex response, details on CVS)Oct 30 Vertex Pharmaceuticals Inc said it received a subpoena from the U.S. Department of Justice in the third quarter related to its marketed medicines, seeking documents related primarily to its ""good laboratory practices"" in a bioanalytical lab.Good laboratory practices are rules that govern non-clinical safety studies, ensuring quality, integrity and reliability of data. Bioanalytical labs measures drug levels in biological samples, specifically in blood and urine.""We are in the process of responding to the subpoena and intend to cooperate,"" Vertex said in a securities filing.The subpoena will not impact the safety, effectiveness and commercialization of the company's existing drugs or those in development, Vertex spokesman Zach Barber told Reuters. Shares of the cystic fibrosis drugmaker were marginally down after-hours.Separately, drugmaker Mylan NV and drugstore chain CVS Health Corp said in their quarterly filings that they had received subpoenas from federal agencies. CVS said the Drug Enforcement Administration (DEA) in September sought documents related to controlled substance policies, procedures and practices at eight pharmacy locations since May 2012.Last May the company agreed to a fine of $22 million in a settlement with the U.S. Attorney's Office for the Middle District of Florida, resolving alleged violations of the Controlled Substances Act. CVS, in its filing, said it is undergoing several audits by the DEA and is in discussions with the agency and the U.S. Attorney's office in several locations concerning allegations that it has violated certain requirements of the CSA.Mylan said the U.S. Securities and Exchange Commission was seeking documents with regard to certain ""related party matters.""CVS and Mylan's shares were little changed after the bell. Neither company was immediately available for comment.    (Reporting by Natalie Grover and Ramkumar Iyer in Bengaluru; Editing by Anil D'Silva and Leslie Adler)",2015-10-31,CVS,"Fri Oct 30, 2015 | 9:06pm EDT",UPDATE 1-Vertex Pharma receives subpoena from Department of Justice,http://www.reuters.com//article/healthcare-subpeona-idUSL3N12V00P20151031?type=companyNews
122,"  Health insurer WellCare Health Plans said it would change its pharmacy benefit manager to CVS Health Corp from UnitedHealth Corp's Optum Rx, effective Jan. 1.About 3.8 million WellCare members enrolled under its Medicaid, Medicare and prescription drug plans will be able to access CVS' pharmacy network, WellCare said on Thursday.Pharmacy benefit managers administer health plans and run large mail order pharmacies, helping insurers get better prices from drugmakers.   CVS is the second-largest U.S. pharmacy benefit manager and drugstore. WellCare, which focuses on government-sponsored insurance plans, recorded $3.7 million in PBM transitionary costs in the quarter ended Sept. 30. Shares of WellCare were down about 2 percent while those of UnitedHealth and CVS Health were down about 1 percent in early trading on the New York Stock Exchange on Thursday.  (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)",2015-12-31,CVS,"Thu Dec 31, 2015 | 10:43am EST",WellCare makes CVS Health its pharmacy benefit manager,http://www.reuters.com//article/us-wellcare-health-pbm-idUSKBN0UE0YC20151231?type=companyNews
123,"  (Adds details)Dec 31 Health insurer WellCare Health Plans  said it would change its pharmacy benefit manager to CVS Health Corp from UnitedHealth Corp's Optum Rx, effective Jan. 1.About 3.8 million WellCare members enrolled under its Medicaid, Medicare and prescription drug plans will be able to access CVS' pharmacy network, WellCare said on Thursday. Pharmacy benefit managers administer health plans and run large mail order pharmacies, helping insurers get better prices from drugmakers. CVS is the second-largest U.S. pharmacy benefit manager and drugstore. WellCare, which focuses on government-sponsored insurance plans, recorded $3.7 million in PBM transitionary costs in the quarter ended Sept. 30.Shares of WellCare were down about 2 percent while those of UnitedHealth and CVS Health were down about 1 percent in early trading on the New York Stock Exchange on Thursday.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey)",2015-12-31,CVS,"Thu Dec 31, 2015 | 10:41am EST",UPDATE 1-WellCare makes CVS Health its pharmacy benefit manager,http://www.reuters.com//article/wellcare-health-pbm-idUSL3N14K2VA20151231?type=companyNews
124,"  Dec 31 Health insurer WellCare Health Plans  said it would transition its pharmacy benefit management to CVS Health Corp from Jan. 1.About 3.8 million WellCare members enrolled under the company's Medicaid, Medicare and prescription drug plans will be able to access CVS' pharmacy network, WellCare said on Thursday.  Pharmacy benefit managers administer drug benefits for employers and health plans and run large mail order pharmacies, helping them get better prices from drugmakers.      (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey) ",2015-12-31,CVS,"Thu Dec 31, 2015 | 8:43am EST",WellCare to transition pharmacy benefit management to CVS Health,http://www.reuters.com//article/wellcare-health-pbm-idUSL3N14K2QI20151231?type=companyNews
125,"  CVS Health Corp said it would make the opioid overdose antidote, naloxone, available without a prescription at all its pharmacies across Ohio, a state with one of the highest rates of overdose-related deaths.Naloxone quickly reverses the effects of an overdose of heroin or other opioid drugs and U.S. law enforcement officials have embraced its use in the midst of an increase in opioid abuse.Naloxone is already available without a prescription in CVS Health stores in more than a dozen states. Drug overdoses increased 6.5 percent in 2014 from a year earlier, killing 47,055 people. The highest rates of death were in West Virginia, New Mexico, New Hampshire, Kentucky, and Ohio, according to report from the Centers for Disease Control and Prevention in December.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey and Savio D'Souza)",2016-02-01,CVS,"Mon Feb 1, 2016 | 2:02pm EST",CVS to make overdose drug naloxone prescription-free in Ohio,http://www.reuters.com//article/us-cvs-health-nalaxone-idUSKCN0VA38U?type=companyNews
126,"  CVS Health Corp said it would make the opioid overdose antidote, naloxone, available without a prescription at all its pharmacies across Ohio, a state with one of the highest rates of overdose-related deaths.Naloxone quickly reverses the effects of an overdose of heroin or other opioid drugs and U.S. law enforcement officials have embraced its use in the midst of an increase in opioid abuse.Naloxone is already available without a prescription in CVS Health stores in more than a dozen states. Drug overdoses increased 6.5 percent in 2014 from a year earlier, killing 47,055 people. The highest rates of death were in West Virginia, New Mexico, New Hampshire, Kentucky, and Ohio, according to report from the Centers for Disease Control and Prevention in December.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey and Savio D'Souza)",2016-02-01,CVS,"Mon Feb 1, 2016 | 2:02pm EST",UPDATE 1-CVS to make overdose drug naloxone prescription-free in Ohio,http://www.reuters.com//article/cvs-health-nalaxone-idUSL3N15G56K?type=companyNews
127,"  Feb 1 CVS Health Corp said it would make the opioid overdose reversal medicine, naloxone, available without a prescription at all its pharmacies across Ohio beginning in late March.Ohio is among the U.S. states that have the highest rates of opioid overdose-related deaths, according to the Centers for Disease Control and Prevention.  Naloxone has been used to treat opioid overdose for nearly 45 years and is sold in both injectable and nasal spray forms.       (Reporting by Amrutha Penumudi in Bengaluru; Editing by Kirti Pandey) ",2016-02-01,CVS,"Mon Feb 1, 2016 | 1:40pm EST",CVS to sell overdose-reversal drug without prescription in Ohio,http://www.reuters.com//article/cvs-health-nalaxone-idUSL3N15G564?type=companyNews
128,"   By Brendan Pierson  Feb 3 - CVS Health Corp has been hit with a proposed class action accusing it of dramatically overcharging healthcare plans for generic drugs over the past seven years. The complaint, filed Monday in Rhode Island federal court by two union benefit plans, alleges that CVS inflated the ""usual and customary"" drug prices it reported to third-party payors, which relied on those prices to determine what they would reimburse. To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1TEDTeT",2016-02-03,CVS,"Wed Feb 3, 2016 | 5:45pm EST",CVS overcharged health plans for generic drugs - class action,http://www.reuters.com//article/health-cvs-idUSL2N15I380?type=companyNews
129,"   By Subrat Patnaik  CVS Health Corp (CVS.N), the No.2 U.S. drugstore chain by store count, forecast current-quarter profit below analysts' estimates as customer traffic to its retail stores slows.Shares of the company, which sells items such as personal care products, over-the-counter drugs and snacks at its retail stores, fell 2.4 percent in premarket trading on Tuesday.CVS's comparable sales at these stores declined 5 percent in 2015, which the company attributed to its decision to discontinue sales of tobacco products. Research firm Conlumino's Chief Executive Neil Saunders, however, said the argument now held much less weight and CVS's ""front of house offer simply isn't compelling or engaging enough."" ""...Over a holiday period in which sales of beauty and personal care products were robust, CVS is losing ground and losing share,"" Saunders said. Comparable sales in CVS's pharmacy benefits management business rose 4.5 percent in 2015.The company forecast an adjusted profit of $1.14-$1.17 per share for the first quarter, below the average analyst estimate of $1.18, according to Thomson Reuters I/B/E/S. The net income attributable to CVS rose 13.4 percent to $1.50 billion, or $1.34 per share, in the quarter ended Dec. 31.Excluding items, the company earned $1.53 per share, in line with the average analyst estimate.  Net revenue rose 11 percent to $41.15 billion, narrowly beating the average estimate of $41.13 billion.CVS shares were trading at $87.50 before the bell.  (Reporting by Subrat Patnaik in Bengaluru; Editing by Kirti Pandey)",2016-02-09,CVS,"Tue Feb 9, 2016 | 8:31am EST",CVS Health forecasts first-quarter profit below estimates,http://www.reuters.com//article/us-cvs-health-results-idUSKCN0VI126?type=companyNews
130,"   By Subrat Patnaik  CVS Health Corp (CVS.N), the No.2 U.S. drugstore chain by store count, forecast current-quarter profit below analysts' estimates as customer traffic to its retail stores slows.Shares of the company, which sells items such as personal care products, over-the-counter drugs and snacks at its retail stores, fell 2.4 percent in premarket trading on Tuesday.CVS's comparable sales at these stores declined 5 percent in 2015, which the company attributed to its decision to discontinue sales of tobacco products. Research firm Conlumino's Chief Executive Neil Saunders, however, said the argument now held much less weight and CVS's ""front of house offer simply isn't compelling or engaging enough."" ""...Over a holiday period in which sales of beauty and personal care products were robust, CVS is losing ground and losing share,"" Saunders said. Comparable sales in CVS's pharmacy benefits management business rose 4.5 percent in 2015.The company forecast an adjusted profit of $1.14-$1.17 per share for the first quarter, below the average analyst estimate of $1.18, according to Thomson Reuters I/B/E/S. The net income attributable to CVS rose 13.4 percent to $1.50 billion, or $1.34 per share, in the quarter ended Dec. 31.Excluding items, the company earned $1.53 per share, in line with the average analyst estimate.  Net revenue rose 11 percent to $41.15 billion, narrowly beating the average estimate of $41.13 billion.CVS shares were trading at $87.50 before the bell.  (Reporting by Subrat Patnaik in Bengaluru; Editing by Kirti Pandey)",2016-02-09,CVS,"Tue Feb 9, 2016 | 8:31am EST",UPDATE 2-CVS Health forecasts 1st-qtr profit below estimates,http://www.reuters.com//article/cvs-health-results-idUSL3N15O21E?type=companyNews
131,"  Feb 9 CVS Health Corp, the No.2 U.S. drugstore chain by store count, reported an 11 percent rise in quarterly net revenue, helped by strong demand in its pharmacy business.The net income attributable to the company rose to $1.50 billion, or $1.34 per share, in the fourth quarter ended Dec. 31 from $1.32 billion, or $1.14 per share, a year earlier.  Net revenue rose to $41.15 billion from $37.06 billion.   (Reporting by Subrat Patnaik in Bengaluru; Editing by Kirti Pandey) ",2016-02-09,CVS,"Tue Feb 9, 2016 | 6:58am EST",CVS Health's quarterly revenue rises 11 pct,http://www.reuters.com//article/cvs-health-results-idUSL3N15O20T?type=companyNews
132,"   By Caroline Humer | NEW YORK  NEW YORK CVS Health Corp (CVS.N) said on Tuesday its pharmacy benefit customers spent about 5 percent more on prescription drugs in 2015 than in 2014, a year when drug spending jumped nearly 12 percent.The No. 2 U.S. drugstore chain attributed the lower increase to careful management of its coverage plans, saying it negotiated with pharmaceutical makers for rebates and discounts and had more selective coverage that excluded pricey drugs.It also said fewer new high-priced specialty drugs hit the market in 2015 and that inflation in branded drugs for high volume disorders like diabetes had one of the biggest impacts on spending.Drug spending in 2014 was boosted in part by a pricey new hepatitis C treatment from Gilead Sciences (GILD.O), CVS said. In 2015, AbbVie Inc's ABBV.O competing product hit the market and is estimated to have nearly halved the price of Gilead's treatment. CVS competes against Express Scripts Holding Corp (ESRX.O) and Optum, a unit of UnitedHealth Group Inc (UNH.N). Express Scripts also is expected to release a detailed drug spending report for 2015. CVS Chief Medical Officer Troyen Brennan said that the 2015 overall drug price trend would have been nearly the same as in 2014 if it had not made changes to its main coverage plan, called a formulary, or negotiated such steep discounts. Drug companies have a list price but typically provide discounts and rebates to large buyers.One drug Brennan called out as particularly pricey was Valeant Pharmaceuticals' (VRX.N) Jublia, a toenail fungus treatment whose cost trend for customers rose 950 percent during the year, reflecting a combination of increased use and price. A cheaper oral medication that has better clinical results is preferred, he said. Valeant has been criticized for raising prices of its treatments sharply and for using a pharmacy that used aggressive tactics to push sales of its drugs.(This version of the story corrects eighth paragraph to show Jublia increase was utilization and price, not price alone) (Reporting by Caroline Humer; Editing by Tom Brown)",2016-02-23,CVS,"Tue Feb 23, 2016 | 12:45pm EST","CORRECTED-CVS says 2015 drug spending grew 5 percent, far less than in 2014",http://www.reuters.com//article/cvs-health-pricing-idUSL2N1611PM?type=companyNews
133,"  Hospital staffing provider TeamHealth Holdings Inc said on Wednesday it had appointed three nominees of activist hedge fund Jana Partners LLC to its board.Jana said last month TeamHealth would benefit from new directors, after disclosing an 8 percent stake.TeamHealth said it added Edwin Crawford, former chairman of pharmacy benefits manager CVS Caremark Corp, and Scott Ostfeld, a partner at Jana, to its board, increasing its size to 12 directors.The company said Nancy Schlichting, CEO of healthcare provider Henry Ford Health Systems, will be appointed as a director in January 2017.TeamHealth said it would also reduce the size of the board by one director each year over the next three years, beginning at the 2016 shareholder meeting. The company rejected a $5.3 billion takeover offer from AmSurg Corp last year and, instead, bought IPC Healthcare Inc for $1.4 billion. (This story has been corrected in paragraph 4 to say Nancy Schlichting, not Scott Ostfeld, will be appointed to the board in January 2017)  (Reporting by Ankur Banerjee in Bengaluru; Editing by Anupama Dwivedi and Sriraj Kalluvila)",2016-03-23,CVS,"Wed Mar 23, 2016 | 12:52pm EDT",CORRECTED-UPDATE 1-TeamHealth appoints Jana Partners' nominees as directors,http://www.reuters.com//article/teamhealth-holdg-equity-jana-idUSL3N16V3XW?type=companyNews
134,"   By Lewis Krauskopf | NEW YORK  NEW YORK For much of the last three years, investors have been willing to pay more for expected profit at Walgreens than for competitor CVS, but the pharmacy chain may be losing that edge on Wall Street.Analysts are now putting much more favorable ratings on CVS Health Corp (CVS.N), and CVS shares are outrunning Walgreens so far this year and closing the valuation gap.When Walgreens Boots Alliance Inc (WBA.O) reports fiscal second-quarter results on Tuesday, it could win converts. The company is expected to report earnings of $1.28 per share, up 8 percent from a year ago, according to Thomson Reuters data. Evercore ISI analyst Ross Muken rates both stocks as ""buys,"" but said that most investors choose between the companies, with Walgreens now representing a higher-risk, higher-reward play, and CVS the lower-risk stock as Walgreens undergoes changes under a new CEO. Perhaps reflecting the view that CVS is a safer bet, a greater portion of analysts are recommending its shares, with 85 percent placing ""buy"" or ""strong buy"" ratings on the stock against 58 percent for Walgreen, according to Thomson Reuters data. Walgreens shares are trading at 18 times forward earnings estimates compared with 17.4 times for CVS. But that gap has been wider for most of the past year. ACQUISITION PRESCRIPTION With a market cap of about $93 billion, Walgreens has established itself as a massive international retailer and distributor after completing the acquisition of Europe's Alliance Boots more than a year ago. That company's former executive chairman, Stefano Pessina, was named to head Walgreens on a permanent basis last July. Well-regarded by investors, Pessina has been leading changes that include significant cost cutting, according to analysts. Meanwhile, uncertainty clouds Walgreens' latest big deal - its proposed $9.4 billion acquisition of Rite Aid Corp (RAD.N), which would expand its U.S. drugstore footprint but faces antitrust scrutiny.Seattle-based Smead Capital Management holds more than 860,000 Walgreens shares and views the company as a ""best in class player"" in operating pharmacy outlets and convenience stores, said Tony Scherrer, Smead's director of research.CVS has also been on the acquisition path, with recent deals for pharmacy services provider Omnicare and Target Corp's (TGT.N) fleet of pharmacies. CVS, with a market cap of about $115 billion, is one of the biggest U.S. managers of prescription benefits - a business in which Walgreens lacks a comparable big presence - in addition to being the No. 2 U.S. drugstore chain by sales behind Walgreens, according to Euromonitor. That pharmacy benefits business, which has been increasing revenue at a faster pace than the pharmacy side, gives CVS an edge, said Jeff Jonas, a portfolio manager with Gabelli Funds in Rye, New York, who prefers CVS shares to Walgreens. CVS should also merit a higher stock market value, he said, because deals in the pharmacy benefits, or PBM, industry have been struck at higher premiums than for drug-store mergers.""I just think with the PBM in particular, (CVS is) going to have a much better growth rate in both revenue and earnings,"" Jonas said. (Editing by Matthew Lewis)",2016-04-04,CVS,"Mon Apr 4, 2016 | 7:14am EDT",Walgreens' Wall Street edge fades against rival CVS as earnings near,http://www.reuters.com//article/us-walgreens-boots-cvs-health-idUSKCN0X1116?type=companyNews
135,"   By Lewis Krauskopf | NEW YORK  NEW YORK For much of the last three years, investors have been willing to pay more for expected profit at Walgreens than for competitor CVS, but the pharmacy chain may be losing that edge on Wall Street.Analysts are now putting much more favorable ratings on CVS Health Corp (CVS.N), and CVS shares are outrunning Walgreens so far this year and closing the valuation gap.When Walgreens Boots Alliance Inc (WBA.O) reports fiscal second-quarter results on Tuesday, it could win converts. The company is expected to report earnings of $1.28 per share, up 8 percent from a year ago, according to Thomson Reuters data. Evercore ISI analyst Ross Muken rates both stocks as ""buys,"" but said that most investors choose between the companies, with Walgreens now representing a higher-risk, higher-reward play, and CVS the lower-risk stock as Walgreens undergoes changes under a new CEO. Perhaps reflecting the view that CVS is a safer bet, a greater portion of analysts are recommending its shares, with 85 percent placing ""buy"" or ""strong buy"" ratings on the stock against 58 percent for Walgreen, according to Thomson Reuters data. Walgreens shares are trading at 18 times forward earnings estimates compared with 17.4 times for CVS. But that gap has been wider for most of the past year. ACQUISITION PRESCRIPTION With a market cap of about $93 billion, Walgreens has established itself as a massive international retailer and distributor after completing the acquisition of Europe's Alliance Boots more than a year ago. That company's former executive chairman, Stefano Pessina, was named to head Walgreens on a permanent basis last July. Well-regarded by investors, Pessina has been leading changes that include significant cost cutting, according to analysts. Meanwhile, uncertainty clouds Walgreens' latest big deal - its proposed $9.4 billion acquisition of Rite Aid Corp (RAD.N), which would expand its U.S. drugstore footprint but faces antitrust scrutiny.Seattle-based Smead Capital Management holds more than 860,000 Walgreens shares and views the company as a ""best in class player"" in operating pharmacy outlets and convenience stores, said Tony Scherrer, Smead's director of research.CVS has also been on the acquisition path, with recent deals for pharmacy services provider Omnicare and Target Corp's (TGT.N) fleet of pharmacies. CVS, with a market cap of about $115 billion, is one of the biggest U.S. managers of prescription benefits - a business in which Walgreens lacks a comparable big presence - in addition to being the No. 2 U.S. drugstore chain by sales behind Walgreens, according to Euromonitor. That pharmacy benefits business, which has been increasing revenue at a faster pace than the pharmacy side, gives CVS an edge, said Jeff Jonas, a portfolio manager with Gabelli Funds in Rye, New York, who prefers CVS shares to Walgreens. CVS should also merit a higher stock market value, he said, because deals in the pharmacy benefits, or PBM, industry have been struck at higher premiums than for drug-store mergers.""I just think with the PBM in particular, (CVS is) going to have a much better growth rate in both revenue and earnings,"" Jonas said. (Editing by Matthew Lewis)",2016-04-04,CVS,"Mon Apr 4, 2016 | 7:14am EDT",Walgreens' Wall Street edge fades against rival CVS as earnings near,http://www.reuters.com//article/walgreens-boots-cvs-health-idUSL2N1730X3?type=companyNews
136,  April 8 CVS Health Corp :* Chief Executive Officer Larry Merlo total 2015 compensation $28.9 million versus $32.4 million in 2014  * Chief Financial Officer David Denton total 2015 compensation $7 million versus $14.7 million in 2014 - SEC FILING  Source text - bit.ly/1UNzFDq Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780) ,2016-04-08,CVS,"Fri Apr 8, 2016 | 12:19pm EDT",BRIEF-CVS Health CEO Larry Merlo total 2015 compensation $28.9 mln vs. $32.4 mln in 2014,http://www.reuters.com//article/idUSFWN17B0LR?type=companyNews
137,  April 22 CVS Health Corp : * Files for debt shelf of up to $10.0 billion - SEC Filing  Source text: 1.usa.gov/1SzDFUX Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)  ,2016-04-22,CVS,"Fri Apr 22, 2016 | 4:42pm EDT",BRIEF-CVS Health files for debt shelf of up to $10 bln,http://www.reuters.com//article/idUSFWN17P132?type=companyNews
138,"  May 2 CVS Health* Launched expanded health care offerings to support health of people with hepatitis b, hepatitis c and other liver diseases in hawaii  * Cvs health corp says  launched expanded hepatitis care options in hawaii  Source text for Eikon:    (Bengaluru Newsroom; +1 646 223 8780; ) ",2016-05-02,CVS,"Mon May 2, 2016 | 2:10pm EDT",BRIEF-CVS Health launches expanded hepatitis care options in Hawaii,http://www.reuters.com//article/idUSFWN17Z0OV?type=companyNews
139,"  May 3 CVS Health Corp* Presentation - continued to pull back on broad-based promotion at store front in Q1, leading to fewer visits from  lower-value customers* Presentation - negative impact from later flu immaterial to Q1* Presentation - in 2016, expect to return more than $5 billion to shareholders through dividends and share repurchases * Presentation - Q1 EPS outperformance primarily driven by stronger-than-expected volumes and better purchasing economics in the PBM* Presentation - expect 2016 retail net revenue to grow 13-14.25 percent * Exec on conf call- putting more and more effort around health and beauty, don't need to win in edibles or general merchandise* Presentation - have seen no change in level of branded drug inflation * Presentation - expect 2016 PBM net revenue to grow 21.75%- 23.25%* Presentation - expect Q2 net revenue to grow 18.5-20 percent* CEO on conf call- pending successful pilot of CVS Express, goal is to roll out to majority of markets this year   Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-05-03,CVS,"Tue May 3, 2016 | 9:53am EDT",BRIEF-CVS presentation - expect Q2 net revenue to grow 18.5-20 pct,http://www.reuters.com//article/idUSFWN1800PM?type=companyNews
140,"  CVS Health Corp (CVS.N), the No. 2 U.S. drugstore chain by store count, reported better-than-expected quarterly revenue and profit, helped by strong demand for its pharmacy benefit management (PBM) services.Revenue in CVS's PBM business rose 20.5 percent to $28.8 billion in first quarter ended March 31, with the growth being boosted by pharmacy network claim volume and demand for specialty pharmacy services.CVS boosted its specialty pharmacy business, which provides drugs to people with expensive chronic conditions such as rheumatoid arthritis, with its $10.1 billion acquisition of Omnicare Inc in August 2015.Sales at established CVS stores rose 4.2 percent in the quarter, with front-end same-store sales increasing 0.7 percent, after almost three years of decline. The company's net income fell to $1.15 billion, or $1.04 per share, from $1.22 billion, or $1.07 per share, due to higher interest expenses and acquisition costs.Excluding items, CVS earned $1.18 per share, beating analysts average estimate of $1.16, according to Thomson Reuters I/B/E/S. Net revenue rose 19 percent to $43.22 billion, beating analysts' estimates of $43 billion. However, the company second-quarter adjusted earnings forecast of $1.28-$1.31 per share was below analysts average estimate of $1.35 per share. (Reporting by Sruthi Ramakrishnan in Bengaluru; Editing by Don Sebastian and Savio D'Souza)",2016-05-03,CVS,"Tue May 3, 2016 | 7:36am EDT","Drugstore operator CVS's revenue, profit beat estimates",http://www.reuters.com//article/us-cvs-health-results-idUSKCN0XU100?type=companyNews
141,"  May 3 CVS Health Corp* CVS Health reports first quarter results; confirms 2016 adjusted EPS guidance* Q1 adjusted earnings per share $1.18* Q1 GAAP earnings per share $1.04* Q1 revenue $43.2 billion versus I/B/E/S view $43 billion* Q1 earnings per share view $1.16 -- Thomson Reuters I/B/E/S* Sees Q2 adjusted earnings per share $1.28 to $1.31 * Sees Q2 2016 GAAP earnings per share $1.17 to $1.20* FY GAAP diluted EPS is revised, to $5.24 to $5.39 from $5.28 to $5.43* Sees 2016 GAAP diluted EPS is revised, to $5.24 to $5.39 from $5.28 to $5.43 * Qtrly front store same store sales increased 0.7 pct* Qtrly front store same store sales were negatively affected by softer customer traffic* Q2 earnings per share view $1.35 -- Thomson Reuters I/B/E/S * Confirmed full year adjusted eps of $5.73 to $5.88* Company continues to expect to deliver 2016 free cash flow of $5.9 billion to $6.2 billion* Qtrly pharmacy same store sales rose 5.5 pct* FY2016 earnings per share view $5.82 -- Thomson Reuters I/B/E/S* Qtrly front store same store sales increased 0.7 pct  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-05-03,CVS,"Tue May 3, 2016 | 7:09am EDT",BRIEF-CVS Health reports Q1 adjusted earnings per share $1.18,http://www.reuters.com//article/idUSASC08M4R?type=companyNews
142,"   By Amrutha Penumudi and Ransdell Pierson  Allergan Plc (AGN.N), whose $160 billion merger with Pfizer Inc (PFE.N) collapsed last month, reported a higher-than-expected quarterly profit and said it would buy back up to $10 billion in company stock, helping lift its shares 4 percent.The Dublin drugmaker on Tuesday said the planned $40 billion sale of its generics business to Teva Pharmaceutical Industries (TEVA.TA) will close next month and that it will use $8 billion of the money to pay down company debt. Since the U.S. government torpedoed the merger, a deal that would have relocated Pfizer's legal domicile to Ireland to reduce Pfizer's taxes, investors have speculated Allergan might use the Teva proceeds for sizeable new deals.However, Allergan Chief Executive Brent Saunders, in a conference call with industry analysts, said he was more interested for now in ""stepping stone deals"" valued at up to a few billion dollars meant to bolster the company's existing disease areas.Allergan, known as Actavis Inc until it bought Botox-maker Allergan Inc last year and took on its name, said it expects to buy back $4 billion to $5 billion of its shares over the next four to six months and would consider more stock repurchases if  market conditions allow. The company's market value is currently $84.4 billion, according to Thomson Reuters data. Excluding special items, the company earned $3.04 per share in the first quarter, topping the average analysts' estimate of $3.01 largely because of lower than expected research spending.Up to Monday's close of $213.71, Allergan's stock had fallen about 23 percent since Pfizer scrapped the merger, which would have been the biggest-ever in the pharmaceutical industry.The deal collapsed after the U.S. Treasury issued new rules curbing tax inversions, or moves by American companies to relocate their domicile overseas to cut taxes. ""With this highly controversial quarter now in the rear view mirror, we see an attractive setup in Allergan shares going forward based on a combination of attractive valuation, ongoing healthy organic growth and significant capital deployment optionality,"" said JP Morgan analyst Chris Schott.Revenue in its U.S. brands business, including Botox, rose 27.3 percent to $2.30 billion. The unit accounts for about 60 percent of the company's total revenue. The company reported net income of $186.1 million, or 47 cents per share, compared with a loss of $535.2 million, or $1.85 per share, a year earlier. Total revenue rose 48 percent to $3.80 billion, below Wall Street's expectations of $3.95 billion.Revenue fell in the company's generic distribution unit, which lost business from Target Corp's (TGT.N) in-store pharmacies after they were acquired by CVS Health (CVS.N). (Reporting by Amrutha Penumudi in Bengaluru and Ransdell Pierson in New York; Editing by Ted Kerr and Steve Orlofsky)",2016-05-10,CVS,"Tue May 10, 2016 | 12:23pm EDT","UPDATE 5-Allergan profit beats estimates, share buybacks planned",http://www.reuters.com//article/allergan-results-idUSL3N18744H?type=companyNews
143,"  May 16 Cvs Health Corp :* Has commenced cash tender offers for any and all of its 5.75% senior notes due 2017, its 6.60% senior notes due 2019 * Offers for up to $1.5 billion of 6.25% senior notes due 2027,6.125% senior notes due 2039,5.750% senior notes due 2041,5.00% senior notes due 2024 * Purpose of tender offers is to refinance a portion of cvs health's outstanding indebtedness * Cvs health corporation announces cash tender offers for certain outstanding notes  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-05-16,CVS,"Mon May 16, 2016 | 10:04am EDT",BRIEF-CVS Health announces cash tender offers for certain outstanding notes,http://www.reuters.com//article/idUSASC08PTC?type=companyNews
144,"   By Nandita Bose | CHICAGO  CHICAGO Retail chain Target Corp (TGT.N) gave a cautious outlook on Wednesday after reporting a lower-than-expected increase in quarterly sales due to unseasonable weather and weaker demand for electronics and groceries. Shares of the company fell as much as 11 percent, their biggest intraday decline since December 2008, as investors focused on weaker revenues and a poor outlook despite higher-than-expected earnings. Target's woes also encouraged investors to sell shares of rival retailers like Macy's M.N., JC Penney (JCP.N) and Wal-Mart Stores Inc (WMT.N) on Wednesday. Wal-Mart is due to report quarterly results on Thursday.Target is the latest traditional brick-and-mortar chain to report disappointing sales as traditional chain stores spend more at online merchants like Amazon.com Inc (AMZN.O) and as slowly rising wages enable consumers to spend more on big-ticket purchases like cars and home improvements.""We're approaching our business with appropriate caution as sales trends at Target and many of our key competitors (have) weakened,"" Chief Executive Officer Brian Cornell said on a conference call.He said he expected price discounting to intensify as retailers try to shed excess inventory after a slow season.  Target said apparel sales rose during the quarter and were stronger than other retailers', but unseasonable weather hurt demand.In addition, the company's grocery division suffered from a reorganization that increased organic and fresh food offerings but made it harder for customers to find products. The sixth-largest U.S. retailer said customers made larger ""pantry-stocking visits,"" but growth in smaller ""convenience trips"" slowed, highlighting a new challenge for chains like Target that have bet on small format-stores for future growth.Target said sales at stores open at least a year rose 1.2 percent in the first quarter ended on April 30, missing market expectations for a 1.6 percent increase, according to research firm Consensus Metrix.  Net sales fell 5.4 percent to $16.2 billion, mainly due to the sale of the pharmacy and clinic business to CVS Health Corp (CVS.N). Analysts on average had forecast $16.32 billion, according to Thomson Reuters I/B/E/S.Digital sales increased 23 percent, compared with a year-earlier rise of 38 percent, and accounted for 3.5 percent of the company's total. Target said second-quarter comparable sales would be flat to down 2 percent even though it was confident that it would meet its earnings outlook of $1.00 to $1.20 per share before special items.  Analysts blamed the first-quarter performance on short-term weakness in the sector and expressed confidence about Target's growth prospects and Cornell's turnaround strategy. Neil Saunders, managing director of research firm Conlumino, said the comparable sales were not ""spectacular"" but nonetheless were ""a testament to Target's relative strength"" because they remained in positive territory.   Net income fell to $632 million from $635 million a year earlier.Excluding restructuring charges and gains from the CVS deal, earnings were $1.29 per share, better than analysts expectations of $1.20 per share. (Reporting by Nandita Bose in Chicago; Editing by Lisa Von Ahn)",2016-05-18,CVS,"Wed May 18, 2016 | 3:39pm EDT","UPDATE 4-Target shares plunge after sales, outlook disappoint",http://www.reuters.com//article/target-results-idUSL2N18F0FA?type=companyNews
145,"  May 23 CVS Health Corp :* Company will launch digital receipts as a new option for all members of its ExtraCare rewards program  * New option for digital receipts will roll out in early June and eventually be available in 7,900 retail locations  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ",2016-05-23,CVS,"Mon May 23, 2016 | 8:15am EDT",BRIEF-CVS to launch digital receipts option for ExtraCare rewards program members,http://www.reuters.com//article/idUSFWN18K0CE?type=companyNews
146,  May 25 Cvs Health Corp* Cvs health to expand access to opioid overdose-reversal drug for cvs pharmacy patients in seven additional states  * Expansion of company's naloxone program will begin with new mexico in late may  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-05-25,CVS,"Wed May 25, 2016 | 8:55am EDT",BRIEF-CVS Health to expand access to opioid overdose-reversal drug,http://www.reuters.com//article/idUSFWN18M0DT?type=companyNews
147,  June 7 Cvs Health Corp * CVS Pharmacy Now Open In Target Stores Throughout Washington  Source text for Eikon:  Further company coverage:  ,2016-06-07,CVS,"Tue Jun 7, 2016 | 1:03pm EDT",BRIEF-Cvs Pharmacy Now Open In Target Stores Throughout Washington,http://www.reuters.com//article/idUSFWN18Z0IQ?type=companyNews
148,"   By Brendan Pierson  Republican Senate Judiciary Committee Chairman Chuck Grassley  of Iowa is urging a federal appeals court to revive a whistleblower lawsuit accusing pharmacy benefit manager CVS Caremark Corp of defrauding Medicare, saying a lower court decision dismissing the case could undermine the goals of the federal False Claims Act. In an amicus brief accepted by the 3rd U.S. Circuit Court of Appeals on Thursday, Grassley said the lower court wrongly inferred that the federal government knew of Caremark's billing practices based on federal employees' testimony that those practices were widespread. He also said those employees were testifying as individuals, not speaking for the government.  To read the full story on Westlaw Practitioner Insights, click here: bit.ly/1Ua9lRw",2016-06-10,CVS,"Fri Jun 10, 2016 | 6:42am EDT",Grassley urges 3rd Circuit to revive fraud case against Caremark,http://www.reuters.com//article/health-caremark-idUSL1N1920B5?type=companyNews
149,  July 6 CVS Health Corp : * Sets quarterly dividend of $0.425 per share  Source text for Eikon:  Further company coverage:  ,2016-07-06,CVS,"Wed Jul 6, 2016 | 1:09pm EDT",BRIEF-CVS Health sets quarterly dividend of $0.425 per share,http://www.reuters.com//article/idUSFWN19S0N2?type=companyNews
150,"   By Sruthi Ramakrishnan  Walgreens Boots Alliance Inc (WBA.O), the No.1 U.S. drugstore operator by store count, reported a lower-than-expected increase in quarterly sales, hurt by weak demand for over-the-counter drugs and other products.The company's shares fell as much as 3.5 percent on Wednesday.Walgreens has been investing to revive U.S. retail sales, or front-end sales, mainly by sprucing up its beauty business, which is a big traffic driver. It is rolling out a revamped beauty division to more than 1,800 stores by end of 2016.However, comparable sales in the business were underwhelming in the latest third quarter, rising just 0.1 percent, after two quarters of declines.Analysts were expecting U.S. retail sales, which accounts for roughly a third of total U.S. sales, to increase 0.7 percent, according to Evercore ISI.The rest of Walgreens' U.S. sales comes from its pharmacy business, where comparable sales rose 6 percent due to a jump in prescriptions filled for Medicare Part D drugs. Total net sales rose 2.4 percent to $29.5 billion, missing analysts average estimate of $29.71 billion, according to Thomson Reuters I/B/E/S.Excluding items, Walgreens' profit of $1.18 per share beat analysts average estimate of $1.14.Walgreens said its acquisition of Rite Aid Corp (RAD.N) was on track to close later this year and that it was looking for buyers for the stores it needed to divest to get regulatory clearance. Rite Aid's shares rose 2 percent. ""While USA Retail is facing some pressure, we believe that the RAD deal will cause sentiment in USA Retail to shift positively once integration efforts begin,"" Leerink Partners analyst David Larsen wrote in a note.Walgreens also said it was bracing for a long period of volatility following Britain's shock vote to leave the European Union.The company's revenue from UK, about 9 percent of sales last fiscal, could be a cause for concern, especially with the pound falling about 13 percent against the dollar since the vote on June 23. ""The situation is very volatile at this time. For sure, the period of uncertainty will be quite long,"" Chief Executive Stefano Pessina said.The depreciation of the pound would hit Walgreens' sales in the near term and more than offset any sales gains in local currency terms, said Neil Saunders, chief executive of research firm Conlumino.Still, the company bumped up the lower end of its fiscal 2016 profit forecast  to $4.45-$4.55 per share from $4.35-$4.55. (Reporting by Sruthi Ramakrishnan in Bengaluru; Editing by Savio D'Souza)",2016-07-06,CVS,"Wed Jul 6, 2016 | 1:07pm EDT",Walgreens U.S. retail sales rise less than expected,http://www.reuters.com//article/us-walgreens-boots-results-idUSKCN0ZM10G?type=companyNews
151,"   By Sruthi Ramakrishnan  Walgreens Boots Alliance Inc (WBA.O), the No.1 U.S. drugstore operator by store count, reported a lower-than-expected increase in quarterly sales, hurt by weak demand for over-the-counter drugs and other products.The company's shares fell as much as 3.5 percent on Wednesday.Walgreens has been investing to revive U.S. retail sales, or front-end sales, mainly by sprucing up its beauty business, which is a big traffic driver. It is rolling out a revamped beauty division to more than 1,800 stores by end of 2016.However, comparable sales in the business were underwhelming in the latest third quarter, rising just 0.1 percent, after two quarters of declines.Analysts were expecting U.S. retail sales, which accounts for roughly a third of total U.S. sales, to increase 0.7 percent, according to Evercore ISI.The rest of Walgreens' U.S. sales comes from its pharmacy business, where comparable sales rose 6 percent due to a jump in prescriptions filled for Medicare Part D drugs. Total net sales rose 2.4 percent to $29.5 billion, missing analysts average estimate of $29.71 billion, according to Thomson Reuters I/B/E/S.Excluding items, Walgreens' profit of $1.18 per share beat analysts average estimate of $1.14.Walgreens said its acquisition of Rite Aid Corp (RAD.N) was on track to close later this year and that it was looking for buyers for the stores it needed to divest to get regulatory clearance. Rite Aid's shares rose 2 percent. ""While USA Retail is facing some pressure, we believe that the RAD deal will cause sentiment in USA Retail to shift positively once integration efforts begin,"" Leerink Partners analyst David Larsen wrote in a note.Walgreens also said it was bracing for a long period of volatility following Britain's shock vote to leave the European Union.The company's revenue from UK, about 9 percent of sales last fiscal, could be a cause for concern, especially with the pound falling about 13 percent against the dollar since the vote on June 23. ""The situation is very volatile at this time. For sure, the period of uncertainty will be quite long,"" Chief Executive Stefano Pessina said.The depreciation of the pound would hit Walgreens' sales in the near term and more than offset any sales gains in local currency terms, said Neil Saunders, chief executive of research firm Conlumino.Still, the company bumped up the lower end of its fiscal 2016 profit forecast  to $4.45-$4.55 per share from $4.35-$4.55. (Reporting by Sruthi Ramakrishnan in Bengaluru; Editing by Savio D'Souza)",2016-07-06,CVS,"Wed Jul 6, 2016 | 1:07pm EDT",UPDATE 4-Walgreens U.S. retail sales rise less than expected,http://www.reuters.com//article/walgreens-boots-results-idUSL4N19S30N?type=companyNews
152,  July 25 CVS Health Corp * Says overdose-reversal drug available without a prescription at all CVS pharmacy locations in Texas  Source text for Eikon:  Further company coverage:  ,2016-07-25,CVS,"Mon Jul 25, 2016 | 8:49am EDT",BRIEF-CVS Health makes overdose-reversal drug available without prescription in Texas,http://www.reuters.com//article/idUSFWN1AB0FM?type=companyNews
153,  July 29 CVS Health Corp:* Says to increase access to FDA-approved nasal naloxone for patients without insurance  * CVS Pharmacy patients purchasing Narcan nasal spray without insurance will receive a $35 discount coupon to purchase medication  Source text for Eikon:  Further company coverage: ,2016-07-29,CVS,"Fri Jul 29, 2016 | 10:51am EDT",BRIEF-CVS Health to increase access to FDA-approved nasal naloxone for patients without insurance,http://www.reuters.com//article/idUSFWN1AF14A?type=companyNews
154,"   By Subrat Patnaik  Drugstore chain operator CVS Health Corp (CVS.N) reported a better-than-expected profit, helped by strong demand for its pharmacy benefit management (PBM) services, and raised its full-year adjusted profit forecast.Shares of the No. 2 U.S. drugstore chain by store count, rose 3 percent to $96.30 in premarket trading on Tuesday.Revenue in CVS's pharmacy business rose 20.7 percent to $5.1 billion in the second quarter ended June 30, due to increased pharmacy network claim volume and growth in specialty pharmacy.CVS boosted its specialty pharmacy business, which provides drugs to people with expensive chronic conditions such as rheumatoid arthritis, with its $10.1 billion acquisition of Omnicare Inc in August 2015.""We see 2017 shaping up to be another very successful PBM selling season, with substantial gross and net new business to date,"" Chief Executive Larry Merlo said. The Woonsocket, Rhode Island-based company raised full-year adjusted earnings to $5.81-$5.89 per share, from $5.73-$5.88 it had expected earlier.Net income attributable to CVS Health fell 27.4 percent to $924 million in the second quarter.Excluding items, CVS earned $1.32 per share, topping the average analyst estimate of $1.30 per share, according to Thomson Reuters I/B/E/S. However, comparable front-end store sales, which include over-the-counter drugs and cosmetics, fell 2.5 percent in the quarter, due to lower customer traffic.CVS is not investing in its front-end operations, while rivals such as Walgreens Boots Alliance Inc (WBA.O) are stepping up the pace of innovation and investment, said Neil Saunders, CEO of research firm Conlumino. Walgreens has been working to revive front-end sales, mainly by sprucing up its beauty business, which is a big traffic driver. It is rolling out a revamped beauty section at more than 1,800 stores by end of 2016.The company's net revenue rose 17.6 percent to $43.73 billion, rising by double-digit percentages for the fourth straight quarter. Analysts on average had expected revenue of $44.28 billion.Up to Monday's close, the stock had fallen nearly 17 percent in the last 12 months. (Reporting by Subrat Patnaik in Bengaluru; Editing by Saumyadeb Chakrabarty and Shounak Dasgupta)",2016-08-02,CVS,"Tue Aug 2, 2016 | 9:24am EDT",CVS Health's profit beats estimates on pharma business strength,http://www.reuters.com//article/us-cvs-health-results-idUSKCN10D113?type=companyNews
155,"   By Subrat Patnaik  Drugstore chain operator CVS Health Corp (CVS.N) reported a better-than-expected profit, helped by strong demand for its pharmacy benefit management (PBM) services, and raised its full-year adjusted profit forecast.Shares of the No. 2 U.S. drugstore chain by store count, rose 3 percent to $96.30 in premarket trading on Tuesday.Revenue in CVS's pharmacy business rose 20.7 percent to $5.1 billion in the second quarter ended June 30, due to increased pharmacy network claim volume and growth in specialty pharmacy.CVS boosted its specialty pharmacy business, which provides drugs to people with expensive chronic conditions such as rheumatoid arthritis, with its $10.1 billion acquisition of Omnicare Inc in August 2015.""We see 2017 shaping up to be another very successful PBM selling season, with substantial gross and net new business to date,"" Chief Executive Larry Merlo said. The Woonsocket, Rhode Island-based company raised full-year adjusted earnings to $5.81-$5.89 per share, from $5.73-$5.88 it had expected earlier.Net income attributable to CVS Health fell 27.4 percent to $924 million in the second quarter.Excluding items, CVS earned $1.32 per share, topping the average analyst estimate of $1.30 per share, according to Thomson Reuters I/B/E/S. However, comparable front-end store sales, which include over-the-counter drugs and cosmetics, fell 2.5 percent in the quarter, due to lower customer traffic.CVS is not investing in its front-end operations, while rivals such as Walgreens Boots Alliance Inc (WBA.O) are stepping up the pace of innovation and investment, said Neil Saunders, CEO of research firm Conlumino. Walgreens has been working to revive front-end sales, mainly by sprucing up its beauty business, which is a big traffic driver. It is rolling out a revamped beauty section at more than 1,800 stores by end of 2016.The company's net revenue rose 17.6 percent to $43.73 billion, rising by double-digit percentages for the fourth straight quarter. Analysts on average had expected revenue of $44.28 billion.Up to Monday's close, the stock had fallen nearly 17 percent in the last 12 months. (Reporting by Subrat Patnaik in Bengaluru; Editing by Saumyadeb Chakrabarty and Shounak Dasgupta)",2016-08-02,CVS,"Tue Aug 2, 2016 | 9:24am EDT",UPDATE 2-CVS Health's profit beats estimates on pharma business strength,http://www.reuters.com//article/cvs-health-results-idUSL3N1AJ3KN?type=companyNews
156,"  Aug 2 Cvs Health Corp :* CVS health reports second quarter results* Q2 GAAP earnings per share $0.86* Q2 same store sales rose 2.1 percent* Sees q3 2016 adjusted earnings per share $1.55 to $1.58 excluding items* Q2 adjusted earnings per share $1.32* Q2 revenue $43.7 billion versus i/b/e/s view $44.28 billion * Q2 earnings per share view $1.30 -- Thomson Reuters I/B/E/S* Sees q3 2016 gaap earnings per share $1.38 to $1.41* Full year adjusted eps guidance raised and narrowed * Raised and narrowed full year adjusted eps to $5.81 to $5.89 from $5.73 to $5.88* Q3 earnings per share view $1.55 -- Thomson Reuters I/B/E/S* Raised cash flow guidance for 2016 and now expects to deliver cash flow from operations of $8.8 billion to $9.1 billion * Qtrly same store sales increased 2.1% versus q2 of 2015* Revised full year gaap diluted eps to $4.92 to $5.00 from $5.24 to $5.39* When co reports subsequent qts, fy earnings per share guide expected to be cut to reflect impact from future acquisition-related integration costs* Fy2016 earnings per share view $5.82 -- Thomson Reuters I/B/E/S* Cvs Health Corp sees q3 adjusted eps of $1.55 to $1.58  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-08-02,CVS,"Tue Aug 2, 2016 | 7:39am EDT",BRIEF-CVS Health Q2 GAAP earnings per share $0.86,http://www.reuters.com//article/idUSASC08ZW5?type=companyNews
157,"  Aug 2 CVS Health Corp, the No. 2 U.S. drugstore chain by store count, reported a 17.6 percent rise in quarterly revenue, helped by strength in its pharmacy business.The company's net revenue rose to $43.73 billion in the second quarter ended June 30, from $37.17 billion, a year earlier.  Net income attributable to CVS Health fell to $924 million, or 86 cents per share, from $1.27 billion, or $1.12 per share.   (Reporting by Subrat Patnaik in Bengaluru; Editing by Saumyadeb Chakrabarty) ",2016-08-02,CVS,"Tue Aug 2, 2016 | 7:01am EDT",Drugstore chain CVS's revenue jumps on pharma business,http://www.reuters.com//article/cvs-health-results-idUSL3N1AJ3JV?type=companyNews
158,"   By Paul Arnold and John Miller | ZURICH  ZURICH Big U.S. pharmacy chain CVS Health's move to jettison an Actelion drug from a list of covered medications is not expected to have a ""meaningful impact"" on the Swiss biotechnology company's sales, a spokesman said on Wednesday.CVS on Tuesday released a list of more than 30 drugs it was removing from its 2017 standard formulary, including Actelion's Opsumit for deadly pulmonary arterial hypertension, or PAH.Andrew Weiss, an Actelion spokesman, said CVS Health was merely continuing its current policy regarding Opsumit prescriptions. This would not stop doctors who believe patients should receive Opsumit from making special demands that they get it from stores within the CVS chain, Weiss said.Furthermore, just a fraction of U.S. PAH sufferers get medications through CVS, he said, adding that government-supported programs Medicaid and Medicare were more important when it comes to covering Opsumit. ""We don't expect the decision by CVS Health to have a meaningful impact on our business with Opsumit,"" Weiss said.Actelion's shares fell 1.2 percent by 1015 GMT.Analysts from Barclays also said they were not overly concerned, opting not to change their outlook for 24 percent growth in Opsumit sales from 2015 to 2018.  That is, in part, because they already expected Opsumit to face competition from generic PAH treatments likely to come onto the market later this year or early next, said analyst Olivia Capra.Opsumit, approved by U.S. regulators in 2013, is Actelion's follow-on drug to Tracleer, which has lost patent protection. Opsumit made 378 million Swiss francs ($390.2 million) in sales in the first half of the year, up 76 percent. Actelion is banking on Opsumit and another newer PAH drug, Uptravi, to help offset falling Tracleer sales. (Editing by Louise Heavens)",2016-08-03,CVS,"Wed Aug 3, 2016 | 7:07am EDT",Actelion does not see significant CVS hit to Opsumit sales,http://www.reuters.com//article/us-actelion-opsumit-cvs-idUSKCN10E16L?type=companyNews
159,"   By Paul Arnold and John Miller | ZURICH  ZURICH Big U.S. pharmacy chain CVS Health's move to jettison an Actelion drug from a list of covered medications is not expected to have a ""meaningful impact"" on the Swiss biotechnology company's sales, a spokesman said on Wednesday.CVS on Tuesday released a list of more than 30 drugs it was removing from its 2017 standard formulary, including Actelion's Opsumit for deadly pulmonary arterial hypertension, or PAH.Andrew Weiss, an Actelion spokesman, said CVS Health was merely continuing its current policy regarding Opsumit prescriptions. This would not stop doctors who believe patients should receive Opsumit from making special demands that they get it from stores within the CVS chain, Weiss said.Furthermore, just a fraction of U.S. PAH sufferers get medications through CVS, he said, adding that government-supported programs Medicaid and Medicare were more important when it comes to covering Opsumit. ""We don't expect the decision by CVS Health to have a meaningful impact on our business with Opsumit,"" Weiss said.Actelion's shares fell 1.2 percent by 1015 GMT.Analysts from Barclays also said they were not overly concerned, opting not to change their outlook for 24 percent growth in Opsumit sales from 2015 to 2018.  That is, in part, because they already expected Opsumit to face competition from generic PAH treatments likely to come onto the market later this year or early next, said analyst Olivia Capra.Opsumit, approved by U.S. regulators in 2013, is Actelion's follow-on drug to Tracleer, which has lost patent protection. Opsumit made 378 million Swiss francs ($390.2 million) in sales in the first half of the year, up 76 percent. Actelion is banking on Opsumit and another newer PAH drug, Uptravi, to help offset falling Tracleer sales. (Editing by Louise Heavens)",2016-08-03,CVS,"Wed Aug 3, 2016 | 7:07am EDT",Actelion does not see significant CVS hit to Opsumit sales,http://www.reuters.com//article/actelion-opsumit-cvs-idUSL8N1AK2W3?type=companyNews
160,"  (Corrects headline to drop extraneous character)Aug 11 CVS Health Corp : * CVS Pharmacy launches breakthrough, end-to-end mobile payment experience  * Says CVS pay is currently available in select markets and a nationwide rollout is expected to kick off later this year.  Source text for Eikon:  Further company coverage:",2016-08-11,CVS,"Thu Aug 11, 2016 | 9:17am EDT",REFILE-BRIEF-CVS Health launches end-to-end mobile payment experience,http://www.reuters.com//article/idUSFWN1AS0JF?type=companyNews
161,  Aug 12 CVS Health Corp * Opioid overdose-reversal medication Naloxone is now available without a prescription at CVS Pharmacy locations in Idaho  Source text for Eikon:  Further company coverage:  ,2016-08-12,CVS,"Fri Aug 12, 2016 | 9:41am EDT",BRIEF-CVS Health Makes Overdose-Reversal Drug Naloxone Available Without A Prescription in Idaho,http://www.reuters.com//article/idUSFWN1AT0MS?type=companyNews
162,"  Aug 17 CVS Health Corp :* Makes overdose reversal drug available without a prescription at all CVS pharmacy locations in Colorado  * In addition to Colorado, CVS pharmacy locations in 30 other states able to dispense naloxone to patients without individual prescription  Source text for Eikon:  Further company coverage: ",2016-08-17,CVS,"Wed Aug 17, 2016 | 10:44am EDT",BRIEF-CVS Health makes overdose-reversal drug available without prescription in Colorado,http://www.reuters.com//article/idUSFWN1AY0FZ?type=companyNews
163,"  Aug 25 FamilyMart Co Ltd :* Says the company plans to split its CVS (convenience store) business (69 stores) and subleasing real estate to Mitsuuroko Group Holdings ' unit, which is engaged in CVS development support business * Transaction amount is 57 million yen* Says effective on Oct. 1  Source text in Japanese: goo.gl/Dt0L2QFurther company coverage:     (Beijing Headline News)",2016-08-25,CVS,"Thu Aug 25, 2016 | 2:43am EDT",BRIEF-FamilyMart to split CVS business to Mitsuuroko Group Holdings' unit for 57 mln yen,http://www.reuters.com//article/idUSL3N1B62CN?type=companyNews
164,"   By Jonathan Stempel  A federal appeals court on Tuesday revived a lawsuit accusing CVS Health Corp, one of the largest U.S. drugstore chains, of deceiving consumers with labels touting how CVS-branded vitamin E promotes ""heart health.""The 1st U.S. Circuit Court of Appeals in Boston said the plaintiff, Ronda Kaufman, can pursue a proposed class action accusing CVS of violating a New York consumer protection law, and that a lower court judge erred in dismissing her case.CVS spokesman Mike DeAngelis said the company's store-branded products are designed to be ""safe, work as intended, comply with regulations and satisfy customers. We intend to continue vigorously defending against this complaint.""Kaufman, a New Yorker who bought CVS-branded vitamin E from a Long Island store, said scientific studies show that vitamin E offers no cardiovascular benefits, and that CVS misled her and other consumers who relied on contrary statements on its labels. CVS, based in Woonsocket, Rhode Island, countered that the studies Kaufman relied on substantiated its health claims, and that the federal Food, Drug and Cosmetic Act prevented her from suing under New York law.Writing for a three-judge panel, however, Circuit Judge William Kayatta said most of the studies tested whether vitamin E prevented disease, not whether it supported heart health, and that one said it could actually damage the heart. ""The cited studies do not on their face render implausible the allegation that CVS lacks substantiation that the 'heart health' and 'supports heart health' statements are truthful and not misleading descriptions of the function of vitamin E supplements in humans,"" Kayatta wrote.Tuesday's decision did not address the merits of the lawsuit, which was returned to U.S. District Judge Mary Lisi in Providence, Rhode Island. Kaufman had sued CVS in May 2014, seeking actual and punitive damages plus an injunction against improper labeling.Her lawyer Brian Penny did not immediately respond on Tuesday to requests for comment.The case is Kaufman v CVS Caremark Corp et al, 1st U.S. Circuit Court of Appeals, No. 16-1199.",2016-09-06,CVS,"Tue Sep 6, 2016 | 4:52pm EDT",CVS must face revived lawsuit in U.S. over vitamin E label,http://www.reuters.com//article/cvs-health-lawsuit-vitamine-idUSL1N1BI1MB?type=companyNews
165,"   By Jonathan Stempel  A federal appeals court on Tuesday revived a lawsuit accusing CVS Health Corp, one of the largest U.S. drugstore chains, of deceiving consumers with labels touting how CVS-branded vitamin E promotes ""heart health.""The 1st U.S. Circuit Court of Appeals in Boston said the plaintiff, Ronda Kaufman, can pursue a proposed class action accusing CVS of violating a New York consumer protection law, and that a lower court judge erred in dismissing her case.CVS spokesman Mike DeAngelis said the company's store-branded products are designed to be ""safe, work as intended, comply with regulations and satisfy customers. We intend to continue vigorously defending against this complaint.""Kaufman, a New Yorker who bought CVS-branded vitamin E from a Long Island store, said scientific studies show that vitamin E offers no cardiovascular benefits, and that CVS misled her and other consumers who relied on contrary statements on its labels. CVS, based in Woonsocket, Rhode Island, countered that the studies Kaufman relied on substantiated its health claims, and that the federal Food, Drug and Cosmetic Act prevented her from suing under New York law.Writing for a three-judge panel, however, Circuit Judge William Kayatta said most of the studies tested whether vitamin E prevented disease, not whether it supported heart health, and that one said it could actually damage the heart.""The cited studies do not on their face render implausible the allegation that CVS lacks substantiation that the 'heart health' and 'supports heart health' statements are truthful and not misleading descriptions of the function of vitamin E supplements in humans,"" Kayatta wrote. Tuesday's decision did not address the merits of the lawsuit, which was returned to U.S. District Judge Mary Lisi in Providence, Rhode Island.Kaufman had sued CVS in May 2014, seeking actual and punitive damages plus an injunction against improper labeling. Her lawyer Brian Penny did not immediately respond on Tuesday to requests for comment.The case is Kaufman v CVS Caremark Corp et al, 1st U.S. Circuit Court of Appeals, No. 16-1199.     (Reporting by Jonathan Stempel in New York; Editing by Andrew Hay and Dan Grebler)",2016-09-06,CVS,"Tue Sep 6, 2016 | 5:21pm EDT",UPDATE 1-CVS must face revived lawsuit in U.S. over vitamin E label,http://www.reuters.com//article/cvs-health-lawsuit-vitamine-idUSL1N1BI1OH?type=companyNews
166,  Sept 22 CVS Health Corp * Sets quarterly dividend of $0.425 per share  Source text for Eikon:  Further company coverage:  ,2016-09-22,CVS,"Thu Sep 22, 2016 | 12:18pm EDT",BRIEF-CVS Health sets quarterly dividend of $0.425 per share,http://www.reuters.com//article/idUSFWN1BY0IV?type=companyNews
167,"  Sept 23 Consolidated-Tomoka Land Co * Consolidated Tomoka announces acquisition of a CVS ground lease in Dallas, texas for approximately $14.9 million  Source text for Eikon:  Further company coverage:  ",2016-09-23,CVS,"Fri Sep 23, 2016 | 4:27pm EDT",BRIEF-Consolidated Tomoka acquires a CVS ground lease in Dallas,http://www.reuters.com//article/idUSFWN1BZ0P6?type=companyNews
168,"  The U.S. Food and Drug Administration warned against the use of homeopathic teething tablets and gels on Friday, citing potential risks to infants and children and prompting CVS Health Corp Inc to withdraw the products.The FDA is currently testing samples of the products and analyzing reports linking them to seizures in infants and children since 2010, the health regulator said in a statement. bit.ly/2dhHDDwCVS announced a voluntary withdrawal of homeopathic teething products following the FDA's announcement. Homeopathic teething tablets and gels are sold in retail stores and online and are distributed by companies including both CVS and Hyland.   (Reporting by Vishal Sridhar in Bengaluru; Editing by Tom Brown)",2016-09-30,CVS,"Fri Sep 30, 2016 | 7:10pm EDT",FDA warns against use of homeopathic teething products,http://www.reuters.com//article/us-healthcare-teething-usa-idUSKCN1202RG?type=companyNews
169,"  The U.S. Food and Drug Administration warned against the use of homeopathic teething tablets and gels on Friday, citing potential risks to infants and children and prompting CVS Health Corp Inc to withdraw the products.The FDA is currently testing samples of the products and analyzing reports linking them to seizures in infants and children since 2010, the health regulator said in a statement. bit.ly/2dhHDDwCVS announced a voluntary withdrawal of homeopathic teething products following the FDA's announcement. Homeopathic teething tablets and gels are sold in retail stores and online and are distributed by companies including both CVS and Hyland.   (Reporting by Vishal Sridhar in Bengaluru; Editing by Tom Brown)",2016-09-30,CVS,"Fri Sep 30, 2016 | 7:10pm EDT",FDA warns against use of homeopathic teething products,http://www.reuters.com//article/healthcare-teething-usa-idUSL3N1C656N?type=companyNews
170,"  Sept 30 CVS Health Corp* Voluntary withdrawal being conducted in light of FDA's announcement recommending consumers stop using homeopathic teething products * CVS Pharmacy announces voluntary withdrawal of homeopathic teething products  * A ""do not sell"" block has been placed in co's store register system to prevent further sale of any affected items  Source text for Eikon:  Further company coverage:",2016-09-30,CVS,"Fri Sep 30, 2016 | 5:58pm EDT",BRIEF-CVS Pharmacy announces voluntary withdrawal of homeopathic teething products,http://www.reuters.com//article/idUSFWN1C60UP?type=companyNews
171,"  Oct 19 CVS Health Corp - * National rollout of CVS pay, an end-to-end mobile payment solution at CVS pharmacy  Source text for Eikon:  Further company coverage:  ",2016-10-19,CVS,"Wed Oct 19, 2016 | 9:16am EDT",BRIEF-CVS Pharmacy takes CVS pay nationwide following successful pilot,http://www.reuters.com//article/idUSFWN1CP0PT?type=companyNews
172,"  Oct 31 FamilyMart UNY Holdings Co Ltd    :* Says its unit, FamilyMart Co.,Ltd, plans to split its CVS business and subleasing real estate to transfer to Mitsuuroko Group Holdings unit, which is engaged in support of convenient store development business * Transaction amount is 1 yen* Says effective on Dec. 10  Source text in Japanese:goo.gl/09Mq8w; goo.gl/PqvFrp;Further company coverage:    (Beijing Headline News)",2016-10-31,CVS,"Mon Oct 31, 2016 | 5:30am EDT",BRIEF-FamilyMart UNY Holdings unit to split CVS business and subleasing real estate to Mitsuuroko Group Holdings' unit,http://www.reuters.com//article/idUSL4N1D1395?type=companyNews
173,"  CVS Health Corp (CVS.N) said it would cut about 600 jobs, mostly at its corporate offices in Rhode Island, Illinois and Arizona over the next two months, citing an increasingly competitive environment.The drugstore chain operator, which is expected to report third-quarter results next week, employs more than 240,000 people in the United States. Employees being affected will be allowed to apply for other positions in the company, the company said in a statement.   (Reporting by Nikhil Subba in Bengaluru)",2016-11-03,CVS,"Thu Nov 3, 2016 | 3:12pm EDT",CVS Health to cut about 600 jobs over next two months,http://www.reuters.com//article/us-cvs-health-jobs-idUSKBN12Y2IR?type=companyNews
174,"  CVS Health Corp (CVS.N) said it would cut about 600 jobs, mostly at its corporate offices in Rhode Island, Illinois and Arizona over the next two months, citing an increasingly competitive environment.The drugstore chain operator, which is expected to report third-quarter results next week, employs more than 240,000 people in the United States. Employees being affected will be allowed to apply for other positions in the company, the company said in a statement.   (Reporting by Nikhil Subba in Bengaluru)",2016-11-03,CVS,"Thu Nov 3, 2016 | 3:12pm EDT",CVS Health to cut about 600 jobs over next two months,http://www.reuters.com//article/cvs-health-jobs-idUSL4N1D44P9?type=companyNews
175,"  Nov 3 CVS Health Corp* CVS Health Corp - eliminating a small percentage of positions at CVS health in November and December 2016  * CVS Health Corp - about 600 positions located primarily in our corporate facilities in Rhode Island, Illinois and Arizona will be affected  Further company coverage: ",2016-11-03,CVS,"Thu Nov 3, 2016 | 2:35pm EDT",BRIEF-CVS Health says eliminating small percentage of positions in Nov and Dec 2016,http://www.reuters.com//article/idUSFWN1D41HO?type=companyNews
176,"  Nov 3 (Reuters) -* CVS Health Inc to eliminate 600 jobs - WSJ, citing statement * CVS is eliminating  jobs at corporate offices in Rhode Island, Illinois and Arizona over the next two months- WSJ, citing statement  Source : (on.wsj.com/2fj28Rg)",2016-11-03,CVS,"Thu Nov 3, 2016 | 1:37pm EDT","BRIEF-CVS Health Inc to eliminate 600 jobs - WSJ, citing statement",http://www.reuters.com//article/idUSFWN1D41FE?type=companyNews
177,"   By Gayathree Ganesan and Siddharth Cavale  Drugstore chain and pharmacy benefits manager CVS Health Corp (CVS.N) cut its profit forecast for this year and projected weak growth for 2017, saying it expected to lose more than 40 million retail prescriptions to other pharmacy chains, sending its shares down as much as 17 percent to a more than two-year low.In a major blow, CVS lost contracts to fill prescriptions for Tricare, a Department of Defense health care program, and for customers of pharmacy benefits manager (PBM) Prime Therapeutics, to Walgreens Boots Alliance Inc (WBA.O) this year.Tricare has about 9.7 million members while Prime Therapeutics, the fourth-largest PBM, has 22 million.Slower-than-expected accretion from the acquisition of specialty pharmacy business Omnicare and Target Corp's (TGT.N) pharmacies and reimbursement pressures will also be a drag on earnings growth, the company said.Rising generic drug prices have squeezed retail pharmacies as well as PBMs - which help private sector medical insurers negotiate better prices from drugmakers - because insurers are raising reimbursement rates slowly. CVS is particularly vulnerable to rising drug prices because it has both retail and PBM businesses.""2017 will be a challenging year..."" Chief Financial Officer David Denton said on a call with analysts.CVS's shares fell as much as 16.9 percent to $69.30 on Tuesday, their lowest since February 2014. Rival Walgreens' shares also fell, by 4.24 percent.Woonsocket, Rhode Island-based CVS said it expected a 2017 adjusted profit of $5.77-$5.93 per share, below the average analysts' estimate of $6.52, according to Thomson Reuters I/B/E/S.  The company cut its 2016 adjusted earnings forecast to $5.77-$5.83 per share from $5.81-$5.89, citing slowing prescription growth and a ""soft"" seasonal business.Net sales rose 15.5 percent to $44.62 billion in the third quarter ended Sept. 30, helped by demand for PBM services, but this was short of the average estimate of $45.29 billion.Net income attributable to CVS rose 23 percent to $1.54 billion, or $1.43 per share. The company approved a new $15 billion share repurchase program. This is in addition to the $3.7 billion that remains from a previous buyback program, the company said.CVS's shares were down 12.9 percent in afternoon trading, while Walgreen's stock was down 1.8 percent. (Reporting by Gayathree Ganesan, Siddarth Cavale and Ankur Banerjee in Bengaluru; Editing by Martina D'Couto)",2016-11-08,CVS,"Tue Nov 8, 2016 | 3:01pm EST","CVS cuts forecast after contract losses to Walgreens, shares dive",http://www.reuters.com//article/us-cvs-health-results-idUSKBN1331ET?type=companyNews
178,"   By Gayathree Ganesan and Siddharth Cavale  Drugstore chain and pharmacy benefits manager CVS Health Corp (CVS.N) cut its profit forecast for this year and projected weak growth for 2017, saying it expected to lose more than 40 million retail prescriptions to other pharmacy chains, sending its shares down as much as 17 percent to a more than two-year low.In a major blow, CVS lost contracts to fill prescriptions for Tricare, a Department of Defense health care program, and for customers of pharmacy benefits manager (PBM) Prime Therapeutics, to Walgreens Boots Alliance Inc (WBA.O) this year.Tricare has about 9.7 million members while Prime Therapeutics, the fourth-largest PBM, has 22 million.Slower-than-expected accretion from the acquisition of specialty pharmacy business Omnicare and Target Corp's (TGT.N) pharmacies and reimbursement pressures will also be a drag on earnings growth, the company said.Rising generic drug prices have squeezed retail pharmacies as well as PBMs - which help private sector medical insurers negotiate better prices from drugmakers - because insurers are raising reimbursement rates slowly. CVS is particularly vulnerable to rising drug prices because it has both retail and PBM businesses.""2017 will be a challenging year..."" Chief Financial Officer David Denton said on a call with analysts.CVS's shares fell as much as 16.9 percent to $69.30 on Tuesday, their lowest since February 2014. Rival Walgreens' shares also fell, by 4.24 percent.Woonsocket, Rhode Island-based CVS said it expected a 2017 adjusted profit of $5.77-$5.93 per share, below the average analysts' estimate of $6.52, according to Thomson Reuters I/B/E/S.  The company cut its 2016 adjusted earnings forecast to $5.77-$5.83 per share from $5.81-$5.89, citing slowing prescription growth and a ""soft"" seasonal business.Net sales rose 15.5 percent to $44.62 billion in the third quarter ended Sept. 30, helped by demand for PBM services, but this was short of the average estimate of $45.29 billion.Net income attributable to CVS rose 23 percent to $1.54 billion, or $1.43 per share. The company approved a new $15 billion share repurchase program. This is in addition to the $3.7 billion that remains from a previous buyback program, the company said.CVS's shares were down 12.9 percent in afternoon trading, while Walgreen's stock was down 1.8 percent. (Reporting by Gayathree Ganesan, Siddarth Cavale and Ankur Banerjee in Bengaluru; Editing by Martina D'Couto)",2016-11-08,CVS,"Tue Nov 8, 2016 | 3:01pm EST","UPDATE 4-CVS cuts forecast after contract losses to Walgreens, shares dive",http://www.reuters.com//article/cvs-health-results-idUSL4N1D93YO?type=companyNews
179,"  Nov 8 CVS Health Corp :* CVS Health reports third quarter results* Q3 adjusted earnings per share $1.64* Q3 GAAP earnings per share $1.43 from continuing operations* Q3 revenue $44.6 billion versus I/B/E/S view $45.29 billion* Q3 same store sales rose 2.3 percent* Q3 earnings per share view $1.57 -- Thomson Reuters I/B/E/S* Sees FY 2017 adjusted earnings per share $5.77 to $5.93* Sees FY 2017 GAAP earnings per share $5.16 to $5.33 * Lowers and narrows 2016 guidance* raised outlook for full year cash flow from operations to $9.1 billion-$9.3 billion; sees FY free cash flow $6.8 billion-$7.0 billion* In Q4 of 2016, expects to deliver GAAP diluted eps of $1.52 to $1.58 and adjusted eps of $1.64 to $1.70* sees full year GAAP diluted eps lowered and narrowed to $4.84 to $4.90 from $4.92 to $5.00 * sees full year adjusted eps lowered and narrowed to $5.77 to $5.83 from $5.81 to $5.89* Board of directors approved a new share repurchase program for up to $15 billion of company's outstanding common stock* Qtrly same store sales increased 2.3% versus Q3 of 2015* Included in preliminary 2017 outlook is impact from projected loss of more than 40 million retail prescriptions related to marketplace changes * Qtrly pharmacy same store sales rose 3.4%* Recent pharmacy network changes in marketplace expected to cause some retail prescriptions to migrate out of cvs pharmacies this quarter* Qtrly front store same store sales decreased 1.0%* ""We are currently experiencing slowing prescription growth in overall market as well as a soft seasonal business""* FY2016 earnings per share view $5.85; FY2017 earnings per share view $6.52 -- Thomson Reuters I/B/E/S* ""While we expect a healthy increase in pbm operating profit growth in 2017, we expect a decrease in retail operating profit growth""* Pharmacy network changes, slowing prescription growth in  market leading us to reduce mid-point of our guidance for this year by 5 cents per share  Source text for Eikon:  Further company coverage:",2016-11-08,CVS,"Tue Nov 8, 2016 | 10:26am EST",BRIEF-CVS reports Q3 adjusted EPS of $1.64,http://www.reuters.com//article/idUSB8N19602Y?type=companyNews
180,"  Nov 8 Cvs Health Corp* CVS Health executive says for Q4 2016 total same-store sales at retail are expected to be flat to down 1.75 percent -conf call* CVS Health executive says ""For the fourth quarter, we expect enterprise revenues to be up 12.25 percent to 14 percent driven primarily by PBM growth"" -conf call* Currently expect an increase in PBM EBIT of about 8 percent and the decrease in retail EBIT of about 8 percent in 2017 * Says ""Caught a little bit off guard"" in bid process for Prime and TRICARE network * CVS- Although both Omnicare, Target pharmacy acquisitions are performing well, ramp-up in level of accretion is slightly slower than anticipated* CVS Health- Given recent network changes it has become more difficult to grow share and therefore offset ongoing margin pressures in the near term * CVS - Maintaining 10 percent to 14 percent adjusted EPS growth rate annually off a larger base is becoming more challenging; now anticipate growth of about 10 percent on average* Expect annual EPS growth to generate to $7-$8 billion in free cash flow per year on average- conf call  Further company coverage:",2016-11-08,CVS,"Tue Nov 8, 2016 | 9:44am EST","BRIEF-CVS says ""Caught a little bit off guard"" in bid process for Prime, TRICARE network",http://www.reuters.com//article/idUSFWN1D90OV?type=companyNews
181,"  Nov 8 CVS Health Corp* Lowers and narrows 2016 guidance* In Q4 of 2016, expects to deliver gaap diluted EPS of $1.52 to $1.58 and adjusted EPS of $1.64 to $1.70* Sees full year gaap diluted EPS lowered and narrowed to $4.84 to $4.90 from $4.92 to $5.00* Sees full year adjusted eps lowered and narrowed to $5.77 to $5.83 from $5.81 to $5.89* Raised outlook for full year cash flow from operations to $9.3 to $9.5 billion; free cash flow to $6.8 to $7.0 billion* Board of directors approved a new share repurchase program for up to $15 billion of company's outstanding common stock* Qtrly same store sales increased 2.3% versus q3 of 2015* Included in preliminary 2017 outlook is impact from projected loss of more than 40 million retail prescriptions related to marketplace changes * Qtrly pharmacy same store sales rose 3.4%* Recent pharmacy network changes in marketplace expected to cause some retail prescriptions to migrate out of cvs pharmacies this quarter* Qtrly front store same store sales decreased 1.0%* ""We are currently experiencing slowing prescription growth in overall market as well as a soft seasonal business"" * FY2016 earnings per share view $5.85 -- Thomson Reuters I/B/E/S* FY2017 earnings per share view $6.52 -- Thomson Reuters I/B/E/S* ""While we expect a healthy increase in pbm operating profit growth in 2017, we expect a decrease in retail operating profit growth""* Pharmacy network changes, slowing prescription growth in  market leading us to reduce mid-point of our guidance for this year by 5 cents per share * CVS Health reports third quarter results* Q3 adjusted earnings per share $1.64* Q3 gaap earnings per share $1.43 from continuing operations* Q3 revenue $44.6 billion versus i/b/e/s view $45.29 billion* Q3 same store sales rose 2.3 percent* Q3 earnings per share view $1.57 -- Thomson Reuters I/B/E/S* Sees FY 2017 adjusted earnings per share $5.77 to $5.93* Sees FY 2017 gaap earnings per share $5.16 to $5.33  Source text for Eikon:  Further company coverage:    (Bangalore.newsroom@thomsonreuters.com)",2016-11-08,CVS,"Tue Nov 8, 2016 | 7:16am EST",BRIEF-CVS Health posts Q3 adjusted earnings per share of $1.64,http://www.reuters.com//article/idUSASC09GYZ?type=companyNews
182,"  Nov 8 CVS Health Corp, the No. 2 U.S. drugstore chain by store count, reported a 15.5 percent rise in quarterly revenue, helped by strong demand for its pharmacy benefit management (PBM) services.Net income attributable to CVS rose to $1.54 billion, or $1.43 per share, in the third quarter ended Sept. 30, from $1.25  billion, or $1.11 per share, a year earlier.  The Woonsocket, Rhode Island-based company's net revenue rose to $44.62 billion from $38.64 billion.   (Reporting by Gayathree Ganesan in Bengaluru; Editing by Martina D'Couto) ",2016-11-08,CVS,"Tue Nov 8, 2016 | 7:03am EST",CVS's quarterly revenue rises 15.5 pct,http://www.reuters.com//article/cvs-health-results-idUSL4N1D93XW?type=companyNews
